Oligonucleotide-binding e-tag probe compositions

ABSTRACT

Compositions for the multiplexed detection of known, selected nucleotide target sequences are provided. The compositions include one or more uncleaved or partially cleaved electrophoretic tag (e-tag) probes from a set of e-tag probes, at least one e-tag reporter out of a possible set of e-tag reporters and a capture agent. The e-tag probes comprise a detection region and a mobility-defining region called the mobility modifier, both linked to a target-binding moiety. Detection involves the release of identifying tags as a consequence of target recognition. The target-binding moiety of the e-tag probes hybridizes to complementary target sequences followed by nuclease cleavage of the e-tag probes and release of detectable e-tags or e-tag reporters. The mixture is exposed to a capture agent which binds uncleaved and/or partially cleaved e-tag probes, followed by electrophoretic separation. In a multiplexed assay, different released e-tag reporters may be separated and detected providing for target identification.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of Ser. No. 09/303,029 filedApr. 30, 1999; Ser. No. 09/561,579 filed Apr. 28, 2000; Ser. No.09/602,586 filed Jun. 21, 2000; Ser. No. 09/684,386 filed Oct. 4, 2000;and Ser. No. 09/698,846 filed Oct. 27, 2000, all of which areincorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present invention relates to separable compositions, methods,and kits for use in multiplexed assay detection of known, selectedtarget nucleotide sequences.

BACKGROUND OF THE INVENTION

[0003] The need to determine many analytes or nucleic acid sequences(for example multiple pathogens or multiple genes or multiple geneticvariants) in blood or other biological fluids has become increasinglyapparent in many branches of medicine. Most multi-analyte assays, suchas assays that detect multiple nucleic acid sequences, involve multiplesteps, have poor sensitivity, a limited dynamic range (typically on theorder of 2 to 100-fold differences and some require sophisticatedinstrumentation. Some of the known classical methods for multianalyteassays include the following:

[0004] a. The use of two different radioisotope labels to distinguishtwo different analytes.

[0005] b. The use of two or more different fluorescent labels todistinguish two or more analytes.

[0006] c. The use of lanthanide chelates where both lifetime andwavelength are used to distinguish two or more analytes.

[0007] d. The use of fluorescent and chemiluminescent labels todistinguish two or more analytes.

[0008] e. The use of two different enzymes to distinguish two or moreanalytes.

[0009] f. The use of enzyme and acridinium esters to distinguish two ormore analytes.

[0010] g. Spatial resolution of different analytes, for example onarrays, to identify and quantify multiple analytes.

[0011] h. The use of acridinium ester labels where lifetime ordioxetanone formation is used to quantify two different viral targets.

[0012] As the human genome is elucidated, there will be numerousopportunities for performing assays to determine the presence ofspecific sequences, distinguishing between alleles in homozygotes andheterozygotes, determining the presence of mutations, evaluatingcellular expression patterns, etc. In many of these cases one will wishto determine in a single reaction, a number of different characteristicsof the same sample. In many assays, there will be an interest indetermining the presence of specific sequences, whether genomic,synthetic, or cDNA. These sequences may be associated particularly withgenes, regulatory sequences, repeats, multimeric regions, expressionpatterns, and the like. There will also be an interest in determiningthe presence of one or more pathogens, their antibiotic resistancegenes, genetic subtype and the like. The need to identify and quantify alarge number of bases or sequences, potentially distributed overcentimorgans of DNA, offers a major challenge. Any method should beaccurate, reasonably economical in limiting the amount of reagentsrequired and provide for a highly multiplexed assay, which allows fordifferentiation and quantitation of multiple genes, and/or snpdetermination, and/or gene expression at the RNA or protein level.

[0013] The need to study differential expression of multiple genes todetermine toxicologically relevant outcomes or the need to screentransfused blood for viral contaminants with high sensitivity is clearlyevident. Finally, while nucleic acid sequences provide extreme diversityfor situations that may be of biological or other interest, there areother types of compounds, such as proteins in proteomics that may alsooffer opportunities for multiplexed determinations.

[0014] There is and will continue to be comparisons of the sequences ofdifferent individuals. It is believed that there will be about onepolymorphism per 1,000 bases, so that one may anticipate that there willbe an extensive number of differences between individuals. By singlenucleotide polymorphism (SNPs) is intended that there will be aprevalent nucleotide at the site, with one or more of the remainingbases being present in a substantially smaller percent of thepopulation. While other genetic markers are available, the large numberof SNPs and their extensive distribution in the chromosomes make SNPs anattractive target. Also, by determining a plurality of SNPs associatedwith a specific phenotype, one may use the SNP pattern as an indicationof the phenotype, rather than requiring a determination of the genesassociated with the phenotype. For the most part, the SNPs will be innon-coding regions, primarily between genes, but will also be present inexons and introns. In addition, the great proportion of the SNPs willnot affect the phenotype of the individual, but will clearly affect thegenotype. The SNPs have a number of properties of interest. Since theSNPs will be inherited, individual SNPs and/or SNP patterns may berelated to genetic defects, such as deletions, insertions and mutations,involving one or more bases in genes. Rather than isolating andsequencing the target gene, it will be sufficient to identify the SNPsinvolved. In addition, the SNPs may also be used in forensic medicine toidentify individuals.

[0015] Thus an assay for the differentiation and quantitation ofmultiple genes, and/or snp determination, and/or gene expression at theRNA or protein level, that has higher sensitivity, a large dynamic range(10³ to 10⁴-fold differences in target levels), a greater degree ofmultiplexing, and fewer and more stable reagents would increase thesimplicity and reliability of multianalyte assays, and reduce theircosts.

BRIEF DESCRIPTION OF THE RELATED ART

[0016] Holland (Proc. Natl. Acad. Sci. USA (1991) 88:7276) disclosesthat the exonuclease activity of the thermostable enzyme Thermusaquaticus DNA polymerase in PCR amplification to generate specificdetectable signal concomitantly with amplification.

[0017] The TaqMan® assay is discussed by Lee in Nucleic Acid Research(1993) 21:16 3761).

[0018] White (Trends Biotechnology (1996) 14(12): 478-483) discusses theproblems of multiplexing in the TaqMan assay.

[0019] Marino, Electrophoresis (1996) 17:1499 describeslow-stringency-sequence specific PCR (LSSP-PCR). A PCR amplifiedsequence is subjected to single primer amplification under conditions oflow stringency to produce a range of different length amplicons.Different patterns are obtained when there are differences in sequence.The patterns are unique to an individual and of possible value foridentity testing.

[0020] Single strand conformational polymorphism (SSCP) yields similarresults. In this method the PCR amplified DNA is denatured and sequencedependent conformations of the single strands are detected by theirdiffering rates of migration during gel electrophoresis. As withLSSP-PCR above, different patterns are obtained that signal differencesin sequence.

[0021] However, neither LSSP-PCR nor SSCP gives specific sequenceinformation and both depend on the questionable assumption that any basethat is changed in a sequence will give rise to a conformational changethat can be detected. Pastinen, Clin. Chem. (1996) 42:1391 amplifies thetarget DNA and immobilizes the amplicons. Multiple primers are thenallowed to hybridize to sites 3′ and contiguous to a SNP (singlenucleotide polymorphism) site of interest. Each primer has a differentsize that serves as a code. The hybridized primers are extended by onebase using a fluorescently labeled dideoxynucleoside triphosphate. Thesize of each of the fluorescent products that is produced, determined bygel electrophoresis, indicates the sequence and, thus, the location ofthe SNP. The identity of the base at the SNP site is defined by thetriphosphate that is used. A similar approach is taken by Haff, NucleicAcids Res. (1997) 25:3749 except that the sizing is carried out by massspectrometry and thus avoids the need for a label. However, both methodshave the serious limitation that screening for a large number of siteswill require large, very pure primers that can have troublesomesecondary structures and be very expensive to synthesize.

[0022] Hacia, Nat. Genet. (1996) 14:441 uses a high-density array ofoligonucleotides.

[0023] Labeled DNA samples were allowed to bind to 96,600 20-baseoligonucleotides and the binding patterns produced from differentindividuals were compared. The method is attractive in that SNPs can bedirectly identified, but the cost of the arrays is high and non-specifichybridization may confound the accuracy of the genetic information.

[0024] Fan (1997, October 6-8, IBC, Annapolis Md.) has reported resultsof a large scale screening of human sequence-tagged sites. The accuracyof single nucleotide polymorphism screening was determined byconventional ABI resequencing.

[0025] Ross in Anal. Chem. (1997) 69:4197 discusses allele specificoligonucleotide hybridization along with mass spectrometry.

[0026] Brenner and Lerner, PNAS (1992) 89:5381, suggested that compoundsprepared by combinatorial synthesis can each be labeled with acharacteristic DNA sequence. If a given compound proves of interest, thecorresponding DNA label is amplified by PCR and sequenced, therebyidentifying the compound.

[0027] W. Clark Still, in U.S. Pat. No. 5,565,324 and in Accounts ofChem. Res., (1996) 29:155, uses a releasable mixture of halocarbons onbeads to code for a specific compound on the bead that is producedduring synthesis of a combinatorial library. Beads bearing a compound ofinterest are treated to release the coding molecules and the mixture isanalyzed by gas chromatography with flame ionization detection.

[0028] U.S. Pat. No. 5,807,682 describes probe compositions fordetecting a plurality of nucleic acid targets.

SUMMARY OF THE INVENTION

[0029] Compositions for the multiplexed detection of known, selectedtarget nucleotide sequences is provided. The compositon comprises one ormore uncleaved or partially cleaved electrophoretic tag (e-tag) probesfrom a set of e-tag probes, at least one e-tag reporter out of apossible set of e-tag reporters and a cpature agent.

[0030] The e-tag probe sets comprise j members, and have the form, (D,M_(j))-N-T_(j), where (a) D is a detection group comprising a detectablelabel; (b) M_(j) is a mobility modifier, having a particular charge/massratio; (c) N is a nucleotide joined to U₁ in T_(j) through anuclease-cleavable bond; and (d) T_(j) is an oligonucleotidetarget-binding moiety that has a sequence of nucleotides U_(i) connectedby intersubunit linkages B_(i, i+1), where i includes all integers from1 to n, and n is sufficient to allow the moiety to specificallyhybridize with a target nucleotide sequence.

[0031] The e-tag reporters have the form, (D, M_(j))-N. e-tag reportersare generated when a set of e-tag probes is combined with one or moretarget sequences under conditions that allow hybridization of thetarget-binding moiety of the probes to complementary target sequences.The hybridized target sequences are treated with a nuclease underconditions effective to cleave target-hybridized probes at the N-U₁linkage, producing a mixture of one or more corresponding e-tagreporters of the form (D, M_(j))-N, and uncleaved and/or partiallycleaved probes.

[0032] The capture agent binds to uncleaved and/or partially cleavede-tag probes and either (i) prevents the probes bound to it frommigrating within a selected range of electrophoretic mobilities or (ii)immobilizes the probes on a solid support, thereby facilitating theseparation of e-tag reported from uncleaved and/or partially cleavede-tag probes.

[0033] The mobility modifier imparts a unique and known electrophoreticmobility to each released e-tag reporter which is within a selectedrange of electrophoretic mobilities with respect to other e-tagreporters of the same form, where the e-tag reporter does not itselfcontain nuclease-cleavable bonds.

[0034] e-tag probes having the form, M_(j)-D-N-T_(j) andD-M_(j)-N-T_(j), result in the generation of e-tag reporters having theform M_(j)-D-N and D-M_(j)-N, respectively.

[0035] The e-tag probes may further include a capture ligand bound to atleast one nucleotide U₁, i≧1 in the target binding moiety of the e-tagprobe.

[0036] Exemplary capture ligands include: (i) biotin, capable of bindingspecifically to capture agents such as avidin or streptavidin and (ii)an antigen, capable of binding specifically to capture agents such as anantibody or an antibody fragment.

[0037] A polycation may serve as the capture agent, where theoligonucleotide has a negatively charged backbone.

[0038] In one approach, the N-U₁ nuclease-cleavable bond of the e-tagprobes is a phosphodiester bond, and the nuclease-resistant bond(s) inthe target-binding moiety may be one or more of thiophosphate,phosphinate, phosphoramidate, amide, and boronate linkages. Such e-tagprobes may further include a capture ligand bound to at least onenucleotide U₁, i≧1 in the target binding moiety of the e-tag probe.

[0039] The mobility modifier component of the e-tag reporters and e-tagprobes may have one or more of the following characteristics:

[0040] (i) a unique charge/mass ratio due to variations in mass, but notcharge;

[0041] (ii) a unique charge/mass ratio due to changes in both mass andcharge;

[0042] (iii) a unique charge/mass ratios of between −0.001 and 0.5;

[0043] (iv) a structure that includes a selected number of negativelycharged and/or positively charged amino acids; and

[0044] (v) a structure that includes an alkyl chain, and differs fromother M_(j) in the set by 1-3 methylene groups in the chain.

[0045] In one aspect, the probe sets comprise at least 5 probes, and ina related aspect, the probe sets comprise at least 9 probes.

[0046] The label component of the e-tag reporters and e-tag probes ofthe invention may be a fluorophore, a chromophore, or an electrochemicalcompound capable of a detectable reaction in the presence of a redoxagent. In addition, the label component of the probe set may have aselected mass and charge.

[0047] Further, the composition may contain subsets of probes, eachsubset having a label with a unique mass/charge ratio.

BRIEF DESCRIPTION OF THE DRAWINGS

[0048]FIGS. 1A, B and C depict the snp detection sequences for two snpalleles (A), the optical characteristics of the fluorescent dyes (B),and the cleaved fragments from the snp detection sequences (C).

[0049]FIG. 2 shows the structure of several benzoic acid derivativesthat can serve as mobility modifiers.

[0050] FIGS. 3A-D provide a schematic illustration of the generalizedmethods of the invention employing a nucleotide target and a 5′exonuclease indicating that only one eTag is generated per target formaximum multiplexing capabilities (A); the use of a capture ligand,biotin, to facilitate the removal of uncleaved or partially cleavede-tag probe from the reaction mixture (B) and (C); and the use ofnuclease resistant modifications (e.g., phosphorothioates) to thebackbone of the target binding region (D).

[0051]FIG. 4 illustrates the design and synthesis of e-tags using aLabCard (Detection: 4.7 cm; 200 V/cm) and standard phosphoramiditecoupling chemistry.

[0052]FIG. 5 illustrates E-tags that have been separated on a LabCard.(Detection: 4.7 cm; 200 V/cm.)

[0053]FIG. 6 provides predicted and experimental (*) elution times ofe-tag reporters separated by capillary electrophoresis. C₃, C₆, C₉, andC₁₈ are commercially available phosphoramidite spacers from GlenResearch, Sterling Va. The units are derivatives of N,N-diisopropyl,O-cyanoethyl phosphoramidite, which is indicated by “Q”. C₃ is DMT(dimethoxytrityl)oxypropyl Q; C₆ is DMToxyhexyl Q; C₉ isDMToxy(triethyleneoxy) Q; C₁₂ is DMToxydodecyl Q; C₁₈ isDMToxy(hexaethyleneoxy) Q.

[0054]FIG. 7 gives the structure of several mobility-modified nucleicacid phosphoramidites that can be employed at the penultimate couplingduring e-tag probe synthesis on a standard DNA synthesizer.

[0055]FIG. 8 shows multiple electropherograms showing separation ofindividual e-tag reporters. The figure illustrates obtainable resolutionof the reporters, which are identified by their ACLA numbers.

[0056]FIG. 9 shows charge modifier phosphoramidites. (EC or CE iscyanoethyl).

[0057]FIG. 10 shows polyhydroxylated charge modifier phosphoramidites.

[0058]FIG. 11 illustrates one exemplary synthetic approach starting withcommercially available 6-carboxy fluorescein, wherre the phenolichydroxyl groups are protected using an anhydride. Upon standardextractive workup, a 95% yield of product is obtained. This material isphosphitylated to generate the phosphoramidite monomer.

[0059]FIG. 12 illustrates the use of a symmetrical bis-amino alcohollinker as the amino alcohol with the second amine then coupled with amultitude of carboxylic acid derivatives.

[0060]FIG. 13 illustrates the use of an alternative strategy that uses5-aminofluorescein as starting material and the same series of steps toconvert it to its protected phosphoramidite monomer.

[0061]FIG. 14 illustrates several mobility modifiers that can be usedfor conversion of amino dyes into e-tag phosphoramidite monomers.

[0062]FIG. 15 gives the structure of several e-tags derived frommaleimide-linked precursors.

[0063]FIG. 16 is a diagram of a system for performing multiplexeddeterminations using e-tags.

[0064] FIGS. 17A-J shows the structures of numerous exemplary e-tagreporters. FIGS. 18A and B depict the CE separation of the reactionproducts of Allele 1 after 0 and 40 cycles. CE instrument: BeclmanP/ACE/ 5000 with LIF detection. BGE: 2.5% LLD 30, 7M urea, 1×TBE.Capillary: 100 μm i.d., 375 μm o.d., Lc=27 cm, Ld=6.9 cm. Detection;λ_(ex)=488 nm, λ_(em)=520 nm. Injection: 5s at 2.0 kV. Field strength:100V/cm at rt. Peaks: P=unreacted snp detection sequence or e-tag probe,P′=snp detection sequence or e-tag reporter product,TET=tetrachlorofluorescein. (from 00 app)

[0065]FIGS. 19A and B depict the CE separation of the reaction products(or e-tag reporters) of Allele 2 after 0 and 40 cycles. Experimentalconditions are the same as FIG. 18, except for BGE composition; 2%LDD30, 1×TBE, FAM=fluorescein.

[0066]FIG. 20 is a graph of the CE separation of a 1:1 mixture of the 40cycles products of Alleles 1 and 2, with experimental conditions asdescribed for FIG. 18.

[0067]FIG. 21 is a graph of the CE separation of a 1:10 mixture of the40 cycles products of Alleles 1 and 2, with experimental conditions asdescribed for FIG. 18.

[0068]FIG. 22 is an electropherogram of electrophoretic tags forelectrophoresis differing by a 1000-fold concentration.

[0069] FIGS. 23A-E and G are electropherograms from analysis of 5 snpsof the cystic fibrosis genes, using multiplexed PCR and the subjecte-tag probes. Three individual snp loci and a triplex reaction areshown, using multiplexed PCR and the subject e-tag probes (FIGS. 23A-Eand G), along with an image of agarose gel separation of the triplexreaction (23F).

[0070]FIG. 24 is an electropherogram of a separation of nine negativelycharged e-tag reporters.

[0071] FIGS. 25A-D are electropherograms of probes employing apenultimate thiophosphate linkage in the e-tag probes to inhibitcleavage after the first phosphate linkage. FIGS. 25A and B reflect theresults of experiments showing the formation of 5 different cleavageproducts in the PCR amplification of ANF (anti-nuclear factor) with (A)and without (B) the thiophosphate linkage. FIGS. 25C and D reflect theresults of experiments showing the formation of 5 different cleavageproducts in the PCR amplification of GAPDH, with (C) and without (D) thethiophosphate linkage.

[0072]FIG. 26 shows multiple electropherograms from a separation on a310 analyzer, after an amplification reaction in the presence of probeand primer, and without the addition of avidin.

[0073]FIG. 27 shows multiple electropherograms from a separation on a310 analyzer, after an amplification reaction in the presence of probeand primer, and with the addition of avidin.

[0074] FIGS. 28A-C are schematic illustrations of a CE² LabCard™ device(28A) and exemplary high voltage configurations utilized in this devicefor the injection (28B) and separation (28C) of products of an enzymeassay.

[0075]FIG. 29 shows two electropherograms demonstrating e-tag reporteranalysis using a CE² LabCard. The figure shows the separation ofpurified labeled aminodextran with and without sensitizer beads. Theaddition of the sensitizer beads lead to the release of the e-tagreporter from the aminodextran using singlet oxygen produced bysensitizer upon the irradiation at 680 nm. Experimental conditions:separation buffer 20 mM HEPES pH=7.4, and 0.5% PEO; voltageconfigurations as described for FIG. 28; assay mixture had 29 μg/mlstreptavidin coated sensitizer beads and irradiated for 1 min at 680 nmusing 680±10 nm filter and a 150 W lamp.

[0076]FIG. 30 shows multiple electropherograms demonstrating e-tagreporter analysis using a CE² LabCard. The figure shows the separationof purified labeled aminodextran using different concentrations ofsensitizer beads. The higher concentration of sensitizer beads leads tothe higher release of e-tag reporters from the labeled aminodextran.Experimental conditions: separation buffer 20.0 mM HEPES pH=7.4, and0.5% PEO; voltage configurations as described for FIG. 28; assay mixturewas irradiated for 1 min at 680 nm using 680±10 nm filter and a 150 Wlamp.

[0077]FIG. 31 depicts the linear calibration curve for the release ofe-tag reporters as a function of the sensitizer bead concentration.Results were obtained using a CE² LabCard.

[0078] Experimental conditions: separation buffer 20.0 mM HEPES pH=7.4,and 0.5% PEO; voltage configurations as described for FIG. 28; assaymixture was irradiated for 1 min at 680 nm using 680±10 nm filter and a150 W lamp.

[0079]FIG. 32 shows a data curve of the effect of the concentration oflabeled aminodextran on the e-tag reporter release. As demonstrated inthis figure, the lower concentration of labeled aminodextran for a givenconcentration of sensitizer beads leads to more efficient e-tag reporterrelease Results were obtained using a CE² LabCard. Experimentalconditions: separation buffer 20.0 mM HEPES pH=7.4, and 0.5% PEO;voltage configurations as described for FIG. 28; assay mixture had 29μg/ml of sensitizer beads and was irradiated for 1 min at 680 nm using680±10 nm filter and a 150 W lamp.

[0080]FIG. 33 is a schematic diagram of the steps involved in thesynthesis of the phosphoroamidite of biotin-deoxycytosine (dC) (ReagentC).

[0081]FIG. 34 is a schematic diagram of the steps involved in thesynthesis of the phosphoroamidite of biotin-deoxyadenosine (dA) (ReagentD).

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

[0082] I. Definitions

[0083] In defining the terms below, it is useful to consider the makeupof the “electrophoretic probes” that form part of the invention and/orare used in practicing the method of the invention. An electrophoreticprobe has four basic components or moieties: (i) a detection group ormoiety, (ii) a mobility modifier, (iii) a target-binding moiety, and(iv) a linking group that links the mobility modifier and detectiongroup to the target-bonding moiety. These terms will first be examinedin the context of the functioning of the electrophoretic probes in theinvention, then more fully defined by their structural features.

[0084] The function of an electrophoretic probe in the invention isfirst to interact with a target, such as a single-stranded nucleic acid,a ligand-binding agent, such as an antibody or receptor, or an enzyme,e.g., as an enzyme substrate. The “portion”, “region” or “moiety” of theprobe which binds to the target is the “target-binding moiety” or“target-binding region” or “target-binding portion” (“T”). After thetarget-binding moiety of an electrophoretic probe binds to a target, andtypically as a result of such binding, the linking group of theelectrophoretic probe may be cleaved to release an “electrophoretic tag”or “e-tag” or “e-tag reporter” which has a unique charge-to-mass ratioand thus a unique electrophoretic mobility in a defined electrophoreticsystem. The e-tag reporter is composed of the detection group, mobilitymodifier, and any residue of the linking group that remains associatedwith released reporter e-tag after cleavage. Therefore, the secondfunction of the electrophoretic probe is to release an e-tag reporterwhich can be identified according to its unique and knownelectrophoretic mobility.

[0085] According to an important feature of the invention, there isprovided a set of electrophoretic probes, each of which has a uniquetarget-binding moiety and an associated “e-tag moiety” that imparts tothe associated e-tag reporter, a unique electrophoretic mobility byvirtue of a unique charge to mass ratio. In general, the unique chargeto mass ratio of an e-tag moiety is due to the chemical structure of themobility modifier, since the detection group and linking-group residue(if any) will be common to any set of electrophoretic probes. However,it is recognized that unique charge and/or mass contributions to thee-tag reporters can be made by the detection group as well. For example,a set of electrophoretic probes may be made up of a first subset havinga group of mobility modifiers which impart unique electrophoreticmobilities to the subset in combination with a detection group havingone defined charge and/or mass, and a second subset having the samegroup of mobility modifiers in combination with a second detection groupwith a different charge and/or mass, thus to impart electrophoreticmobilities which are unique among both subsets.

[0086] The different target-binding moieties in a set of electrophoreticprobes are typically designated “T_(j)”, where the set of probescontains n members, and each T_(j), j=1 to j=n is different, i.e., willbind specifically and/or with unique affinities to different targets. Aset of electrophoretic probes of the invention typically includes atleast about 5 members, i.e., n is preferably 5 or more, typically 10-100or more.

[0087] A “reporter moiety” “R” or a “detection group” “D” are equivalentterms referring to a chemical group or moiety that is capable of beingdetected by a suitable detection system, particular in the context ofdetecting molecules containing the detection group after or duringelectrophoretic separation. One preferred detection group is afluorescent group that can be readily detected during or afterelectrophoretic separation of molecules by illuminating the moleculeswith a light source in the excitation wavelength and detectingfluorescence emission from the irradiated molecules. Exemplaryfluorescent moieties will be given below. As noted above, the detectiongroup is typically common among a set or subset of differentelectrophoretic probes, but may also differ among probe subsets,contributing to the unique electrophoretic mobilities of the releasede-tag reporter.

[0088] The “mobility modifier” “M” is a generally a chemical group ormoiety that is designed to have a particular charge to mass ratio, andthus a particular electrophoretic mobility in a defined electrophoreticsystem. Exemplary types of mobility modifiers are discussed below. In aset of n electrophoretic probes, each unique mobility modifier isdesignated M_(j), where j=1 to n, as above. The mobility modifier may beconsidered to include a mass-modifying region and/or a charge-modifyingregion or a single region that acts as both a mass- and charge-modifyingregion. The mobility modifying region may also be referred to as M*, C*,L, a bond, a linking group, a mobility/mass identifying region or “mir”,a charge-imparting moiety and a mobility region.

[0089] The detection group and mobility modifier in the electrophoreticprobe form an “e-tag moiety” which is linked to the target-bindingmoiety by a “linking group” which may be only a covalent bond which iscleavable under selected cleaving conditions, or a chemical moiety orchain, such as a nucleotide and associated phosphodiester bond, anoligonucleotide with an internal cleavable bond, an oligopeptide, or anenzyme substrate, that contains a cleavable chemical bond. Cleavagetypically occurs as the result of binding of the probe to the target,which is followed by enzyme or catalyzed cleavage of the linking-groupbond. The linking group is variously referred to herein as “L” and “N”,depending on the nature and role of the linking group as will be definedbelow.

[0090] The linking group may or may not contribute a linking-group“residue” to the released e-tag reporter, also dependent on the natureof the linking group and the site of cleavage. For example, where thelinking group is a covalent bond, or cleavage of the linking groupoccurs immediately adjacent the “e-tag moiety”, the linking group willleave no residue, i.e., will not contribute additional mass and chargeto the released e-tag reporter. Similarly, where the linking group is achemical group or chain which is cleaved internally or immediatelyadjacent the target-binding moiety, cleavage of the linking group willleave a residual mass and, possible charge contribution to the releasede-tag reporter. In general, this contribution will be relatively small,and the same for each different released e-tag (assuming a commonlinking group within the probe set). As such, the residue will noteffect the relative electrophoretic mobilities of the released e-tagreporters, nor the ability to resolve the e-tag reporters intoelectrophoretic species that can be uniquely identified.

[0091] The following definitions are to be understood in the context ofthe above function of the various components of electrophoretic probesand e-tag reporters. In some case, structure designations based ondifferent lettering schemes are employed, and the equivalency between oramong structures with different lettering schemes will be understood bythose skilled in the art, in view of the intended function of thestructure being referred to.

[0092] An “electrophoretic probe” refers to one of a set of probes ofthe type described above having unique target-binding moieties andassociated e-tag moieties. The probes are variously expressed by thefollowing equivalent forms herein:

[0093] (a) (D, M_(j))-L-T_(j), or (D, M_(j))-N-T_(j), where D is adetection moiety, M_(j) is the jth mobility modifier, T_(j) is the jthtarget binding agent, and the linking group is represented by L and by N(when the linking group is the 5′-terminal nucleotide of anoligonucleotide target-binding moiety). In this and the followingstructural designations, (D, M_(j))- indicates that either the detectiongroup or the mobility modifier is joined to the linking group, i.e.,either (D, M_(j)) or (M_(j),D)-.

[0094] (b) (R, M_(j))-L-T_(j), or (R, M_(j))-N-T_(j), where R is adetection moiety or reporter group, and M_(j), T_(j) , and L and N areas in (a).

[0095] (c) R-L-T or L-R-T, where R is a label, particularly afluorescer, L is a mir, a bond or a linking group, where L and theregions to which L is attached provide for the variation in mobility ofthe e-tags. T comprises a portion of the target-binding region,particularly a nucleoside base, purine or pyrimidine, and is the base, anucleoside, nucleotide or nucleotide triphosphate, an amino acid, eithernaturally occurring or synthetic, or other functionality that may serveto participate in the synthesis of an oligomer, when T is retained, andis otherwise a functionality resulting from the cleavage between L, themir, and the target-binding region. (in the corresponding e-tagreporter).

[0096] A “set” or “group”, “plurality” or “library” of electrophoreticprobes refers to a plurality of electrophoretic probes having typicallyat least five, typically 10-100 or more probes with different uniquetarget-binding moieties and associated e-tag moieties.

[0097] As used herein, the term “electrophoretic tag probe set” or“e-tag probe set” refers to a set of probes for use in detecting each orany of a plurality of known, selected target nucleotide sequences, orfor detecting the binding of, or interaction between, each or any of aplurality of ligands and one or more target antiligands.

[0098] The term “target-binding moiety” or “T_(j)” refers to thecomponent of an e-tag probe that participates in recognition andspecific binding to a designated target. The target-binding moiety mayalso be referred to as T or T′, or may be defined based on the type oftarget, e.g., as a snp detection sequence or an oligonucleotidedetection sequence.

[0099] In one general embodiment of the target-binding moiety for use indetection of nucleic acid targets, T_(j) is an oligonucleotidetarget-binding moiety. In such cases, T_(j) has a sequence ofnucleotides U_(i) connected by intersubunit linkages:

U ₁ =U ₂ =U ₃ =U ₄ =U ₅ =U ₆ =U _(i)

[0100] where=corresponds to intersubunit linkages B_(1, i+1), where iincludes all integers from 1 to n, and n is sufficient to allow themoiety to hybridize specifically with a target nucleotide sequence.Where the target-binding moiety is an oligonucleotide, and enzymecleavage to release the e-tag reporter occurs between the first andsecond 5′ nucleotides (between U₁ and U₂ above), the linking group andnucleotides forming the target-binding sequence can be expressed ineither of two equivalent representations.

[0101] In one exemplary representation, U₁ is considered the 5′nucleotide of the target-binding moiety (as in the representationabove), and cleavage occurs within this moiety, that is, at anuclease-susceptible bond between the first and the second nucleotidesof the target moiety (between U₁ and U₂, above). In this representation,the bond between the first and second nucleotides (B_(1,2) in the abovenomenclature) is the site of cleavage and all downstream bonds arerepresented by B_(i, i+1), where “i” is 2 or greater. Typically thepenultimate bond is nuclease-resistant, however the target bindingmoiety may include more than one nuclease-resistant linkage adjacent tothe nuclease-susceptible linkage, such that the probe will yield asingle released e-tag reporter species upon cleavage. In thisrepresentation, a capture ligand (“C”), may be bound to the penultimatenucleotide (U₂).

[0102] In another exemplary representation, the 5′ nucleotide isdesignated “N”, and the nuclease-susceptible bond that links it to the5′ nucleotide (U₁) of the target binding moiety is considered as thelinking group. In other words, in this representation, N and alldownstream nucleotides are considered as the target binding region. Thesame oligonucleotide above would now be expressed asN=U₁=U₂=U₃=U₄=U₅=U₆=U_(i), where N is the 5′ nucleotide and participatesin target recognition. In this representation, a capture ligand (“C”),may be bound to the ultimate nucleotide (U₁).

[0103] In one application of this embodiment, the e-tag probe isreferred to as a snp detection sequence, a fluorescence snp detectionsequence or an oligonucleotide detection sequence.

[0104] In another generalized embodiment for use in detection ofnon-nucleic acid targets, the target-binding moiety, T_(j) is orincludes a ligand capable of binding to or interacting with a targetantiligand and L is a linking group connected to T_(j) by a bond that iscleavable by a selected cleaving agent when the probe is bound to orinteracting with the target antiligand. L may also be referred to as aL″, a terminal linking region, a terminal linking group.

[0105] “Electrophoretic tag” refers to a composition or reagent forunique identification of an entity of interest during separation. Ane-tag has the fundamental structure given as (D, M_(j))-L, where D andM_(j) are the detection group and jth mobility modifier, as definedabove, and L is the linking group, and in particular, the bond orresidue of the linking group remaining after cleavage. Here the e-tagmoiety (D, M_(j)) is intended to include both of the structuresD-M_(j)-L and M_(j)-D-L. Other equivalent forms of expressing the e-tagare: (R, M_(j)), (R, M), R-L or L-R where R is a reporter group, M_(j)or M is a mobility modifier and L is a mobility identifying region(mir), a bond or a linking group.

[0106] For purposes of clarity, the concept of an electrophoretic tag isconsistently referred to herein as an “e-tag”, however variousreferences to “Etag”, “ETAG”, “eTAG” and “eTag” may be made whenreferring to an electrophoretic tag. As used herein, the term“electrophoretic tag probe” or “e-tag probe” refers to a reagent usedfor target recognition, which comprises an e-tag and a target-bindingmoiety. Upon interaction with the corresponding target, the e-tagundergoes a change resulting in the release of an e-tag reporter. Suchan e-tag probe may also be referred to as a binding member.

[0107] E-tag probes of the invention find utility in performingmultiplexed for detection/analysis of targets including, but not limitedto nucleic acid detection, such as sequence recognition, snp detection,transcription analysis or mrna determination, allelic determination,mutation determination, hla typing or mhc determination and haplotypedetermination, in addition to detection of other ligands, such asproteins, polysaccharides, etc.

[0108] As used herein, the term “e-tag reporter” refers to the cleavageproduct generated as a result of the interaction between an e-tag probeand its target. In one representation, an e-tag reporter comprises thee-tag plus a residual portion of the target binding moiety (T_(j))(where, as in the nucleotide example, above, one or more nucleotides inthe target-binding moiety contain the cleavable linking group), or aresidual portion of the linking group (when the latter is consideredseparate from the target-binding moiety). In another embodiment, thee-tag does not retain any of the target binding moiety. E-tag reporterscan be differentiated by electrophoretic mobility or mass and areamenable to electrophoretic separation and detection, although othermethods of differentiating the tags may also find use. An e-tag reporterresulting from the interaction of an e-tag probe and a nucleic acidtarget typically has the form (D, M_(j))-N, where N is as defined above,the 5′-end terminal nucleotide of a target-binding oligonucleotide.

[0109] An e-tag reporter resulting from the interaction of an e-tagprobe used to detect the binding of or interaction between a ligand andan antiligand typically has the form (D, M_(j))-L′.

[0110] D and M_(j) are defined above and L′ is the residue of L thatremains attached to (D, M_(j)) after an e-tag reporter is cleaved fromthe corresponding e-tag probe.

[0111] e-tag reporters may also be described as electrophoretic tags oreTags for use in electrophoresis, released eTags, released e-tags, etc.The e-tag for use in electrophoresis may also be represented by theformula: R-L-T, as described above, where T is retained, and isotherwise a functionality resulting from the cleavage between L, themir, and the target-binding region.

[0112] As used herein, the term “binding event” generally refers to thebinding of the target binding moiety of an e-tag probe to its target. Byway of example, such binding may involve the interaction betweencomplementary nucleotide sequences or the binding between a ligand andtarget antiligand.

[0113] As used herein, the term “capture ligand”, refers to a group thatis typically included within the target binding moiety or portion of ane-tag probe and is capable of binding specifically to a “capture agent”or receptor. The interaction between such a capture ligand and thecorresponding capture agent may be used to separate uncleaved e-tagprobes from released e-tag reporters.

[0114] II. Compositions of the Invention

[0115] The subject invention provides compositions and methods forimproved analysis of complex mixtures, where one is interested in thesimultaneous identification of a plurality of entities, such as nucleicacid or amino acid sequences, snps, alleles, mutations, proteins,haptens, protein family members, expression products, etc., analysis ofthe response of a plurality of entities to an agent that can affect themobility of the entities, and the like. Libraries of differentiablecompounds are provided, where the compounds comprise amobility-identifying region (including mass-identifying region) (“mir”),that provides for ready identification by electrophoresis or massspectrometry (differentiation by mobility in an electrical field ormagnetic field), by itself or in conjunction with a detectable label.Depending on the determination the product may also include one or morenucleotides or their equivalent, one or more amino acids or theirequivalent, a functionality resulting from the release of thetarget-binding region or a modified functionality as a result of theaction of an agent on the target-binding region. Themobility-identifying region or mir may be designated as a mobilitymodifier given that it provides for ready identification byelectrophoresis, by itself or in conjunction with a detectable label.

[0116] The methodology involves employing detectable tags that can bedifferentiated by electrophoretic mobility or mass. The tags comprisemobility-identifying regions joined to a moiety that will undergo achange to produce a product. Depending on the nature of the change, thechange may involve a change in mass and/or charge of the mir, therelease of the mir from all or a portion of the target-binding region ormay provide for the ability to sequester the mir from the startingmaterial for preferential release of the mir. The differentiable tags,whether identified by electrophoresis or mass spectrometry, comprisingthe mir, with or without the detectable label and a portion of thetarget-binding region will be referred to as “e-tags.”

[0117] Such differentiable e-tags, comprising the e-tag with or withouta portion of the target-binding region for use in detection may beconveniently referred to as “e-tag reporters”. The e-tag reporters aregenerated as the result of the interaction between an e-tag probe (whichcomprises an e-tag joined to a target-binding region) and acorresponding target.

[0118] In addition, the subject invention employs a variety of reagentsystems, where a binding event results in a change in mobility of thee-tag. The binding event is between a target-binding region and atarget, and the reagent system recognizes this event and changes thenature of the e-tag containing target-binding region, so that themobility and/or mass of the product is different from the startingmaterial. The reagent system will frequently involve an enzyme and thereagent system may comprise the target. The effect of the reagent systemis to make or break a bond by physical, chemical or enzymatic means.Each of the products of the different e-tag containing target-bindingregions can be accurately detected, so as to determine the occurrence ofthe binding event. Following the binding event, one or more reactionproducts are produced that exhibit mobilities different from the e-tagprobe or probes from which the reaction products derive. The releasedform of the eag or the eag reporter exhibits a different mobility and/ormass than the e-tag from which it derives.

[0119] The subject invention may be used for a variety of multiplexedanalyses involving the action of one or more agents on a plurality ofreagents comprising the mir and a target-binding region that undergoes achange as a result of a chemical reaction, resulting in a change inmobility of the product as compared to the starting material. Thereaction may be the result of addition or deletion in relation to thetarget-binding region, so that the resulting product may be sequesteredfrom the starting material. The subject systems find use in nucleic acidand protein analyses, reactions, particularly enzyme reactions, whereone or more enzymes are acting on a group of different potential oractual substrates, and the like.

[0120] A system is provided for the simultaneous multiplexeddetermination of a plurality of events employing electrophoresis todistinguish the events, comprising an electrophoretic device forelectrophoretic separation and detection, a container containing a firstset of first agents, referred to as “e-tags,” comprising differingmobility regions and a second reagent composition comprising at leastone active second agent, under conditions where said second agentmodifies at least one member of said first agent set resulting in achange of electrophoretic mobility of said at least one member toprovide a modified member retaining said mobility region, and transferof said at least one modified member to said electrophoretic device forseparation and detection of said at least one modified member. Theelectrophoretic device may be connected to a data processor forreceiving and processing data from the device, as well as operating theelectrophoretic device.

[0121] The first set of first agents are considered to be “e-tagprobes,” and the modified members that retain the mobility region ormobility modifying region and are subjected to analysis are referred toas “e-tag reporters”. In general, the e-tag probes comprise a mobilitymodifying region that is joined to a target binding region by a linker,which may include or be a reactive functionality, a cleavable linkage, abond which may or may not be releasable or a group for joining to one ormore of the other regions.

[0122] The systems are based on having libraries available comprising aplurality of e-tags that comprise at least a plurality of differentmobility-identifying regions, so as to be separable by electrophoresiswith the entities to which the mobility-identifying regions areattached. The mobility-identifying regions are retained in the productof the reaction, where the product is modified by the gain and/or lossof a group that changes the mass and may also change the charge of theproduct, as compared to the starting material. In some instances, themobility-identifying region may be joined to a target-binding region bya cleavable bond, so that the mobility-identifying region is releasedfor analysis subsequent to the modification of the target-bindingregion, e.g. complex formation.

[0123] In one aspect, the subject assays are predicated on having areagent that has a high affinity for a reciprocal binding member, theanalyte. Usually, the binding affinity will be at least about 10⁻⁷M⁻¹,more usually, at least about 10⁻⁸M⁻¹. For the most part, the reagentswill be receptors, which includes antibodies, IgA, IgD, IgG, IgE and IgMand subtypes thereof, enzymes, lectins, nucleic acids, nucleic acidbinding proteins, or any other molecule that provides the desiredspecificity for the analyte in the assay. The antibodies may bepolyclonal or monoclonal or mixtures of monoclonal antibodies dependingon the nature of the target composition and the targets. The targets oranalytes may be any molecule, such as small organic molecules of fromabout 100 to 2500 Da, poly(amino acids) including peptides of from about3 to 100 amino acids and proteins of from about 100 to 50,000 or moreamino acids, saccharides, lipids, nucleic acids, etc., where theanalytes may be part of a larger assemblage, such as a cell, microsome,organelle, virus, protein complex, chromosome or fragment thereof,nucleosome, etc.

[0124] A. Electrophoretic Tags

[0125] An e-tag will be a molecule, which is labeled with a directlydetectable label or can be made so by functionalization. Theelectrophoretic tags will be differentiated by their electrophoreticmobility, usually their mass/charge ratio, to provide differentmobilities for each electrophoretic tag. Although in some instances theelectrophoretic tags may have identical mass/charge ratios, such asoligonucleotides but differ in size or shape and therefore exhibitdifferent electrophoretic mobilities under appropriate conditions.Therefore, the tags will be amenable to electrophoretic separation anddetection, although other methods of differentiating the tags may alsofind use. The e-tag may be joined to any convenient site on the targetbinding reagent, without interfering with the synthesis, release andbinding of the e-tag labeled reagent. For nucleotides, the e-tag may bebound to a site on the base, either an annular carbon atom or a hydroxylor amino substituent.

[0126] In mass spectrometry, the E-TAGs may be different from the E-TAGsused in electrophoresis, since the E-TAGs do not require a label, nor acharge. Thus, these E-TAGs may be differentiated solely by mass, whichcan be a result of atoms of different elements, isotopes of suchelements, and numbers of such atoms.

[0127] Electrophoretic tags are small molecules (molecular weight of 150to 10,000), usually other than oligonucleotides, which can be used inany measurement technique that permits identification by mass, e.g. massspectrometry, and or mass/charge ratio, as in mobility inelectrophoresis. Simple variations in mass and/or mobility of theelectrophoretic tag leads to generation of a library of electrophoretictags, that can then be used to detect multiple snp's or multiple targetsequences. The electrophoretic tags are easily and rapidly separated infree solution without the need for a polymeric separation media.Quantitation is achieved using internal controls. Enhanced separation ofthe electrophoretic tags in electrophoresis is achieved by modifying thetags with positively charged moieties.

[0128] The e-tags are a group of reagents having a mir that with theother regions to which the mir is attached during separation provide forunique identification of an entity of interest. The mir of the e-tagscan vary from a bond to about 100 atoms in a chain, usually not morethan about 60 atoms, more usually not more than about 30 atoms, wherethe atoms are carbon, oxygen, nitrogen, phosphorous, boron and sulfur.Generally, when other than a bond, the mir will have from 0 to 40, moreusually from 0 to 30 heteroatoms, which in addition to the heteroatomsindicated above will include halogen or other heteroatom. The totalnumber of atoms other than hydrogen will generally be fewer than 200atoms, usually fewer than 100 atoms. Where acid groups are present,depending upon the pH of the medium in which the mir is present, variouscations may be associated with the acid group. The acids may be organicor inorganic, including carboxyl, thionocarboxyl, thiocarboxyl,hydroxamic, phosphate, phosphite, phosphonate, sulfonate, sulfinate,boronic, nitric, nitrous, etc. For positive charges, substituents willinclude amino (includes ammonium), phosphonium, sulfonium, oxonium,etc., where substituents will generally be aliphatic of from about 1-6carbon atoms, the total number of carbon atoms per heteroatom, usuallybe less than about 12, usually less than about 9. The mir may be neutralor charged depending on the other regions to which the mir is attached,at least one of the regions having at least one charge. Neutral mirswill generally be polymethylene, halo- or polyhaloalkylene or aralkylene(a combination of aromatic-includes heterocyclcic—and aliphatic groups),where halogen will generally be fluorine, chlorine, bromine or iodine,polyethers, particularly, polyoxyalkylene, wherein alkyl is of from 2-3carbon atoms, polyesters, e.g. polyglycolide and polylactide,dendrimers, comprising ethers or thioethers, oligomers of addition andcondensation monomers, e.g. acrylates, diacids and diols, etc. The sidechains include amines, ammonium salts, hydroxyl groups, includingphenolic groups, carboxyl groups, esters, amides, phosphates,heterocycles, particularly nitrogen heterocycles, such as the nucleosidebases and the amino acid side chains, such as imidazole and quinoline,thioethers, thiols, or other groups of interest to change the mobilityof the e-tag. The mir may be a homooligomer or a heterooligomer, havingdifferent monomers of the same or different chemical characteristics,e.g., nucleotides and amino acids. Desirably neutral massdifferentiating groups will be combined with short charged sequences toprovide the mir.

[0129] The charged mirs will generally have only negative or positivecharges, although, one may have a combination of charges, particularlywhere a region to which the mir is attached is charged and the mir hasthe opposite charge. The mirs may have a single monomer that providesthe different functionalities for oligomerization and carry a charge ortwo monomers may be employed, generally two monomers. One may usesubstituted diols, where the substituents are charged and dibasic acids.Illustrative of such oligomers are the combination of diols or diamino,such as 2,3-dihydroxypropionic acid, 2,3-dihydroxysuccinic acid,2,3-diaminosuccinic acid, 2,4-dihydroxyglutaric acid, etc. The diols ordiamino compounds can be linked by dibasic acids, which dibasic acidsinclude the inorganic dibasic acids indicated above, as well as dibasicacids, such as oxalic acid, malonic acid, succinic acid, maleic acid,furmaric acid, carbonic acid, etc. Instead of using esters, one may useamides, where amino acids or diamines and diacids may be employed.Alternatively, one may link the hydroxyls or amines with alkylene orarylene groups.

[0130] By employing monomers that have substituents that provide forcharges or which may be modified to provide charges, one can provide formirs having the desired mass/charge ratio. For example, by using serineor threonine, one may modify the hydroxyl groups with phosphate toprovide negatively charged mirs. With arginine, lysine and histidine,one provides for positively charged mirs. Oligomerization may beperformed in conventional ways to provide the appropriately sized mir.The different mirs having different orders of oligomers, generallyhaving from 1 to 20 monomeric units, more usually about 1 to 12, where aunit intends a repetitive unit that may have from 1 to 2 differentmonomers. For the most part, oligomers will be used with other thannucleic acid target-binding regions. The polyfunctionality of themonomeric units provides for functionalities at the termini that may beused for conjugation to other moieties, so that one may use theavailable functionality for reaction to provide a differentfunctionality. For example, one may react a carboxyl group with anaminoethylthiol, to replace the carboxyl group with a thiolfunctionality for reaction with an activated olefin.

[0131] By using monomers that have 1-3 charges, one may employ a lownumber of monomers and provide for mobility variation with changes inmolecular weight. Of particular interest are polyolpolycarboxylic acidshaving from about two to four of each functionality, such as tartaricacid, 2,3-dihydroxyterephthalic acid, 3,4-dihydroxyphthalic acid,Δ⁵-tetrahydro-3,4-dihydroxyphthalic acid, etc. To provide for anadditional negative charge, these monomers may be oligomerized with adibasic acid, such as a phosphoric acid derivative to form the phosphatediester. Alternatively, the carboxylic acids could be used with adiamine to form a polyamide, while the hydroxyl groups could be used toform esters, such as phosphate esters, or ethers such as the ether ofglycolic acid, etc. To vary the mobility, various aliphatic groups ofdiffering molecular weight may be employed, such as polymethylenes,polyoxyalkylenes, polyhaloaliphatic or -aromatic groups, polyols, e.g.sugars, where the mobility will differ by at least about 0.01, moreusually at least about 0.02 and more usually at least about 0.5.Alternatively, the libraries may include oligopeptides for providing thecharge, particularly oligopeptides of from 2-6, usually 2-4 monomers,either positive charges resulting from lysine, arginine and histidine ornegative charges, resulting from aspartic and glutamic acid. Of course,one need not use naturally occurring amino acids, but unnatural orsynthetic amino acids, such as taurine, phosphate substituted serine orthreonine, S-α-succinylcysteine, co-oligomers of diamines and aminoacids, etc.

[0132] Where the e-tags are used for mass detection, as with massspectrometry, the e-tags need not be charged but merely differ in mass,since a charge will be imparted to the e-tag reporter by the massspectrometer. Thus, one could use the same or similar monomers, wherethe functionalities would be neutral or made neutral, such as esters andamides of carboxylic acids. Also, one may vary the e-tags by isotopicsubstitution, such as ²H, ¹⁸O, ¹⁴C, etc.

[0133] The e-tag may be linked by a stable bond or one, which may becleavable, thermally, photolytically or chemically. There is an interestin cleaving the e-tag from the target-binding region in situations wherecleavage of the target-binding region results in significant cleavage atother than the desired site of cleavage, resulting in satellite cleavageproducts, such as di- and higher oligonucleotides and this family ofproducts interferes with the separation and detection of the e-tags.However, rather than requiring an additional step in the identificationof the tags by releasing them from the base to which they are attached,one can modify the target binding sequence to minimize obtainingcleavage at other than the desired bond, for example, the ultimate orpenultimate phosphate link in a nucleic acid sequence. For immunoassaysinvolving specific binding members, bonding of the e-tag will usually bethrough a cleavable bond to a convenient functionality, such as carboxy,hydroxy, amino or thiol, particularly as associated with proteins,lipids and saccharides.

[0134] If present, the nature of the releasable or cleavable link may bevaried widely. Numerous linkages are available, which are thermally,photolytically or chemically labile. See, for example, U.S. Pat. No.5,721,099. Where detachment of the product from all or a portion of thetarget-binding region is desired, there are numerous functionalities andreactants, which may be used. Conveniently, ethers may be used, wheresubstituted benzyl ether or derivatives thereof, e.g. benzhydryl ether,indanyl ether, etc. may be cleaved by acidic or mild reductiveconditions. Alternatively, one may employ beta-elimination, where a mildbase may serve to release the product. Acetals, including the thioanalogs thereof, may be employed, where mild acid, particularly in thepresence of a capturing carbonyl compound, may serve. By combiningformaldehyde, HCl and an alcohol moiety, an α-chloroether is formed.This may then be coupled with an hydroxy functionality to form theacetal. Various photolabile linkages may be employed, such aso-nitrobenzyl, 7-nitroindanyl, 2-nitrobenzhydryl ethers or esters, etc.

[0135] For a list of cleavable linkages, see, for example, Greene andWuts, Protective Groups in Organic Synthesis, 2^(nd) ed. Wiley, 1991.The versatility of the various systems that have been developed allowsfor broad variation in the conditions for attachment of the e-tagentities.

[0136] Various functionalities for cleavage are illustrated by: silylgroups being cleaved with fluoride, oxidation, acid, bromine orchlorine; o-nitrobenzyl with light; catechols with cerium salts; olefinswith ozone, permanganate or osmium tetroxide; sulfides with singletoxygen or enzyme catalyzed oxidative cleavage with hydrogen peroxide,where the resulting sulfone can undergo elimination; furans with oxygenor bromine in methanol; tertiary alcohols with acid; ketals and acetalswith acid; α- and β-substituted ethers and esters with base, where thesubstituent is an electron withdrawing group, e.g., sulfone, sulfoxide,ketone, etc., and the like.

[0137] In one embodiment, the electrophoretic tags will have a linker,which provides the linkage between the base and the detectable labelmolecule, usually a fluorescer, or a functionality which may be used forlinking to a detectable label molecule. By having differentfunctionalities, which may be individually bonded to a detectable labelmolecule, one enhances the opportunity for diversity of theelectrophoretic tags. Using different fluorescers for joining to thedifferent functionalities, the different fluorescers can providedifferences in light emission and mass/charge ratios for theelectrophoretic tags.

[0138] For the most part, the linker may be a bond, where the label isdirectly bonded to the nucleoside, or a link of from 1 to 500 or more,usually 1 to 300 atoms, more usually 2 to 100 atoms in the chain. Thetotal number of atoms in the chain will depend to a substantial degreeon the diversity required to recognize all the snp's to be determined.The chain of the linker for the most part will be comprised of carbon,nitrogen, oxygen, phosphorous, boron, and sulfur. Various substituentsmay be present on the linker, which may be naturally present as part ofthe naturally occurring monomer or introduced by synthesis.Functionalities which may be present in the chain include amides,phosphate esters, ethers, esters, thioethers, disulfides, borate esters,sulfate esters, etc. The side chains include amines, ammonium salts,hydroxyl groups, including phenolic groups, carboxyl groups, esters,amides, phosphates, heterocycles, particularly nitrogen heterocycles,such as the nucleoside bases and the amino acid side chains, such asimidazole and quinoline, thioethers, thiols, or other groups of interestto change the mobility of the electrophoretic tag. The linker may be ahomooligomer or a heterooligomer, having different monomers of the sameor different chemical characteristics, e.g., nucleotides and aminoacids.

[0139] The linker or mir may be joined in any convenient manner to aunit of the target-binding region, such as the base of the nucleoside orthe amino acid of a protein. Various functionalities which may be usedinclude alkylamine, amidine, thioamide, ether, urea, thiourea,guanidine, azo, thioether and carboxylate, sulfonate, and phosphateesters, amides and thioesters.

[0140] The linkers may be oligomers, where the monomers may differ as tomass and charge. For convenience and economy, monomers will generally becommercially available, but if desired, they may be originallysynthesized. Monomers which are commercially available and readily lendthemselves to oligomerization include amino acids, both natural andsynthetic, nucleotides, both natural and synthetic, and monosaccharides,both natural and synthetic, while other monomers include hydroxyacids,where the acids may be organic or inorganic, e.g. carboxylic,phosphoric, boric, sulfonic, etc., and amino acids, where the acid isinorganic, and the like. In some instances, nucleotides, natural orsynthetic, may find use. The monomers may be neutral, negatively chargedor positively charged. Normally, the charges of the monomers in thelinkers will be the same, so that in referring to the mass/charge ratio,it will be related to the same charge. Where the label has a differentcharge from the linker or mir, this will be treated as if the number ofcharges are reduced by the number of charges on the linker or mir. Fornatural amino acids, the positive charges may be obtained from lysine,arginine and histidine, while the negative charges may be obtained fromaspartic and glutamic acid. For nucleotides, the charges will beobtained from the phosphate and any substituents that may be present orintroduced onto the base. For sugars sialic acid, uronic acids of thevarious sugars, or substituted sugars may be employed.

[0141] It will be understood that the mir or mobility/mass identifyingregion, also referred to herein as “L”, M*, C*, the mobility identifyingregion, the mobility region, the mobility modifying region, the mobilitymodifier or M_(j) is the component of an e-tag or e-tag reporter whichhas a known charge/mass ratio and imparts a known and uniqueelectrophoretic mobility to an e-tag reporter comprising the mir ormobility modifier.

[0142] The linker L may include charged groups, uncharged polar groupsor be non-polar. The groups may be alkylene and substituted alkylenes,oxyalkylene and polyoxyalkylene, particularly alkylene of from 2 to 3carbon atoms, arylenes and substituted arylenes, polyamides, polyethers,polyalkylene amines, etc. Substituents may include heteroatoms, such ashalo, phosphorous, nitrogen, oxygen, sulfur, etc., where the substituentmay be halo, nitro, cyano, non-oxo-carbonyl, e.g. ester, acid and amide,oxo-carbonyl, e.g. aldehyde and keto, amidine, urea, urethane,guanidine, carbamyl, amino and substituted amino, particularly alkylsubstituted amino, azo, oxy, e.g. hydroxyl and ether, etc., where thesubstituents will generally be of from about 0 to 10 carbon atoms, whileL will generally be of from about 1 to 100 carbon atoms, more usually offrom about 1 to 60 carbon atoms and preferably about 1 to 36 carbonatoms. L will be joined to the label and the target-binding region byany convenient functionality, such as carboxy, amino, oxy, phospho,thio, iminoether, etc., where in many cases the label and thetarget-binding region will have a convenient functionality for linkage.

[0143] The number of heteroatoms in L is sufficient to impart thedesired charge to the label conjugate, usually from about 1 to about200, more usually from about 2 to 100, heteroatoms. The heteroatoms in Lmay be substituted with atoms other than hydrogen.

[0144] The charge-imparting moieties of L may be, for example, aminoacids, tetraalkylammonium, phosphonium, phosphate diesters, carboxylicacids, thioacids, sulfonic acids, sulfate groups, phosphate monoesters,and the like and combinations of one or more of the above. The number ofthe above components of L is such as to achieve the desired number ofdifferent charge-imparting moieties. The amino acids may be, forexample, lysine, aspartic acid, alanine, gamma-aminobutyric acid,glycine, β-alanine, cysteine, glutamic acid, homocysteine, β-alanine andthe like. The phosphate diesters include, for example, dimethylphosphate diester, ethylene glycol linked phosphate diester, and soforth. The thioacids include, by way of example, thioacetic acid,thiopropionic acid, thiobutyric acid and so forth. The carboxylic acidspreferably have from 1 to 30 carbon atoms, more preferably, from 2 to 15carbon atoms and preferably comprise one or more heteroatoms and may be,for example, acetic acid derivatives, formic acid derivatives, succinicacid derivatives, citric acid derivatives, phytic acid derivatives andthe like.

[0145] Of particular interest for L is to have two sub-regions, a commoncharged sub-region, which will be common to a group of e-tags, and avarying uncharged, a non-polar or polar sub-region, that will vary themass/charge ratio. This permits ease of synthesis, provides forrelatively common chemical and physical properties and permits ease ofhandling. For negative charges, one may use dibasic acids that aresubstituted with functionalities that permit low orders ofoligomerization, such as hydroxy and amino, where amino will usually bepresent as neutral amide. These charge-imparting groups provide aqueoussolubility and allow for various levels of hydrophobicity in the othersub-region. Thus the uncharged sub-region could employ substituteddihydroxybenzenes, diaminobenzenes, or aminophenols, with one or greaternumber of aromatic rings, fused or non-fused, where substituents may behalo, nitro, cyano, alkyl, etc., allowing for great variation inmolecular weight by using a common building block. Where the otherregions of the e-tag impart charge to the e-tag, L may be neutral.

[0146] In one preferred embodiment of the present invention, thecharge-imparting moiety is conveniently composed primarily of aminoacids but also may include thioacids and other carboxylic acids havingfrom one to five carbon atoms. The charge imparting moiety may have from1 to 30, preferably 1 to 20, more preferably, 1 to 10 amino acids permoiety and may also comprise 1 to 3 thioacids or other carboxylic acids.However, when used with an uncharged sub-region, the charged sub-regionwill generally have from 1-4, frequently 1-3 amino acids. As mentionedabove, any amino acid, both naturally occurring and synthetic, may beemployed.

[0147] The e-tag for use in electrophoresis may be represented by theformula:

R-L-T

[0148] wherein R is a label, particularly a fluorescer, L is a mir, abond or a linking group where L and the regions to which L is attachedprovide for the variation in mobility of the e-tags. T comprises aportion of the target-binding region, particularly a nucleoside base,purine or pyrimidine, and is the base, a nucleoside, nucleotide ornucleotide triphosphate, an amino acid, either naturally occurring orsynthetic, or other functionality that may serve to participate in thesynthesis of an oligomer, when T is retained, and is otherwise afunctionality resulting from the cleavage between L, the mir, and thetarget-binding region. L provides a major factor in the differences inmobility between the different e-tags, in combination with the label andany residual entity, which remain with the mir. L may or may not includea cleavable linker, depending upon whether the terminal entity to whichL is attached is to be retained or completely removed.

[0149] In one representation of the invention, L has been substantiallydescribed as the mir and as indicated previously may include chargedgroups, uncharged polar groups or be non-polar. The groups may bealkylene and substituted alkylenes, oxyalkylene and polyoxyalkylene,particularly alkylene of from 2 to 3 carbon atoms, arylenes andsubstituted arylenes, polyamides, polyethers, polyalkylene amines, etc.Substituents may include heteroatoms, such as halo, phosphorous,nitrogen, oxygen, sulfur, etc., where the substituent may be halo,nitro, cyano, non-oxo-carbonyl, e.g. ester, acid and amide,oxo-carbonyl, e.g. aldehyde and keto, amidine, urea, urethane,guanidine, carbamyl, amino and substituted amino, particularly alkylsubstituted amino, azo, oxy, e.g. hydroxyl and ether, etc., where thesubstituents will generally be of from about 0 to 10 carbon atoms, whileL will generally be of from about 1 to 100 carbon atoms, more usually offrom about 1 to 60 carbon atoms and preferably about 1 to 36 carbonatoms. L will be joined to the label and the target-binding region byany convenient functionality, such as carboxy, amino, oxy, phospo, thio,iminoether, etc., where in many cases the label and the target-bindingregion will have a convenient functionality for linkage.

[0150] The number of heteroatoms in L is sufficient to impart thedesired charge to the label conjugate, usually from about 1 to about200, more usually from about 2 to 100, heteroatoms. The heteroatoms in Lmay be substituted with atoms other than hydrogen.

[0151] In one embodiment of the present invention the label conjugateshaving different charge to mass ratios may comprise fluorescentcompounds, each of which are linked to molecules that impart a charge tothe fluorescent compound conjugate. As indicated previously, desirablythe linking group has an overall negative charge, preferably having inthe case of a plurality of groups, groups of the same charge, where thetotal charge may be reduced by having one or more oppositely chargedmoiety.

[0152] Of particular interest for L is to have two sub-regions, a commoncharged sub-region, which will be common to a group of e-tags, and avarying uncharged, a non-polar or polar sub-region, that will vary themass/charge ratio. This permits ease of synthesis, provides forrelatively common chemical and physical properties and permits ease ofhandling. For negative charges, one may use dibasic acids that aresubstituted with functionalities that permit low orders ofoligomerization, such as hydroxy and amino, where amino will usually bepresent as neutral amide. These charge imparting groups provide aqueoussolubility and allow for various levels of hydrophobicity in the othersub-region. Thus the uncharged sub-region could employ substituteddihydroxybenzenes, diaminobenzenes, or aminophenols, with one or greaternumber of aromatic rings, fused or non-fused, where substituents may behalo, nitro, cyano, alkyl, etc., allowing for great variation inmolecular weight by using a common building block. Where the otherregions of the e-tag impart charge to the e-tag, L may be neutral.

[0153] In some instances, where release of the e-tag results in anavailable functionality that can be used to react with a detectablelabel, there will be no need for R to be a functionality.

[0154] The release of the e-tag can provide an hydroxyl, amino, carboxyor thiol group, where each may serve as the site for conjugation to thedetectable label. To the extent that the e-tag is released free of acomponent of the target-binding region, this opportunity will bepresent. In that case, R is the unreactive (under the conditions of theconjugation) terminus of L and T is a functionality for release of thee-tag that may be joined to all or a portion of the target-bindingregion or may be available for binding to all or a portion of thetarget-binding region.

[0155] Conjugates of particular interest comprise a fluorescent compoundand a different amino acid or combinations thereof in the form of apeptide or combinations of amino acids and thioacids or other carboxylicacids. Such compounds are represented by the formula:

R′-L′-T′

[0156] wherein R′ is a fluorescer, L′ is an amino acid or a peptide orcombinations of amino acids and thioacids or other carboxylic acids andT′ is a functionality for linking to a nucleoside base or is anucleoside, nucleotide or nucleotide triphosphate.

[0157] In a particular embodiment the label conjugates may berepresented by the formula:

Fluorescer-L″-(amino acid)_(n)-T″

[0158] wherein L″ is a bond or a linking group of from 1 to 20 atomsother than hydrogen, n is 1 to 20, and T″ comprises a nucleoside base,purine or pyrimidine, including a base, a nucleoside, a nucleotide ornucleotide triphosphates, an amino acid, or functionality for linking tothe target-binding region. An example of label conjugates in thisembodiment, by way of illustration and not limitation, is one in whichthe fluorescer is fluorescein, L″ is a bond in the form of an amidelinkage involving the meta-carboxyl of the fluorescein and the terminalamine group of lysine, and T″ is a nucleotide triphosphate. These labelconjugates may be represented as follows:

Fluorescein-(CO)NH—CH(CH₂)₃CH(NH₂)(amino acid)_(n)COX″

[0159] wherein X is as set forth in Table 1. TABLE 1 No. X Charge  1 OH−2  2 NH-lysine −1  3 NH-(lysine)₂ neutral  4 NH-alanine −3  5NH-aspartic acid −4  6 NH-(aspartic acid)₂ −5  7 NH-(aspartic acid)₃ −6 8 NH-(aspartic acid)₄ −7  9 NH-(aspartic acid)₅ −8 10 NH-(asparticacid)₆ −9 11 NH-(aspartic acid)₇ −10 12 NH-alanine-lysine −2 (uniqueq/M) 13 NH-aspartic acid-lysine −3 (unique q/M) 14 NH-(asparticacid)₂-lysine −4 (unique q/M) 15 NH-(aspartic acid)₃-lysine −5 (uniqueq/M) 16 NH-(aspartic acid)₄-lysine −6 (unique q/M) 17 NH-(asparticacid)₅-lysine −7 (unique q/M) 18 NH-(aspartic acid)₆-lysine −8 (uniqueq/M) 19 NH-(aspartic acid)₇-lysine −9 (unique q/M) 20 NH-(asparticacid)₈-lysine −10 (unique q/M) 21 NH-(lysine)4 + 22 NH-(lysine)5 +2

[0160] TABLE 2 Various Characteristics For The Label Conjugates No.Mass(M) Charge(q) M^(2/3) q/M^(2/3) Mobility  1 744.82  0 82.16765 0 0 2 877.02  0 91.62336 0 0  3 828.71 −1 88.22704 −0.01133 −0.16546  4970.71 −1 98.03767 −0.0102  −0.1489   5 700.82 −2 78.89891 −0.02535−0.37004  6 842.83 −2 89.22639 −0.2241  −0.32721  7 815.92 −3 87.31692−0.03436 −0.50155  8 957.92 −3 97.17461 −0.03087 −0.45067  9 931.02 −495.34677 −0.04195 −0.61242 10 1073.02 −4 104.8106 −0.03816 −0.55712 111046 −5 103.0436 −0.04852 −0.70834 12 1188 −5 112.1702 −0.04458 −0.6507113 1161 −6 110.4642 −0.05432 −0.79291 14 1303 −6 119.297 −0.05029−0.7342  15 1276 −7 117.6433 −0.0595  −0.86861 16 1418 −7 126.2169−0.05546 −0.80961 17 1391 −8 124.6096 −0.0642  −0.9372  18 1533 −8132.952 −0.06017 −0.87839 19 1506 −9 131.3863 −0.0685  −0.99997 20 1648−9 139.6205 −0.06451 −0.94167 21 793.52  1 85.7114  0.011667  0.17031622 935.52  1 95.65376  0.010454  0.152613

[0161] Another group of e-tags has a mir which is dependent on using analkylene or aralkylene (comprising a divalent aliphatic group having 1-2aliphatic regions and 1-2 aromatic regions, generally benzene), wherethe groups may be substituted or unsubstituted, usually unsubstituted,of from 2-16, more usually 2-12, carbon atoms, where the mir may linkthe same or different fluorescers to a monomeric unit, e.g. anucleotide. The mir may terminate in a carboxy, hydroxy or amino group,being present as an ester or amide. By varying the substituents on thefluorophor, one can vary the mass in units of at least 5 or more,usually at least about 9, so as to be able to obtain satisfactoryseparation in capillary electrophoresis. To provide further variation, athiosuccinimide group may be employed to join alkylene or aralkylenegroups at the nitrogen and sulfur, so that the total number of carbonatoms may be in the range of about 2-30, more usually 2-20. Instead ofor in combination with the above groups and to add hydrophilicity, onemay use alkyleneoxy groups.

[0162] Besides the nature of the mir, as already indicated, diversitycan be achieved by the chemical and optical characteristics of thelabel, the use of energy transfer complexes, variation in the chemicalnature of the mir, which affects mobility, such as folding, interactionwith the solvent and ions in the solvent, and the like. In oneembodiment of the invention, the mir will usually be an oligomer, wherethe mir may be synthesized on a support or produced by cloning orexpression in an appropriate host. Conveniently, polypeptides can beproduced where there is only one cysteine or serine/threonine/tyrosine,aspartic/glutamic acid, or lysine/arginine/histidine, other than an endgroup, so that there is a unique functionality, which may bedifferentially functionalized. By using protective groups, one candistinguish a side chain functionality from a terminal amino acidfunctionality. Also, by appropriate design, one may provide forpreferential reaction between the same functionalities present atdifferent sites on the mir. Whether one uses synthesis or cloning forpreparation of oligopeptides, will to a substantial degree depend on thelength of the mir.

[0163] Substituted aryl groups can serve as both mass- andcharge-modifying regions (FIG. 2). Various functionalities may besubstituted onto the aromatic group, e.g. phenyl, to provide mass aswell as charges to the e-tag reporter. The aryl group may be a terminalgroup, where only one linking functionality is required, so that a freehydroxyl group may be acylated, may be attached as a side chain to anhydroxyl present on the e-tag reporter chain, or may have twofunctionalities, e.g. phenolic hydroxyls, that may serve for phophiteester formation and other substituents, such as halo, haloalkyl, nitro,cyano, alkoxycarbonyl, alkylthio, etc. where the groups may be chargedor uncharged.

[0164] The label conjugates may be prepared utilizing conjugatingtechniques that are well known in the art. The charge-imparting moiety Lmay be synthesized from smaller molecules that have functional groupsthat provide for linking of the molecules to one another, usually in alinear chain. Such functional groups include carboxylic acids, amines,and hydroxy- or thiol-groups. In accordance with the present inventionthe charge-imparting moiety may have one or more side groups pendingfrom the core chain. The side groups have a functionality to provide forlinking to a label or to another molecule of the charge-impartingmoiety.

[0165] Common functionalities resulting from the reaction of thefunctional groups employed are exemplified by forming a covalent bondbetween the molecules to be conjugated. Such functionalities aredisulfide, amide, thioamide, dithiol, ether, urea, thiourea, guanidine,azo, thioether, carboxylate and esters and amides containing sulfur andphosphorus such as, e.g. sulfonate, phosphate esters, sulfonamides,thioesters, etc., and the like.

[0166] The electrophoretic tags comprise a linker, which provides thelinkage between the base and the fluorescent molecule or a functionalitywhich may be used for linking to a fluorescent molecule. By havingdifferent functionalities that may be individually bonded to adetectable label, one enhances the opportunity for diversity of thee-tags. Using different fluorescers for joining to the differentfunctionalities, the different fluorescers can provide differences inlight emission and mass/charge ratios for the e-tags.

[0167] B. Electrophoretic Tags For Use in Electrophoresis

[0168] The electrophoretic tag, which is detected, will comprise themir, generally a label, and optionally a portion of the target-bindingregion, all of the target-binding region when the target is an enzymeand the target-binding region is the substrate. Generally, theelectrophoretic tag will have a charge/mass ratio in the range of about−0.0001 to 0. 1, usually in the range of about −0.001 to about 0.5.Mobility is q/M^(⅔), where q is the charge on the molecule and M is themass of the molecule. Desirably, the difference in mobility under theconditions of the determination between the closest electrophoreticlabels will be at least about 0.001, usually 0.002, more usually atleast about 0.01, and may be 0.02 or more.

[0169] In those instances where a label is not present on the e-tagbound to the target-binding moiety (e.g., a snp detection sequence), themixture may be added to a functionalized fluorescent tag to label thee-tag with a fluorescer. For example, where a thiol group is present,the fluorescer could have an activated ethylene, such as maleic acid toform the thioether. For hydroxyl groups, one could use activated halogenor pseudohalogen for forming an ether, such as an α-haloketone. Forcarboxyl groups, carbodiimide and appropriate amines or alcohols wouldform amides and esters, respectively. For an amine, one could useactivated carboxylic acids, aldehydes under reducing conditions,activated halogen or pseudohalogen, etc. When synthesizingoligopeptides, protective groups are used. These could be retained whilethe fluorescent moiety is attached to an available functionality on theoligopeptide.

[0170] C. Capture Ligands

[0171] Other reagents that are useful include a ligand-modifiednucleotide and its receptor.

[0172] Ligands and receptors include biotin and strept/avidin, ligandand antiligand, e.g. digoxin or derivative thereof and antidigoxin, etc.By having a ligand conjugated to the oligonucleotide, one can sequesterthe eTag conjugated oligonucleotide probe and its target with thereceptor, remove unhybridized eTag reporter conjugated oligonucleotideand then release the bound eTag reporters or bind an oppositely chargedreceptor, so that the ligand -receptor complex with the eTag reportermigrates in the opposite direction.

[0173] In one exemplary use of capture ligands, a snp detection sequencemay be further modified to improve separation and detection of thereleased e-tags. By virtue of the difference in mobility of the e-tags,the snp detection sequences will also have different mobilities.Furthermore, these molecules will be present in much larger amounts thanthe released e-tags, so that they may obscure detection of the releasede-tags. Also, it is desirable to have negatively charged snp detectionsequence molecules, since they provide for higher enzymatic activity anddecrease capillary wall interaction. Therefore, by providing that theintact snp detection sequence molecule can be modified with a positivelycharged moiety, but not the released e-tag, one can change theelectrostatic nature of the snp detection sequence molecules during theseparation. By providing for a capture ligand on the snp detectionsequence molecule to which a positively charged molecule can bind, oneneed only add the positively charged molecule to change theelectrostatic nature of the snp detection sequence molecule.Conveniently, one will usually have a ligand of under about 1 kDa. Thismay be exemplified by the use of biotin as the ligand and avidin, whichis highly positively charged, as the receptor (capture agent)/positivelycharged molecule. Instead of biotin/avidin, one may have other pairs,where the receptor, e.g. antibody, is naturally positively charged or ismade so by conjugation with one or more positively charged entities,such as arginine, lysine or histidine, ammonium, etc. The presence ofthe positively charged moiety has many advantages in substantiallyremoving the snp detection sequence molecules.

[0174] If desired, the receptor may be used to physically sequester themolecules to which it binds, removing entirely intact e-tags containingthe target-binding region or modified target-binding regions retainingthe ligand. These modified target-binding regions may be as a result ofdegradation of the starting material, contaminants during thepreparation, aberrant cleavage, etc. or other nonspecific degradationproducts of the target binding sequence. As above, a ligand, exemplifiedby biotin, is attached to the target-binding region, e.g. thepenultimate nucleoside, so as to be separated from the e-tag uponcleavage.

[0175] After a 5′ nuclease assay, a receptor for the ligand, for biotinexemplified by strept/avidin (hereafter “avidin”) is added to the assaymixture (Example 10). Other receptors include natural or syntheticreceptors, such as immunoglobulins, lectins, enzymes, etc. Desirably,the receptor is positively charged, naturally as in the case of avidin,or is made so, by the addition of a positively charged moiety ormoieties, such as ammonium groups, basic amino acids, etc. Avidin bindsto the biotin attached to the detection probe and its degradationproducts. Avidin is positively charged, while the cleavedelectrophoretic tag is negatively charged. Thus the separation of thecleaved electrophoretic tag from, not only uncleaved probe, but also itsdegradation products, is easily achieved by using conventionalseparation methods. Alternatively, the receptor may be bound to a solidsupport or high molecular weight macromolecule, such as a vessel wall,particles, e.g. magnetic particles, cellulose, agarose, etc., andseparated by physical separation or centrifugation, dialysis, etc. Thismethod further enhances the specificity of the assay and allows for ahigher degree of multiplexing.

[0176] As a general matter, one may have two ligands, if the nature ofthe target-binding moiety permits. As described above, one ligand can beused for sequestering e-tags bound to the target-binding region,retaining the first ligand from products lacking the first ligand.Isolation and concentration of the e-tags bound to a modifiedtarget-binding region lacking the first ligand would then be performed.In using the two ligands, one would first combine the reaction mixturewith a first receptor for the first ligand for removing target-bindingregion retaining the first ligand. One could either separate the firstreceptor from the composition or the first receptor would be retained inthe composition, as described. This would be followed by combining theresulting composition, where the target-binding region containing thefirst ligand is bound to the first receptor, with the second receptor,which would serve to isolate or enrich for modified target-bindingregion lacking the first ligand, but retaining the second ligand. Thesecond ligand could be the detectable label; a small molecule for whicha receptor is available, e.g. a hapten, or a portion of the e-tag couldserve as the second ligand. After the product is isolated or enriched,the e-tag could be released by denaturation of the receptor,displacement of the product, high salt concentrations and/or organicsolvents, etc.

[0177] For e-tags associated with nucleic acid sequences, improvementsinclude employing a blocking linkage between nucleotides in thesequence, particularly at least one of the links between the second tofourth nucleotides to inhibit cleavage at this or subsequent sites, andusing control sequences for quantitation. Further improvements in thee-tags provide for having a positively multicharged moiety joined to thee-tag probe during separation.

[0178] While the ligand may be present at a position other than thepenultimate position and one may make the ultimate linkage nucleaseresistant, so that cleavage is directed to the penultimate linkage, thiswill not be as efficient as having cleavage at the ultimate linkage.

[0179] The above are generally applicable not only to generating asingle e-tag per sequence detected, but also to generation of a singleoligonucleotide fragment for fragment separation and identification byelectrophoresis or by mass spectra, as it is essential to get onefragment per sequence detected. For purpose of explanation, thesemethods are illustrated below. FIGS. 3A-C provide a schematicillustration of the generalized methods of the invention employing anucleotide target and a 5′ exonuclease indicating that only one eTag isgenerated per target for maximum multiplexing capabilities.

[0180] D. E-tag Reagents-Synthesis

[0181] The chemistry for performing the types of syntheses to form thecharge-imparting moiety or mobility modifier as a peptide chain is wellknown in the art. See, for example, Marglin, et al., Ann. Rev. Biochem.(1970) 39:841-866. In general, such syntheses involve blocking, with anappropriate protecting group, those functional groups that are not to beinvolved in the reaction. The free functional groups are then reacted toform the desired linkages. The peptide can be produced on a resin as inthe Merrifield synthesis (Merrifield, J. Am. Chem. Soc. (1980)85:2149-2154 and Houghten et al., Int. J. Pep. Prot. Res. (1980)16:311-320. The peptide is then removed from the resin according toknown techniques.

[0182] A summary of the many techniques available for the synthesis ofpeptides may be found in J. M. Stewart, et al., “Solid Phase PeptideSynthesis, W. H. Freeman Co, San Francisco (1969); and J. Meienhofer,“Hormonal Proteins and Peptides”, (1973), vol. 2, p 46, Academic Press(New York), for solid phase peptide synthesis; and E. Schroder, et al.,“The Peptides, vol. 1, Academic Press (New York), 1965 for solutionsynthesis.

[0183] In general, these methods comprise the sequential addition of oneor more amino acids, or suitably protected amino acids, to a growingpeptide chain. Normally, a suitable protecting group protects either theamino or carboxyl group of the first amino acid. The protected orderivatized amino acid can then be either attached to an inert solidsupport or utilized in solution by adding the next amino acid in thesequence having the complementary (amino or carboxyl) group suitablyprotected, under conditions suitable for forming the amide linkage. Theprotecting group is then removed from this newly added amino acidresidue and the next amino acid (suitably protected) is then added, andso forth. After all the desired amino acids have been linked in theproper sequence, any remaining protecting groups (and any solid support)are removed sequentially or concurrently, to afford the final peptide.The protecting groups are removed, as desired, according to knownmethods depending on the particular protecting group utilized. Forexample, the protecting group may be removed by reduction with hydrogenand palladium on charcoal, sodium in liquid ammonia, etc.; hydrolysiswith trifluoroacetic acid, hydrofluoric acid, and the like.

[0184] In one exemplary approach, after the synthesis of the peptide iscomplete, the peptide is removed from the resin by conventional meanssuch as ammonolysis, acidolysis and the like. The fully deprotectedpeptide may then be purified by techniques known in the art such aschromatography, for example, adsorption chromatography, ion exchangechromatography, partition chromatography, high performance liquidchromatography, thin layer chromatography, and so forth.

[0185] As can be seen, the selected peptide representing acharge-imparting moiety may be synthesized separately and then attachedto the label either directly or by means of a linking group. On theother hand, the peptide may be synthesized as a growing chain on thelabel. In any of the above approaches, the linking of the peptide oramino acid to the label may be carried out using one or more of thetechniques described above for the synthesis of peptides or for linkingmoieties to labels.

[0186] Synthesis of e-tags comprising nucleotides can be easily andeffectively achieved via assembly on a solid phase support during probesynthesis, using standard phosphoramidite chemistries. The e-tags areassembled at the 5 end of probes after coupling of a final nucleosidicresidue, which becomes part of the e-tag during the assay.

[0187] In one approach, the e-tag probe is constructed sequentially froma single or several monomeric phosphoramidite building blocks (onecontaining a dye residue), which are chosen to generate tags with uniqueelectrophoretic mobilities based on their mass to charge ratio. Thee-tag probe is thus composed of monomeric units of variable charge tomass ratios bridged by phosphate linkers. FIG. 4 illustrates the designand synthesis of e-tags using a LabCard (Detection: 4.7 cm; 200 V/cm)and standard phosphoramidite coupling chemistry.). The separation ofe-tags on a LabCard (FIG. 5) has been demonstrated.

[0188] The penultimate coupling during probe synthesis is initiallycarried out using commercially available modified (and unmodified)phosphoramidites. FIG. 7 shows the structure of severalmobility-modified nucleic acid phosphoramidites that can be employed atthe penultimate coupling during e-tag probe synthesis on a standard DNAsynthesizer.

[0189] This residue is able to form hydrogen bonds to its partner in thetarget strand and is considered a mass modifier but could potentially bea charge modifier as well. The phosphate bridge formed during thiscoupling is the linkage severed during the 5′-nuclease assay. The finalcoupling is done using a phosphoramidite analogue of a dye. Fluoresceinis conveniently employed, but other dyes can be used as well.

[0190]FIG. 6 illustrates predicted and experimental (*) elution times ofe-tag reporters. C₃, C₆, C₉, and C₁₈ are commercially availablephosphoramidite spacers from Glen Research, Sterling Va. The units arederivatives of N,N-diisopropyl, O-cyanoethyl phosphoramidite, which isindicated by “Q”. C₃ is DMT (dimethoxytrityl)oxypropyl Q; C₆ isDMToxyhexyl Q; C₉ is DMToxy(triethyleneoxy) Q; C₁₂ is DMToxydodecyl Q;C₁₈ is DMToxy(hexaethyleneoxy) Q. e-tags are synthesized to generate acontiguous spectrum of signals, one eluting after another with none ofthem coeluting (FIG. 8).

[0191] All of the above e-tags work well and are easily separable andelute at 40 minutes. To generate tags that elute faster, highly chargedlow molecular weight tags are typically employed. Several types ofphosphoramidite monomers allow for the synthesis of highly charged tagswith early elution times. Use of dicarboxylate phosphoramidites (FIG. 9,left) allows for the addition of 3 negative charges per coupling ofmonomer. A variety of fluorescein derivatives (FIG. 9, right) allow thedye component of the tag to carry a higher mass than standardfluorescein. Polyhydroxylated phosphoramidites (FIG. 10) in combinationwith a common phosphorylation reagent enable the synthesis of highlyphosphorylated tags. Combinations of these reagents with other massmodifier linker phosphoramidites allow for the synthesis of tags withearly elution times.

[0192] The aforementioned label conjugates with differentelectrophoretic mobility permit a multiplexed amplification anddetection of multiple targets, e.g. nucleic acid targets. The labelconjugates are linked to oligonucleotides in a manner similar to thatfor labels in general, by means of linkages that are enzymaticallycleavable. It is, of course, within the purview of the present inventionto prepare any number of label conjugates for performing multiplexeddeterminations. Accordingly, for example, with 40 to 50 different labelconjugates separated in a single separation channel and 96 differentamplification reactions with 96 separation channels on a single plasticchip, one can detect 4000 to 5000 single nucleotide polymorphisms.

[0193] One exemplary synthetic approach is outlined in FIG. 1. Startingwith commercially available 6-carboxy fluorescein, the phenolic hydroxylgroups are protected using an anhydride. Isobutyric anhydride inpyridine was employed but other variants are equally suitable. It isimportant to note the significance of choosing an ester functionality asthe protecting group. This species remains intact though thephosphoramidite monomer synthesis as well as during oligonucleotideconstruction. These groups are not removed until the synthesized oligois deprotected using ammonia. After protection the crude material isthen activated in situ via formation of an N-hydroxy succinimide ester(NHS-ester) using DCC as a coupling agent. The DCU byproduct is filteredaway and an amino alcohol is added. Many amino alcohols are commerciallyavailable some of which are derived from reduction of amino acids. Onlythe amine is reactive enough to displace N-hydroxy succinimide. Uponstandard extractive workup, a 95% yield of product is obtained. Thismaterial is phosphitylated to generate the phosphoramidite monomer (FIG.1). For the synthesis of additional e-tags, a symmetrical bis-aminoalcohol linker is used as the amino alcohol (FIG. 12). As such, thesecond amine is then coupled with a multitude of carboxylic acidderivatives (exemplified by several possible benzoic acid derivativesshown in FIG. 2) prior to the phosphitylation reaction. Using thismethodology hundreds, even thousands of e-tags with varying charge tomass ratios can easily be assembled during probe synthesis on a DNAsynthesizer using standard chemistries.

[0194] Alternatively, e-tags are accessed via an alternative strategythat uses 5-aminofluorescein as starting material (FIG. 13). Addition of5-aminofluorescein to a great excess of a diacid dichloride in a largevolume of solvent allows for the predominant formation of themonoacylated product over dimer formation. The phenolic groups are notreactive under these conditions. Aqueous workup converts the terminalacid chloride to a carboxylic acid. This product is analogous to6-carboxyfluorescein, and using the same series of steps is converted toits protected phosphoramidite monomer (FIG. 13). There are manycommercially available diacid dichorides and diacids, which can beconverted to diacid dichlorides using SOCl₂ or acetyl chloride. Thismethodology is highly attractive in that a second mobility modifier isused. As such, if one has access to 10 commercial modifiedphosphoramidites and 10 diacid dichlorides and 10 amino alcohols thereis a potential for 1000 different e-tags. There are many commercialdiacid dichlorides and amino alcohols (FIG. 14). These syntheticapproaches are ideally suited for combinatorial chemistry.

[0195] A variety of maleimide-derivatized e-tags have also beensynthesized. These compounds were subsequently bioconjugated to 5′-thioladorned DNA sequences and subjected to the 5′-nuclease assay. Thespecies formed upon cleavage are depicted in FIG. 15.

[0196] The eTag may be assembled having an appropriate functionality atone end for linking to the binding compound. Thus for oligonucleotides,one would have a phosphoramidite or phosphate ester at the linking siteto bond to an oligonucleotide chain, either 5′ or 3′, particularly afterthe oligonucleotide has been synthesized, while still on a solid supportand before the blocking groups have been removed. While other techniquesexist for linking the oligonucleotide to the eTag, such as having afunctionality at the oligonucleotide terminus that specifically reactswith a functionality on the eTag, such as maleimide and thiol, or aminoand carboxy, or amino and keto under reductive amination conditions, thephosphoramidite addition is preferred. For a peptide-binding compound, avariety of functionalities can be employed, much as with theoligonucleotide functionality, although phosphoramidite chemistry mayonly occasionally be appropriate. Thus, the functionalities normallypresent in a peptide, such as carboxy, amino, hydroxy and thiol may bethe targets of a reactive functionality for forming a covalent bond.

[0197] Of particular interest in preparing eTag labeled nucleic acidbinding compounds (e-tag probes) is using the solid supportphosphoramidite chemistry to build the eTag as part of theoligonucleotide synthesis. Using this procedure, one attaches the nextsucceeding phosphate at the 5′ or 3′ position, usually the 5′ positionof the oligonucleotide chain. The added phosphoramidite may have anatural nucleotide or an unnatural nucleotide. Instead ofphosphoramidite chemistry, one may use other types of linkers, such asthio analogs, amino acid analogs, etc. Also, one may use substitutednucleotides, where the mass-modifying region and/or the charge-modifyingregion may be attached to the nucleotide, or a ligand may be attached tothe nucleotide. In this way, phosphoramidite links are added comprisingthe regions of the eTag probe, whereby when the synthesis of theoligonucleotide chain is completed, one continues the addition of theregions of the eTag to complete the molecule. Conveniently, one wouldprovide each of the building blocks of the different regions with aphosphoramidite or phosphate ester at one end and a blockedfunctionality, where the free functionality can react with aphosphoramidite, mainly a hydroxyl. By using molecules for the differentregions that have a phosphoramidite at one site and a protected hydroxylat another site, the eTag probe can be built up until the terminalregion, which does not require the protected hydroxyl.

[0198] Illustrative of the synthesis would be to employ a diol, such asan alkylene diol, polyalkylene diol, with alkylene of from 2 to 3 carbonatoms, alkylene amine or poly(alkylene amine) diol, where the alkylenesare of from 2 to 3 carbon atoms and the nitrogens are substituted, forexample with blocking groups or alkyl groups of from 1-6 carbon atoms,where one diol is blocked with a conventional protecting group, such asa dimethyltrityl group. This group can serve as the mass-modifyingregion and with the amino groups as the charge-modifying region as well.If desired, the mass modifier can be assembled using building blocksthat are joined through phosphoramidite chemistry. In this way thecharge modifier can be interspersed between within the mass modifier.For example, one could prepare a series of polyethylene oxide moleculeshaving 1, 2, 3 . . . n units. Where one wished to introduce a number ofnegative charges, one could use a small polyethylene oxide unit andbuild up the mass and charge-modifying region by having a plurality ofthe polyethylene oxide units joined by phosphate units. Alternatively,by employing a large spacer, fewer phosphate groups would be present, sothat without large mass differences, one would have large differences inmass-to-charge ratios.

[0199] The chemistry that is employed is the conventional chemistry usedin oligonucleotide synthesis, where building blocks other thannucleotides are used, but the reaction is the conventionalphosphoramidite chemistry and the blocking group is the conventionaldimethoxyltrityl group. Of course, other chemistries compatible withautomated synthesizers can also be used, but there is no reason to addadditional complexity to the process.

[0200] For peptides, the e-tags will be linked in accordance with thechemistry of the linking group and the availability of functionalitieson the peptide-binding compound. For example, with Fab′ fragmentsspecific for a target compound, a thiol group will be available forusing an active olefin, e.g. maleimide, for thioether formation. Wherelysines are available, one may use activated esters capable of reactingin water, such as nitrophenyl esters or pentafluorophenyl esters, ormixed anhydrides as with carbodiimide and half-ester carbonic acid.There is ample chemistry for conjugation in the literature, so that foreach specific situation, there is ample precedent in the literature forthe conjugation.

[0201] For separations based on sorption, adsorption and/or absorption,the nature of the e-tag reporters to provide for differentiation can berelatively simple. By using differences in composition, such asaliphatic compounds, aromatic compounds and halo derivatives thereof,one may make the determinations with gas chromatography, with electroncapture or negative ion mass spectrometry, when electronegative atomsare present. In this way one may use hydrocarbons or halo-substitutedhydrocarbons as the e-tag reporters bonded to a releasable linker. See,U.S. Pat. Nos. 5,565,324 and 6,001,579, which are specificallyincorporated by reference as to the relevant disclosure concerningcleavable groups and detectable groups.

[0202] E. Sets of e-tags

[0203] The libraries will ordinarily have at least about 5 members,usually at least about 10 members, and may have 100 members or more, forconvenience generally having about 50-75 members. Some members may becombined in a single container or be provided in individual containers,depending upon the region to which the mir is attached. The members ofthe library will be selected to provide clean separations inelectrophoresis, when capillary electrophoresis is the analyticalmethod. To that extent, mobilities will differ as described above, wherethe separations may be greater, the larger the larger the number ofmolecules in the band to be analyzed. Particularly, non-sieving mediamay be employed in the separation.

[0204] Besides the nature of the linker, mobility modifer or mir, asalready indicated, diversity can be achieved by the chemical and opticalcharacteristics of the fluorescer, the use of energy transfer complexes,variation in the chemical nature of the linker, which affects mobility,such as folding, interaction with the solvent and ions in the solvent,and the like. As already suggested, the linker will usually be anoligomer, where the linker may be synthesized on a support or producedby cloning or expression in an appropriate host. Conveniently,polypeptides can be produced where there is only one cysteine orserine/threonine/tyrosine, aspartic/glutamic acid, orlysine/arginine/histidine, other than an end group, so that there is aunique functionality which may be differentially functionalized. Byusing protective groups, one can distinguish a side chain functionalityfrom a terminal amino acid functionality. Also, by appropriate design,one may provide for preferential reaction between the samefunctionalities present at different sites on the linking group. Whetherone uses synthesis or cloning for preparation of oligopeptides, will toa substantial degree depend on the length of the linker.

[0205] Depending upon the reagent to which the e-tag is attached, theremay be a single e-tag or a plurality of e-tags, generally ranging fromabout 1-100, more usually ranging from about 1-40, more particularlyranging from about 1-20. The number of e-tags bonded to a singletarget-binding region will depend upon the sensitivity required, thesolubility of the e-tag conjugate, the effect on the assay of aplurality of e-tags, and the like. For oligomers or polymers, such asnucleic acids and poly(amino acids), e.g. peptides and proteins, one mayhave one or a plurality of e-tags, while for synthetic or naturallyoccurring non-oligomeric compounds, usually there will be only 1-3, moreusually 1-2 e-tags.

[0206] For 20 different e-tag reporters, one only requires 5 differentmass-modifying regions, one phosphate link and four different detectableregions. For 120 e-tag reporters, one need only have 10 differentmass-modifying regions, 3 different charge-modifying regions and 4different detectable regions. For 500 different e-tag reporters, oneneed only have 25 different mass-modifying regions, 5 differentcharge-modifying regions and 4 different detectable regions.

[0207] III. Methods for Use of the e-tag Technology

[0208] The methodologies that may be employed involve heterogeneous andhomogeneous techniques, where heterogeneous normally involves aseparation step, where unbound label is separated from bound label,where homogeneous assays do not require, but may employ, a separationstep. One group of assays will involve nucleic acid detection, whichincludes sequence recognition, snp detection and scoring, transcriptionanalysis, allele determinations, HLA determinations, or otherdetermination associated with variations in sequence. The use of thedetermination may be forensic, mRNA determinations, mutationdeterminations, allele determinations, MHC determinations, haplotypedeterminations, single nucleotide polymorphism determinations, etc. Themethodology may include assays dependent on 5′-nuclease activity, as inthe use of the polymerase chain reaction or in Invader technology,3′-nuclease activity, restriction enzymes, or ribonuclease H. All ofthese methods involving catalytic cleavage of a phosphate linkage, whereone to two oligonucleotides are bound to the target template.

[0209] In addition, the subject heterogeneous assays require that theunbound labeled reagent be separable from the bound labeled reagent.This can be achieved in a variety of ways. Each way requires that areagent bound to a solid support that distinguishes between the complexof labeled reagent and target. The solid support may be a vessel wall,e.g. microtiter well plate well, capillary, plate, slide, beads,including magnetic beads, liposomes, or the like. The primarycharacteristics of the solid support is that it permits segregation ofthe bound labeled specific binding member from unbound probe, and thatthe support does not interfere with the formation of the bindingcomplex, nor the other operations of the determination.

[0210] The solid support may have the complex directly or indirectlybound to the support For directly bound, one may have the binding memberor e-tag probe covalently or non-covalently bound to the support. Forproteins, many surfaces provide non-diffusible binding of a protein tothe support, so that one adds the protein to the support and allows theprotein to bind, washes away weakly bound protein and then adds aninnocuous protein to coat any actively binding areas that are stillavailable. The surface may be activated with various functionalitiesthat will form covalent bonds with a binding member. These groups mayinclude imino halides, activated carboxyl groups, e.g. mixed anhydridesor acyl halides, amino groups, α-halo or pseudohaloketones, etc. Thespecific binding member bound to the surface of the support may be anymolecule that permits the binding portion of the molecule, e.g. epitope,to be available for binding by the reciprocal member. Where the bindingmember is polyepitopic, e.g. proteins, this is usually less of aproblem, since the protein will be polyepitopic and even with randombinding of the protein to the surface, the desired epitope will beavailable for most of the bound molecules. For smaller molecules,particularly under 5 kDal, one will usually have an active functionalityon the specific binding member that preserves the binding site, wherethe active functionality reacts with a functionality on the surface ofthe support. The same functionalities described above may find use.Conveniently, one may use the same site for preparing the conjugateimmunogen to produce antibodies as the site for the active functionalityfor linking to the surface.

[0211] Instead of nucleic acid pairing, one may employ specific bindingmember pairing. There are a large number of specific binding pairsassociated with receptors, such as antibodies, poly- and monoclonal,enzymes, surface membrane receptors, lectins, etc., and ligands for thereceptors, which may be naturally occurring or synthetic molecules,protein or non-protein, such as drugs, hormones, enzymes, ligands, etc.The specific binding pair has many similarities to the binding ofhomologous nucleic acids, significant differences being that onenormally cannot cycle between the target and the agent and one does nothave convenient phosphate bonds to cleave. For heterogeneous assays, thebinding of the specific binding pair is employed to separate the boundfrom the unbound e-tag bonded agents, while with homogeneous assays, theproximity of the specific binding pairs allow for release of the e-tagsfrom the complex. For an inclusive but not exclusive listing of thevarious manners in which the subject invention may be used, Tables 3 and4 are provided.

[0212] Once the binding compound (target binding moiety) conjugated withthe e-tag has been prepared, it may find use in a number of differentassays. The samples may be processed using lysis, nucleic acidseparation from proteins and lipids and vice versa, and enrichment ofdifferent fractions. For nucleic acid related determinations, the sourceof the DNA may be any organism, prokaryotic and eukaryotic cells,tissue, environmental samples, etc. The DNA or RNA may be isolated byconventional means, RNA may be reverse transcribed, DNA may beamplified, as with PCR, primers may be used with capture ligands for usein subsequent processing, the DNA may be fragmented using restrictionenzymes, specific sequences may be concentrated or removed usinghomologous sequences bound to a support, or the like. Proteins may beisolated using precipitation, extraction, and chromatography. Theproteins may be present as individual proteins or combined in variousaggregations, such as organelles, cells, viruses, etc. Once the targetcomponents have been preliminarily treated, the sample may then becombined with the e-tag reporter targeted binding proteins.

[0213] For a nucleic acid sample, after processing, the probe mixture ofe-tags for the target sequences will be combined with the sample underhybridization conditions, in conjunction with other reagents, asnecessary. Where the reaction is heterogeneous, the target-bindingsequence will have a capture ligand for binding to a reciprocal bindingmember for sequestering hybrids to which the e-tag probe is bound. Inthis case, all of the DNA sample carrying the capture ligand will besequestered, both with and without e-tag reporter labeled probe. Aftersequestering the sample, and removing non-specifically bound e-tagreporter labeled probe under a predetermined stringency based on theprobe sequence, using washing at an elevated temperature, saltconcentration, organic solvent, etc., the e-tag reporter is releasedinto an electrophoretic buffer solution for analysis.

[0214] As indicated in Table 3, for amplification one may use thermalcycling. Tables 3 and 4 indicate the properties of binding assays(solution phase e-tag generation followed by separation by CE, HPLC ormass spectra) and multiplexed assays (2-1000) leading to release of alibrary of e-tags, where every e-tag codes for a unique binding event orassay.

[0215] The cleavage of the nucleic acid bound to the template results ina change in the melting temperature of the e-tag residue with release ofthe e-tag. By appropriate choice of the primer and/or protocol, one canretain the primer bound to the template and the e-tag containingsequence can be cleaved and released from the template to be replaced byan e-tag containing probe. TABLE 3 Binding and Multiplexed Assays.Formats Recognition Event Amplification Mode e-tag Release Multiplexedassays Solution hybridization PCR, Invader 5′ nuclease Sequencerecognition for followed by enzyme recognition 3′ nuclease example formultiplexed Restriction gene expression, SNP's enzyme scoring etc . . .Ribonuclease H Solution hybridization Amplification due to SingletOxygen followed by channeling turnover of e-tag binding (′O₂) moiety; ORamplification due to release Hydrogen of multiple e-tags (10 to Peroxide(H₂O₂) 100,000) per binding event Light, energy transfer Patches inmicrofluidic Target captured on solid surface; Amplification fromrelease Light, enzyme, channels - e-tag probe mixture hybridized to ofmultiple e-tag reporters ′O₂, integrated assay and target; unboundprobes removed; (10 to 100,000) per probe H₂O₂, Fluoride, separatione-tag reporter is released, separated reducing agent, device andidentified. MS, others

[0216] TABLE 4 Immunoassays Format Recognition Event Amplification Modee-tag Release Proteomics Sandwich assays A few (2-10) e-tags SingletOxygen Multiplexed Antibody-1 decorated with released per binding event(′O₂) Immunoassays Sensitizer while antibody-2 is OR decorated withsinglet oxygen Amplification from cleavable e-tags release of multipleCompetition assays e-tags (10 to 100,000) per Antibody-1 decorated withbinding event Sensitizer while antibody-2 is decorated with singletoxygen cleavable e-tags Sandwich assays Hydrogen Peroxide Antibody-1decorated with Glucose (H₂O₂) oxidase while antibody-2 is decorated withhydrogen peroxide cleavable e-tags Competition assays Antibody-1decorated with Glucose oxidase while antibody-2 is decorated withhydrogen peroxide cleavable e-tags Patches in microfluidic Sandwichassays Light; Enzymes, channels; Antibody-1 is attached to a solidsinglet oxygen, integrated assay and surface while antibody-2 ishydrogen peroxide separation device decorated with cleavable e-tagsfluoride, reducing Competition assays agents, mass spectra, Antibody-1is attached to a solid others surface while antibody-2 is decorated withcleavable e-tags

[0217] The assays may be performed in a competitive mode or a sandwichmode. In the competitive mode, one has the target competing with alabeled binding member for the reciprocal member, which reciprocalmember is bound to the support, either during the complex formation orafter, e.g. where an antibody is a specific binding member andanti-immunoglobulin is the reciprocal binding member and is bound to thesupport. In this mode, the binding sites of the reciprocal bindingmember become at least partially filled by the target, reducing thenumber of available binding sites for the labeled reciprocal bindingmember. Thus, the number of labeled binding members that bind to thereciprocal binding member will be in direct proportion to the number oftarget molecules present. In the sandwich mode, the target is able tobind at the same time to different binding members; a first supportbound member and a second member that binds at a site of the targetmolecule different from the site at which the support bound memberbinds. The resulting complex has three components, where the targetserves to link the labeled binding member to the support.

[0218] In carrying out the assays, the components are combined, usuallywith the target composition added first and then the labeled members inthe competitive mode and in any order in the sandwich mode. Usually, thelabeled member in the competitive mode will be equal to at least 50% ofthe highest number of target molecules anticipated, preferably at leastequal and may be in 2 to 10 fold excess or greater. The particular ratioof target molecules to labeled molecules will depend on the bindingaffinities, the length of time the mixture is incubated, the off ratesfor the target molecule with its reciprocal binding member, the size ofthe sample and the like. In the case of the sandwich assays, one willhave at least an equal amount of the labeled binding member to thehighest expected amount of the target molecules, usually at least 1.5fold excess, more usually at least 2 fold excess and may have 10 foldexcess or more. The components are combined under binding conditions,usually in an aqueous medium, generally at a pH in the range of 5-10,with buffer at a concentration in the range of about 10 to 200 mM. Theseconditions are conventional, where conventional buffers may be used,such as phosphate, carbonate, HEPES, MOPS, Tris, borate, etc., as wellas other conventional additives, such as salts, stabilizers, organicsolvents, etc.

[0219] Usually, the unbound labeled binding member or e-tag probe willbe removed by washing the bound labeled binding member. Where particlesor beads are employed, these may be separated from the supernatantbefore washing, by filtration, centrifugation, magnetic separation, etc.After washing, the support may be combined with a liquid into which thee-tag reporters are to be released and/or the functionality of thee-tags is reacted with the detectable label, followed by or preceded byrelease. Depending on the nature of the cleavable bond and the method ofcleavage, the liquid may include reagents for the cleavage. Wherereagents for cleavage are not required, the liquid is conveniently anelectrophoretic buffer. For example, where the cleavable linkage isphoto labile, the support may be irradiated with light of appropriatewavelength to release the e-tag reporters. Where detectable labels arenot present on the e-tags, the e-tags may be reacted with detectablelabels. In some instances the detectable label may be part of thereagent cleaving the cleavable bond, e.g. a disulfide with a thiol.Where there is a plurality of different functionalities on differentbinding members for reaction with the label, the different labels willhave functionalities that react with one of the functionalities. Thedifferent labels may be added together or individually in a sequentialmanner. For example, where the functionalities involve thiols, carboxylgroups, aldehydes and olefins, the labels could have activated olefins,alcohols, amines and thiol groups, respectively. By having removableprotective groups for one or more of the functionalities, the protectivegroups may be removed stepwise and the labels added stepwise. In thisway cross-reactivity may be avoided. Whether one has the detectablelabel present initially or one adds the detectable label is not criticalto this invention and will frequently be governed by the nature of thetarget composition, the nature of the labeled binding members, and thenature of the detectable labels. For the most part, it will be a matterof convenience as to the particular method one chooses for providing thedetectable label on the e-tag.

[0220] Where a reagent is necessary for cleavage, the e-tag reportersmay be required to be separated from the reagent solution, where thereagent interferes with the electrophoretic analysis. Depending on thenature of the e-tag reporters and the reagent, one may sequester thee-tag reporters from the reagent by using ion exchange columns, liquidchromatography, an initial electrophoretic separation, and the like.Alternatively, as discussed previously, one may have a capture ligandbound to the e-tag or retained portion of the target-binding region forisolating the e-tag probe, so as to remove any interfering components inthe mixture. Once the solution of e-tag reporters is prepared and freeof any interfering components, the solution may be analyzedelectrophoretically. The analysis may employ capillary electrophoresisdevices, microfluidic devices or other devices that can separate aplurality of compounds electrophoretically, providing resolved bands ofthe individual e-tag reporters.

[0221] The protocols for the subject homogeneous assays will follow theprocedures for the analogous heterogeneous assays, which may or may notinclude a releasable e-tag. These protocols employ a signal producingsystem that includes the label on one of the binding members, thecleavable bond associated with the e-tag, electromagnetic radiation orother reagents involved in the reaction or for diminishing backgroundsignal. In assays involving the production of hydrogen peroxide, one maywish to have a molecule in solution that degrades hydrogen peroxide toprevent reaction between hydrogen peroxide produced by a label bound toan analyte molecule and an e-tag labeled binding member that is notbound to the same analyte molecule.

[0222] Generally, the concentrations of the various agents involved withthe signal producing system will vary with the concentration range ofthe individual analytes in the samples to be analyzed, generally beingin the range of about 10 nM to 10 mM. Buffers will ordinarily beemployed at a concentration in the range of about 10 to 200 mM. Theconcentration of each analyte will generally be in the range of about 1pM to about 100 μM, more usually in the range of about 100 pM to 10 μM.In specific situations the concentrations may be higher or lower,depending on the nature of the analyte, the affinity of the reciprocalbinding members, the efficiency of release of the e-tag reporters, thesensitivity with which the e-tags are detected, and the number ofanalytes, as well as other considerations.

[0223] The reactive species that is produced in the assay, analogous tothe subject assay, is employed in a different way than was used in theanalogous assay, but otherwise the conditions will be comparable. Inmany instances, the chemiluminescent compound when activated will resultin cleavage of a bond, so that one may obtain release of the e-tagreporter. Assays that find use are described in U.S. Pat. Nos.4,233,402, 5,616,719, 5,807,675, and 6,002,000. One would combine theanalyte with one or both reagents. The particular order of addition willvary with the nature of the reagents. Generally, one would prefer tocombine the binding reagents and the sample and allow the mixture toincubate, generally at least about 5 min, more usually at least about 15min, before irradiating the mixture or adding the remaining reagents.

[0224] One may also use the subject libraries of e-tags to analyze theeffect of an agent on a plurality of different compounds. For example,one may prepare a plurality of substrates labeled with an e-tag, wherethe enzyme catalyzes a reaction resulting in a change in mobilitybetween the product and the starting material. These assays can find usein determining affinity groups or preferred substrates for hydrolases,oxidoreductases, lyases, etc. For example, with kinases andphosphatases, one adds or removes a charged group, so as to change themobility of the product. By preparing a plurality of alcohols orphosphate esters, one can determine which of the compounds serves as asubstrate. By labeling the substrates with e-tags, one can observe theshift from the substrate to the product as evidence of the activity of acandidate substrate with the enzyme. By preparing compounds as suicideinhibitors, the enzymes may be sequestered and the e-tag reportersreleased to define those compounds that may serve as suicide inhibitorsand, therefore, preferentially bind to the active site of the enzyme.

[0225] One may also use the subject methods for screening for theactivity of one or more candidate compounds, particularly drugs, fortheir activity against a battery of enzymes. In this situation, onewould use active substrates for each of the enzymes to be evaluated,where each of the substrates would have its own e-tag. For those enzymesfor which the drug is an inhibitor, the amount of product would bediminished in relation to the amount of product in the absence of thecandidate compound. In each case the product would have a differentmobility from the substrate, so that the substrates and products couldbe readily distinguished by electrophoresis. By appropriate choice ofsubstrates and detectable labels, one would obtain electropherogramsshowing the effect of the candidate compound on the activity of thedifferent enzymes.

[0226] In determinations involving nucleic acids, since snp detectionis, for the most part, the most stringent in its requirements, most ofthe description will be directed toward the multiplexed detection ofsnps. For other nucleic acid analyses, frequently the protocols will besubstantially the same, although in some instances somewhat differentprotocols will be employed for snps, because of the greater demands snpsmake on fidelity. For proteins, the protocols will be substantiallydifferent and will be described independently of the snp protocols.

[0227] For proteins, the protocols will be different and will bedescribed independently of the SNP protocols.

[0228] A. Primer Extension Reaction in Nucleic Acid Analyses

[0229] The extension reaction is performed by bringing together thenecessary combination of reagents, and subjecting the mixture toconditions for carrying out the desired primer extension.

[0230] Such conditions depend on the nature of the extension, e.g., PCR,single primer amplification, LCR, NASBA, 3SR and so forth, where theenzyme which is used for the extension has 5′-3′ nuclease activity. Theextension reaction may be carried out as to both strands or as to only asingle strand. Where pairs of primer and SNP detection sequence are usedfor both strands, conveniently, the e-tag will be the same but the baseswill be different. In this situation, one may wish to have a cleavablelinkage to the base, so that for the same SNP, one would obtain the samee-tag. Alternatively, if the number of SNPs to be determined is not toohigh, one could use different e-tags for each of the strands. Usually,the reaction will be carried out by using amplifying conditions, so asto provide an amplified signal for each SNP. Amplification conditionsnormally employ thermal cycling, where after the primer extension andrelease of electrophoretic tag reporters associated with snps' which arepresent, the mixture is heated to denature the double-stranded DNA,cooled, where the primer and snp detection sequence can rehybridize andthe extension be repeated.

[0231] Reagents for conducting the primer extension are substantiallythe same reaction materials for carrying out an amplification, such asan amplification indicated above. The nature and amounts of thesereagents are dependent on the type of amplification conducted. Inaddition to oligonucleotide primers, the reagents also comprisenucleoside triphosphates and a nucleotide polymerase having 5′-3′nuclease activity.

[0232] The nucleoside triphosphates employed as reagents in anamplification reaction include deoxyribonucleoside triphosphates such asthe four common deoxyribonucleoside triphosphates DATP, dCTP, dGTP anddTTP. The term “nucleoside triphosphates” also includes derivatives andanalogs thereof, which are exemplified by those derivatives that arerecognized and polymerized in a similar manner to the underivatizednucleoside triphosphates.

[0233] The nucleotide polymerase employed is a catalyst, usually anenzyme, for forming an extension of an oligonucleotide primer along apolynucleotide such as a DNA template, where the extension iscomplementary thereto. The nucleotide polymerase is a template dependentpolynucleotide polymerase and utilizes nucleoside triphosphates asbuilding blocks for extending the 3′-end of a polynucleotide to providea sequence complementary with the polynucleotide template. Usually, thecatalysts are enzymes, such as DNA polymerases, for example, prokaryoticDNA polymerase (I, II, or III), T4 DNA polymerase, T7 DNA polymerase,Vent DNA polymerase, Pfu DNA polymerase, Taq DNA polymerase, and thelike.

[0234] Polymerase enzymes may be derived from any source, such aseukaryotic or prokaryotic cells, bacteria such as E. coli, plants,animals, virus, thermophilic bacteria, genetically modified enzymes, andso forth.

[0235] The conditions for the various amplification procedures are wellknown to those skilled in the art. In a number of amplificationprocedures, thermal cycling conditions as discussed above are employedto amplify the polynucleotides. The combination of reagents is subjectedto conditions under which the oligonucleotide primer hybridizes to thepriming sequence of, and is extended along, the correspondingpolynucleotide. The exact temperatures can be varied depending on thesalt concentration, pH, solvents used, length of and composition of thetarget polynucleotide sequence and the oligonucleotide primers.

[0236] Thermal cycling conditions are employed for conducting anamplification involving temperature or thermal cycling and primerextension such as in PCR or single primer amplification, and the like.The pH and the temperature are selected so as to cause, eithersimultaneously or sequentially, dissociation of any internallyhybridized sequences, hybridization or annealing of the oligonucleotideprimer and snp detection sequence with the target polynucleotidesequence, extension of the primer, release of the e-tag reporter fromsnp detection sequence bound to the target polynucleotide sequence, anddissociation of the extended primer. This usually involves cycling thereaction medium between two or more temperatures. In conducting such amethod, the medium is cycled between two to three temperatures. Thetemperatures for thermal cycling generally range from about 50° C. to100° C., more usually from about 60° C. to 95° C. Relatively lowtemperatures of from about 30° C. to about 65° C. can be employed forthe extension steps, while denaturation and hybridization can be carriedout at a temperature of from about 50° C. to about 105° C. The reactionmedium is initially at about 20° C. to about 45° C., preferably, about25° C. to about 35° C. Relatively low temperatures of from about 50° C.to about 80° C., preferably, 50° C. to about 60° C., are employed forthe hybridization or annealing steps, while denaturation is carried outat a temperature of from about 80° C. to about 100° C., preferably, 90°C. to about 95° C., and extension is carried out at a temperature offrom about 70° C. to about 80° C., usually about 72° C. to about 74° C.The duration of each cycle may vary and is usually about 1 to 120seconds, preferably, about 5 to 60 seconds for the denaturation steps,and usually about 1 to 15 seconds, preferably, about 1 to 5 seconds, forthe extension steps. It is to be understood that the actual temperatureand duration of the cycles employed are dependent on the particularamplification conducted and are well within the knowledge of thoseskilled in the art.

[0237] Generally, an aqueous medium is employed. Other polar co-solventsmay also be employed, usually oxygenated organic solvents of from 1-6,more usually from 1-4, carbon atoms, including alcohols, ethers,formamide and the like. Usually, these co-solvents, if used, are presentin less than about 70 weight percent, more usually in less than about 30weight percent.

[0238] The pH for the medium is usually in the range of about 4.5 to9.5, more usually in the range of about 5.5 to 8.5, and preferably inthe range of about 6 to 8. Various buffers may be used to achieve thedesired pH and maintain the pH during the determination. Illustrativebuffers include borate, phosphate, carbonate, Tris, barbital and thelike. The particular buffer employed is not critical to this inventionbut in individual methods one buffer may be preferred over another. Themedium may also contain materials required for enzyme activity such as adivalent metal ion (usually magnesium).

[0239] Various ancillary materials will frequently be employed in themethods in accordance with the present invention. For example, inaddition to buffers and salts, the medium may also comprise stabilizersfor the medium and the reaction components. Frequently, the medium mayalso include proteins such as albumins, quaternary ammonium salts,polycations such as spermine, surfactants, particularly non-ionicsurfactants, binding enhancers, e.g., polyalkylene glycols, or the like.

[0240] The reaction is conducted for a time sufficient to produce thedesired number of copies of each of the polynucleotides suspected ofbeing present as discussed below. Generally, the time period forconducting the entire method will be from about 10 to 200 minutes. Asmentioned above, it is usually desirable to minimize the time period.

[0241] The concentration of the nucleotide polymerase is usuallydetermined empirically. Preferably, a concentration is used that issufficient such that the amplification is robust. The primary limitingfactor generally is the cost of the reagent. Such enzymes include PfuDNA polymerase (native and recombinant) from Stratagene, La Jolla,Calif., UlTma DNA polymerase from Perkin Elmer, Foster City, Calif.,rBst DNA polymerase from Epicentre Technologies, Madison, Wis., Vent DNApolymerase from New England Biolabs, Beverly, Mass., Tli DNA polymerasefrom Promega Corp., Madison, Wis., and Pwo DNA polymerase fromBoehringer Mannheim, Indianapolis, Ind., and the like.

[0242] The initial concentration of each of the polynucleotidescontaining the respective target-binding moiety for the target snps canbe as low as about 50 pg/μL in a sample. After amplification theconcentration of each polynucleotide should be at least about 10 pM,generally in the range of about 10 pM to about 10 nM, usually from about10 to 10¹⁰, more usually from about 10³ to 10⁸ molecules in a sample,preferably at least 10⁻²¹ M in the sample and may be 10⁻¹⁰ to 10⁻¹⁹ M,more usually 10⁻¹⁴ to 10⁻¹⁹M. In general, the reagents for the reactionare provided in amounts to achieve extension of the oligonucleotideprimers.

[0243] The concentration of the oligonucleotide primer(s) will be about1 to about 20 μM and is usually about 1 to about 10 μM, preferably,about 1 to about 4 μM, for a sample size that is about 10 fM.Preferably, the concentration of the oligonucleotide primer(s) issubstantially in excess over, preferably at least about 10⁷ to about10¹⁰ times greater than, more preferably, at least about 10⁹ timesgreater than, the concentration of the corresponding targetpolynucleotides.

[0244] The amount of the oligonucleotide probes will be 10 to about 500nM and is usually about 50 to about 200 nM for a sample size that isabout 10 fM. Preferably, the concentration of the oligonucleotide probesis substantially in excess over, preferably at least about 10⁷ timesgreater than, more preferably, at least about 10⁸ times greater than,the concentration of each of the target polynucleotides.

[0245] The concentration of the nucleoside triphosphates in the mediumcan vary widely; preferably, these reagents are present in an excessamount. The nucleoside triphosphates are usually present in about 10 μMto about 1 mM, preferably, about 20 to about 400 μM.

[0246] The order of combining of the various reagents to form thecombination may vary. Usually, the sample containing the polynucleotidesis combined with a pre-prepared combination of nucleoside triphosphatesand nucleotide polymerase. The oligonucleotide primers and the SNPdetection sequences may be included in the prepared combination or maybe added subsequently. However, simultaneous addition of all of theabove, as well as other step-wise or sequential orders of addition, maybe employed provided that all of the reagents described above arecombined prior to the start of the reactions. The oligonucleotide pairsmay be added to the combination of the reagents at or prior toinitiation of the primer extension reaction and may be replenished fromtime-to-time during the primer extension reaction.

[0247] For quantitation, one may choose to use controls, which provide asignal in relation to the amount of the target that is present or isintroduced. Where one is dealing with a mixture of nucleic acidmolecules, as in the case of mRNA in a lysate, one may use the knownamounts of one or more different mRNAs in the particular cell types asthe standards. Desirably, one would have at least two controls,preferably at least 3 controls, where the variation in number betweenany two controls is at least about 10², and the total range is at leastabout 10³, usually at least about 10⁴ . However, determining theconsistent ratio of mRNAs occurring naturally may result in a largemargin of error, so that one would usually rely on synthetic targets asthe control. Where a control system is added for quantitation, ascompared to relying on the presence of a known amount of a plurality ofendogenous nucleic acids, the control system will comprise at least twocontrol sequences, usually at least 3 control sequences and generallynot more than about 6 control sequences, where the upper limit isprimarily one of convenience and economy, since additional controlsequences will usually not add significant additional precision. Thecontrol sequences will usually be at least about 50 nucleotides, moreusually at least about 100 nucleotides. The control sequences will havea common primer sequence and different control detection sequences,which are intended to parallel the primer sequence and SNP detectionsequence in size, spacing and response to the primer extensionconditions. In carrying out the primer extension reaction with samplenucleic acid, one would then add different number of molecules of thedifferent control sequences, so that one could graph the result to givea signal/number relationship. This graph could then be used to relatesignals observed with target molecules to the number of moleculespresent.

[0248] As exemplary of the subject invention, four targetpolynucleotides T1, T2, T3 and T4 are employed. Oligonucleotide primersPR1, PR2, PR3 and PR4 are employed, each respectively capable ofhybridizing to a sequence in the respective target polynucleotides. Alsoemployed are four oligonucleotide snp detection sequences, PB1, PB2, PB3and PB4. Each of the snp detection sequences comprises a fluorescentlabel F1, F2, F3 and F4, respectively. In this example, there is amismatch between PB2 and T2, which comprises a single nucleotidepolymorphism. The reaction medium comprising the above reagents andnucleoside triphosphates and a template dependent polynucleotidepolymerase having 5′ to 3′ exonuclease activity is treated underamplification conditions. Primers PR1, PR2, PR3 and PR4 hybridize totheir respective target polynucleotides and are extended to yieldextended primers EPR1, EPR2, EPR3 and EPR4. snp detection sequences PB1,PB3 and PB4, which hybridize with their respective targetpolynucleotides, are acted upon by the exonuclease to cleave a singlenucleotide bearing the respective fluorescent label. PB2, which does notbind to the target polynucleotide, is not cleaved. Cleaved fragments F1,F3 and F4 are injected into a separation channel in a chip forconducting electroseparation. The labels are identified by theirspecific mobility and fluorescence upon irradiation. The separatedlabels are related to the presence and amount of the respective targetpolynucleotide.

[0249] The selection of the snp detection or other target bindingsequence will affect the stringency employed during the primerextension, particularly at the stage of hybridization. Since in asubstantial number of samples, the DNA will be heterozygous for snps′,rather than homozygous, one does not wish to have false positives, wherethe snp detection sequence may bond to the sequence comprising theprevalent nucleotide, as well as the sequence comprising the snp. Wherethe DNA sample is homozygous for the prevalent sequence, it is alsoimportant that the target binding sequence does not bind to give a falsepositive. Therefore, the difference in T_(m) between the targetcontaining sequence and the wild-type sequence will usually be at leastabout 3° C., more usually at least about 5° C., under the conditions ofthe primer extension.

[0250] In one exemplary protocol, the tagged snp detection sequence willbe chosen to bind to the target sequence comprising the snp. The lengthof the snp detector sequence is in part related to the length andbinding affinity of the primer. The two sequences act together to ensurethat the pair of reagents bind to the proper target sequence. Thegreater the fidelity of binding of one member of the pair, the lessfidelity that is required for the other member of the pair. Since theobserved signal will be dependent upon both members of the pair beingpresent, each member serves as a check on the other member forproduction of the signal. However, since except for the cost, it isrelatively easy to make reasonably long oligonucleotides, usually bothmembers of the pair will uniquely hybridize to their respective targetsequences. Therefore, the length of the snp detector sequence will comewithin the parameters indicated for the primer, but the total number ofbases for the two pair members will usually be at least 36, more usuallyat least about 40.

[0251] Depending on the protocol, an e-tag reporter will be separatedfrom a portion or substantially all of the detection sequence, usuallyretaining not more than about 3 nucleotides, more usually not more thanabout 2 nucleotides and preferably from 0 to 1 nucleotide. By having acleavable linker between the e-tag and the detection sequence, the e-tagreporter may be freed of all the nucleotides. By having anuclease-resistant penultimate link, a single nucleotide may be bondedto the e-tag.

[0252] Each snp detection sequence will have at least one nucleotidemodified with an electrophoretic tag, which is fluorescent or can besubsequently made fluorescent, or can be detected electrochemically orby other convenient detection methodologies. Usually, the modifiednucleotide will be at the 5′-end of the sequence, but the modifiednucleotide may be anywhere in the sequence, particularly where there isa single nuclease susceptible linkage in the detection sequence. Sincethe determination is based on at least partial degradation of the snpdetector sequence, having the modified nucleotide at the end ensuresthat if degradation occurs, the electrophoretic tag will be released.Since nucleases may clip at other than the terminal phosphate link, itis desirable to prevent cleavage at other than the terminal phosphatelink. In this way one avoids the confusion of having the sameelectrophoretic tag joined to different numbers of nucleotides aftercleavage. Cleavage at the terminal phosphate can be relatively assuredby using a linker that is not cleaved by the nuclease, more particularlyhaving only the ultimate linkage susceptible to hydrolysis by anuclease. For example, one may use a thiophosphate, phosphinate,phosphoramidate, or a linker other than a phosphorous acid derivative,such as an amide, boronate, or the like. The particular hydrolaseresistive linker will be primarily one of synthetic convenience, so longas degradation of the binding affinity is not sacrificed. If desired,all of the linkers other than the ultimate linker may be resistant tonuclease hydrolysis.

[0253] One, usually a plurality, of snp's, is simultaneously determinedby combining target DNA with one or a plurality, respectively, ofreagent pairs under conditions of primer extension. Each pair ofreagents includes a primer which binds to target DNA and a snp detectionsequence, normally labeled, which binds to the site of the snp and hasan e-tag, usually at its 5′-end and the base complementary to the snp,usually at other than a terminus of the snp detection sequence. Theconditions of primer extension employ a polymerase having 5′-3′exonuclease activity, dNTP's and auxiliary reagents to permit efficientprimer extension. The primer extension is performed, whereby detectorsequences bound to the target DNA are degraded with release of thee-tag. By having each snp associated with its own e-tag, one candetermine the snp's, which are present in the target DNA for which pairsof reagents have been provided.

[0254] The pairs of reagents are DNA sequences which are related to asnp site. The primer binds to the target DNA upstream from the snp sitein the direction of extension. The labeled detector sequence bindsdownstream from the primer in the direction of extension and binds to asequence, which includes the snp. The primer sequence will usually be atleast about 12 bases long, more usually at least 18 bases long andusually fewer than 100 bases, and more usually fewer than 60 bases. Theprimer will be chosen to bind substantially uniquely to a targetsequence under the conditions of primer extension, so that the sequencewill normally be one that is conserved or the primer is long enough tobind in the presence of a few mismatches, usually fewer than about 10number % mismatches. By knowing the sequence, which is upstream from thesnp of interest, one may select a sequence, which has a high G-C ratio,so as to have a high binding affinity for the target sequence. Inaddition, the primer should bind reasonably close to the snp, usuallynot more than about 200 bases away, more usually not more than about 100bases away, and preferably within about 50 bases. Since the farther awaythe primer is from the snp, the greater amount of dNTPs that will beexpended, there will usually be no advantage in having a significantdistance between the primer and the snp detection sequence. Generally,the primer will be at least about 5 bases away from the snp.

[0255] The complementary base to the snp may be anywhere in the detectorsequence, desirably at other than the terminal nucleoside to enhance thefidelity of binding. The SNP detector sequence will be designed toinclude adjacent nucleotides, which provide the desired affinity for thehybridization conditions. The SNP detection sequence may be synthesizedby any convenient means, such as described in Matthews, et al., Anal.Biochem. (1988) 169:1-25; Keller, et al., “DNA Probes,” 2^(nd) edition(1993) Stockton Press, New York, N.Y.; and Wetmur, Critical Reviews inBiochemistry and Molecular Biology (1991) 26:227-259.

[0256] The number of reagent pairs may be varied widely, from a singlepair to two or more pairs, usually at least about 5 pairs, more usuallyat least about 9 pairs and may be 20 pairs or more. By virtue of the useof different e-tags, which have different mobilities and are readilyresolvable under conventional capillary electrophoretic conditions, thesubject pairs may be used to perform multiplexed operations in a singlevessel, where a family of SNPs may be identified. Usually, the totalnumber of different reagent pairs or different target sequences in asingle determination will be under 200, more usually under 100 and inmany cases will not exceed 50.

[0257] B. The Invader™ Reaction in Nucleic Acid Analyses

[0258] In one SNP determination protocol, the primer includes thecomplementary base of the SNP. This protocol is referred to as Invader™technology, and is described in U.S. Pat. No. 6,001,567. The protocolinvolves providing: (a) (i) a cleavage means, which is normally anenzyme, referred to as a cleavase, that recognizes a triplex consistingof the target sequence, a primer which binds to the target sequence andterminates at the SNP position and a labeled probe that bindsimmediately adjacent to the primer and is displaced from the target atthe SNP position, when a SNP is present. The cleavase clips the labeledprobe at the site of displacement, releasing the label, (ii) a source oftarget nucleic acid, the target nucleic acid having a first region, asecond region and a third region, wherein the first region is downstreamfrom the second region and the second region is contiguous to anddownstream from the third region, and (iii) first and secondoligonucleotides having 3′ and 5′ portions, wherein the 3′ portion ofthe first oligonucleotide contains a sequence complementary to the thirdregion of the target nucleic acid and the 5′ portion of the firstoligonucleotide and the 3′ portion of the second oligonucleotide eachcontain sequences usually fully complementary to the second region ofthe target nucleic acid, and the 5′ portion of the secondoligonucleotide contains sequence complementary to the first region ofsaid target nucleic acid; (b) mixing, in any order, the cleavage means,the target nucleic acid, and the first and second oligonucleotides underhybridization conditions that at least the 3′ portion of the firstoligonucleotide is annealed to the target nucleic acid and at least the5′ portion of the second oligonucleotide is annealed to any targetnucleic acid to from a cleavage structure, where the combined meltingtemperature of the complementary regions within the 5′ and 3′ portionsof the first oligonucleotide when annealed to the target nucleic acid isgreater than the melting temperature of the 3′ portion of the firstoligonucleotide and cleavage of the cleavage structure occurs togenerate labeled products; and (c) detecting the labeled cleavageproducts.

[0259] Thus, in an Invader assay, attachment of an e-tag to the 5′ endof the detector sequence results in the formation of an e-tag-labelednucleotide when the target sequence is present. The e-tag labelednucleotide is separated and detected. By having a different e-tag foreach nucleic acid sequence of interest, each having a differentelectrophoretic mobility, one can readily determine the SNPs or measuremultiple sequences, which are present in a sample. The e-tags mayrequire further treatment, depending on the total number of snps ortarget sequences being detected.

[0260] C. Fluorescent Quenching

[0261] If desired, the SNP detection e-tag probe may have a combinationof a quencher and a fluorescer. In this instance the fluorescer would bein proximity to the nucleoside to which the linker is bonded, as well asthe quencher, so that in the primer extension mixture, fluorescence fromfluorescer bound to the SNP detection sequence would be quenched. As thereaction proceeds and fluorescer is released from the SNP detectionsequence and, therefore, removed from the quencher, it would then becapable of fluorescence. By monitoring the primer extension mixture forfluorescence, one would be able to determine when there would probablybe a sufficient amount of individual e-tags to provide a detectablesignal for analysis. In this way, one could save time and reagent byterminating the primer extension reaction at the appropriate time. Thereare many quenchers that are not fluorescers, so as to minimizefluorescent background from the SNP detection sequence. Alternatively,one could take small aliquots and monitor the reaction for detectablee-tag reporters.

[0262] D. Analysis of Reaction Products

[0263] The separation of the e-tag reporters by electrophoresis can beperformed in conventional ways. See, for example, U.S. Pat. Nos.5,750,015, 5,866,345, 5,935,401, 6,103,199, and 6,110,343, andWO98/5269, and references cited therein. Also, the sample can beprepared for mass spectrometry in conventional ways. See, for example,U.S. Pat. Nos. 5,965,363, 6,043,031, 6,057,543, and 6,111,251.

[0264] After completion of the primer extension reaction, either bymonitoring the change in fluorescence as described above or takingaliquots and assaying for total free e-tags, the mixture may now beanalyzed. Depending on the instrument, today from one to four differentfluorescers activated by the same light source and emitting at differentdetectable labels may be used. With improvements, five or more differentfluorescers will be available, where an additional light source may berequired. Electrochemical detection is described in U.S. Pat. No.6,045,676.

[0265] The presence of each of the cleaved e-tags is determined by thelabel. The separation of the mixture of labeled e-tag reporters istypically carried out by electroseparation, which involves theseparation of components in a liquid by application of an electricfield, preferably, by electrokinesis (electrokinetic flow)electrophoretic flow, or electroosmotic flow, or combinations thereof,with the separation of the e-tag reporter mixture into individualfractions or bands. Electroseparation involves the migration andseparation of molecules in an electric field based on differences inmobility. Various forms of electroseparation include, by way of exampleand not limitation, free zone electrophoresis, gel electrophoresis,isoelectric focusing and isotachophoresis. Capillary electroseparationinvolves electroseparation, preferably by electrokinetic flow, includingelectrophoretic, dielectrophoretic and/or electroosmotic flow, conductedin a tube or channel of about 1-200 micrometer, usually, about 10-100micrometers cross-sectional dimensions. The capillary may be a longindependent capillary tube or a channel in a wafer or film comprised ofsilicon, quartz, glass or plastic.

[0266] In capillary electroseparation, an aliquot of the reactionmixture containing the e-tag products is subjected to electroseparationby introducing the aliquot into an electroseparation channel that may bepart of, or linked to, a capillary device in which the amplification andother reactions are performed. An electric potential is then applied tothe electrically conductive medium contained within the channel toeffectuate migration of the components within the combination.Generally, the electric potential applied is sufficient to achieveelectroseparation of the desired components according to practices wellknown in the art. One skilled in the art will be capable of determiningthe suitable electric potentials for a given set of reagents used in thepresent invention and/or the nature of the cleaved labels, the nature ofthe reaction medium and so forth. The parameters for theelectroseparation including those for the medium and the electricpotential are usually optimized to achieve maximum separation of thedesired components. This may be achieved empirically and is well withinthe purview of the skilled artisan.

[0267] For a homogeneous assay, the sample, e-tag -labeled probemixture, and ancillary reagents are combined in a reaction mixturesupporting the cleavage of the linking region. The mixture may beprocessed to separate the e-tag reporters from the other components ofthe mixture. The mixture, with or without e-tag reporter enrichment, maythen be transferred to an electrophoresis device, usually a microfluidicor capillary electrophoresis device and the medium modified as requiredfor the electrophoretic separation. Where one wishes to remove from theseparation channel intact e-tag reporter molecules, a ligand is bound tothe e-tag that is not released when the e-tag reporter is released.Alternatively, by adding a reciprocal binding member that has theopposite charge of the e-tag reporter, so that the overall charge isopposite to the charge of the e-tag reporter, these molecules willmigrate toward the opposite electrode from the released e-tag reportermolecules. For example, one could use biotin and streptavidin, wherestreptavidin carries a positive charge. In the case of anoligonucleotide, the e-tag reporter would be bonded to at least twonucleotides, where cleavage occurs between the two nucleotides withrelease of the e-tag reporter, with the terminal nucleotide of thedinucleotide labeled with a biotin (the e-tag reporter would be releasedwithout the biotinylated nucleotide). In the case of a peptide analyte,one would have cleavage at a site, where the ligand remains with thepeptide analyte. For example, one could have the e-tag reportersubstituted for the methyl group of methionine. Using the pyrazolone ofthe modified methionine, one could bond to an available lysine. Theamino group of the pyrazolone would be substituted with biotin. Cleavagewould then be achieved with cyanogen bromide, releasing the e-tagreporter, but the biotin would remain with the peptide and any e-tagthat was not released from the binding member. Avidin is then used tochange the polarity or sequester the e-tag reporter conjugated to thebinding compound or target-binding moiety.

[0268] Capillary devices are known for carrying out amplificationreactions such as PCR. See, for example, Analytical Chemistry (1996)68:4081-4086. Devices are also known that provide functional integrationof PCR amplification and capillary electrophoresis in a microfabricatedDNA analysis device. One such device is described by Woolley, et al., inAnal. Chem. (1996) 68:4081-4086. The device provides a microfabricatedsilicon PCR reactor and glass capillary electrophoresis chips. In thedevice a PCR chamber and a capillary electrophoresis chip are directlylinked through a photolithographically fabricated channel filled with asieving matrix such as hydroxyethylcellulose. Electrophoretic injectiondirectly from the PCR chamber through the cross injection channel isused as an “electrophoretic valve” to couple the PCR and capillaryelectrophoresis devices on a chip.

[0269] The capillary electrophoresis chip contains a sufficient numberof main or secondary electrophoretic channels to receive the desirednumber of aliquots from the PCR reaction medium or the solutionscontaining the cleaved labels, etc., at the intervals chosen.

[0270] For capillary electrophoresis one may employ one or moredetection zones to detect the separated cleaved labels. It is, ofcourse, within the purview of the present invention to utilize severaldetection zones depending on the nature of the amplification process,the number of cycles for which a measurement is to be made and so forth.There may be any number of detection zones associated with a singlechannel or with multiple channels. Suitable detectors for use in thedetection zones include, by way of example, photomultiplier tubes,photodiodes, photodiode arrays, avalanche photodiodes, linear and arraycharge coupled device (CCD) chips, CCD camera modules,spectrofluorometers, and the like. Excitation sources include, forexample, filtered lamps, LED's, laser diodes, gas, liquid andsolid-state lasers, and so forth. The detection may be laser scannedexcitation, CCD camera detection, coaxial fiber optics, confocal back orforward fluorescence detection in single or array configurations, andthe like.

[0271] Detection may be by any of the known methods associated with theanalysis of capillary electrophoresis columns including the methodsshown in U.S. Pat. No. 5,560,811 (column 11, lines 19-30), U.S. Pat. No.4,675,300, 4,274,240 and 5,324,401, the relevant disclosures of whichare incorporated herein by reference.

[0272] Those skilled in the electrophoresis arts will recognize a widerange of electric potentials or field strengths may be used, forexample, fields of 10 to 1000 V/cm are used with 200-600 V/cm being moretypical. The upper voltage limit for commercial systems is 30 kV, with acapillary length of 40-60 cm, giving a maximum field of about 600 V/cm.For DNA, typically the capillary is coated to reduce electroosmoticflow, and the injection end of the capillary is maintained at a negativepotential.

[0273] For ease of detection, the entire apparatus may be fabricatedfrom a plastic material that is optically transparent, which generallyallows light of wavelengths ranging from 180 to 1500 nm, usually 220 to800 nm, more usually 450 to 700 nm, to have low transmission losses.Suitable materials include fused silica, plastics, quartz, glass, and soforth.

[0274] IV. Systems for Use of the e-tag Technology

[0275] One embodiment of a system according to the present invention ispresented in FIG. 16. This figure illustrates a system 100 for thesimultaneous, multiplexed determination of a plurality of events. Eachevent is distinguished from the others by electrophoresis. For example,a snp locus may be characterized using a pair of reagents, each specificfor one allele of the locus. Each reagent is bonded to an e-tag with aunique electrophoretic mobility and an associated label. When thereagent is combined with a sample of interest in a reaction vessel 101,the associated e-tag is modified in a manner that changes itselectrophoretic mobility if its specific target is present. After thereaction, the mixture is moved 102 onto an electrophoretic device 103for separation of the e-tag reporter products contained in the mixture.A power control box 104 is used in conjunction with the device tocontrol injection of the sample into the separation channel 105. Eache-tag reporter species migrates down the separation channel of thedevice with a mobility unique to that tag, moving past a detector 106that monitors its presence by its associated label. The data collectedby the detector is sent to a data processor 107, which determines thepresence of each snp allele in the sample based on the mobility of itscorresponding e-tag reporter.

[0276] In another example, a group of snp loci or other sequences may bemonitored in a multiplexed reaction. In this case, a plurality of pairsof e-tag reagents corresponding to the target sequences are combinedwith a sample in a single reaction vessel under conditions where thee-tag reporter is released from at least a portion of the targetoligonucleotide sequence to which it is bonded when a pair is bonded toits target. The e-tag reporters are either labeled for detection or thelabel is added by means of a reactive functionality present on thee-tag. The labeled e-tag products of the reaction are resolved from oneanother on the electrophoretic device, and again are monitored as theymove past the detector. The level of multiplexing possible in thissystem is limited only by the degree of resolution that can be obtainedbetween a designated set of e-tag reporters on the electrophoreticdevice.

[0277] An additional degree of flexibility can be conferred on the assayby the stage at which the e-tags are labeled. As described above, eache-tag may already contain a detectable label when introduced into thereaction. Alternatively, an e-tag may contain a functionality allowingit to bind to a label after reaction with the sample is complete (FIG.16; 108). In this embodiment, an e-tag comprising a functionality forbinding to a detectable label is combined with a sample (FIG. 16; 101).After a reaction to modify the mobility of the e-tag if its target ispresent in the sample, additional reagents are combined in a samplevessel (FIG. 16; 109) with the products of the first reaction, whichwill react with the modified e-tag(s) to add a detectable label.

[0278] V. Kits for Use of the e-tag Technology

[0279] As a matter of convenience, predetermined amounts of reagentsemployed in the present invention can be provided in a kit in packagedcombination. One exemplary kit for snp detection can comprise inpackaged combination an oligonucleotide primer for each polynucleotidesuspected of being in said set wherein each of said primers ishybridizable to a first sequence of a respective polynucleotide ifpresent, a template dependent polynucleotide polymerase, nucleosidetriphosphates, and a set of primer and oligonucleotide snp detectionsequences, each of the snp detection sequences having a fluorescentlabel at its 5′-end and having a sequence at its 5′-end that ishybridizable to a respective polynucleotide wherein each of theelectrophoretic labels is cleavable from the snp detection sequence.

[0280] The kit may further comprise a device for conducting capillaryelectrophoresis as well as a template dependent polynucleotidepolymerase having 5′ to 3′ exonuclease activity. The kit can furtherinclude various buffered media, some of which may contain one or more ofthe above reagents.

[0281] The relative amounts of the various reagents in the kits can bevaried widely to provide for concentrations of the reagents necessary toachieve the objects of the present invention. Under appropriatecircumstances one or more of the reagents in the kit can be provided asa dry powder, usually lyophilized, including excipients, which ondissolution will provide for a reagent solution having the appropriateconcentrations for performing a method or assay in accordance with thepresent invention. Each reagent can be packaged in separate containersor some reagents can be combined in one container where cross-reactivityand shelf life permit. For example, the dNTPs, the oligonucleotidepairs, optionally the polymerase, may be included in a single container,which may also include an appropriate amount of buffer. The kits mayalso include a written description of a method in accordance with thepresent invention as described above.

[0282] In one embodiment of the kit, the electrophoretic tags arefluorescent conjugates represented by the formula:

R-L-T^(a)

[0283] wherein R is a fluorescer, L is a linking group, as describedpreviously, and T^(a) is a functionality for binding to a nucleo sidebase, purine or pyrimidine, or a nucleo side base, a nucleoside,nucleotide or nucleotide triphosphate.

[0284] In another embodiment of a kit, the electrophoretic tags arefluorescent conjugates represented by the formula:

R′-L′-T^(b)

[0285] wherein R′ is a fluorescer, L′ is a bond an amino acid or apeptide or combinations of amino acids and thioacids or other carboxylicacids and T^(b) is a nucleotide or nucleotide triphosphate

[0286] In another embodiment of a kit, the electrophoretic tag is afluorescent conjugate represented by the formula:

Fluorescer-L″-(amino acid)_(n)-T^(c)

[0287] wherein L″ is a bond or a linking group of from 1 to 20 atoms inthe chain and n is 1 to 100. The fluorescer may be fluorescein, theamino acid may be lysine and L″ may be a bond in the form of an amidelinkage involving the meta-carboxyl of the fluorescein and the terminalamine group of lysine, and T^(c) is the OH of the carboxyl of the lastamino acid, a moiety of from 0 to 6 carbon atoms for linking the carboxyto a nucleoside, nucleotide or nucleotide triphosphate.

[0288] In another embodiment of a kit in accordance with the invention ,the electrophoretic tag is a label conjugate represented by the formula:

Fluorescein-(CO)NH—CH(CH₂)₃CH(NH₂)COX

[0289] wherein X is selected from the group consisting of: OH,NH-lysine, NH-(lysine)₂, NH-alanine, NH-aspartic acid, NH-(asparticacid)₂, NH-(aspartic acid)₃, NH-(aspartic acid)₄, NH-(aspartic acid)₅,NH-(aspartic acid)₆, NH-(aspartic acid)₇, NH-alanine-lysine, NH-asparticacid-lysine, NH-(aspartic acid)₂-lysine, NH-(aspartic acid)₃-lysine,NH-(aspartic acid)₄-lysine, NH-(aspartic acid)₅-lysine, NH-(asparticacid)₆-lysine, NH-(aspartic acid)₇-lysine, NH-(aspartic acid)₈-lysine,NH-(lysine)₄, and NH-(lysine)₅. The terminal carboxy may be linked toT^(c).

[0290] The e-tags described above may terminate in an appropriatefunctionality for linking to a nucleotide, nucleotide triphosphate, orother molecule of interest, or may terminate in such moieties.

[0291] For convenience, kits can be provided comprising building blocksfor preparation of eTags in situ or have assembled eTags for directbonding to the binding compound. For preparing the eTags in situ duringthe synthesis of oligonucleotides, one would provide phosphoramidites orphosphates, where the esters would include alkyl groups, particularly offrom 1 to 3 carbon atoms, and cyanoethyl groups, while for thephosphoramidite, dialkylamino, where the alkyl groups are of from 1-4carbon atoms, while the other group would be a protected hydroxy, wherethe protecting group would be common to oligonucleotide synthesis, e.g.dimethoxytrityl. For large numbers of eTag probes, that is, 20 or more,one kit would supply at least 3 each of mass-modifying regions andcharge-modifying regions, each having at least the phosphate linkinggroup and a protected hydroxyl. The two functional groups may beseparated by 2 or more atoms, usually not more than about 60 atoms, andmay be vicinal (α,β to α,ω). The nature of the compounds has beendiscussed previously. In the simplest case, the phosphorous acidderivative would serve as the charge-modifying region, so that themass-modifying region and the charge-modifying region would be added asa single group. In addition, one would have at least 2 detectableregions, which would be a fluorescer having the phosphate linker andother functionalities protected for purposes of the synthesis.Alternatively, instead of having the detection region the terminalregion, where the detectable region allows for the presence of twofunctionalities that can be used for linking, one of the other regionsmay serve as the terminal region. Also, one of the regions may beconveniently linked to a mono- or dinucleotide for direct linking to theoligonucleotide chain, where cleavage will occur at the 3′ site of thenucleotide attached to the e-tag reporter. By using tri- ortetra-substituted groups, one can provide a detectable region thatprovides the pair for energy transfer. One need only have one or twodifferent energy transfer agents, while having a plurality of emittingagents to greatly expand the number of different e-tag reporters.

[0292] Where one prepares the e-tag probe, there will be the additionallinking region, which in the above description is served by thephosphorous acid derivative or the mono- or dinucleotide unitphosphorous acid derivative. For these e-tag probes, one need not berestricted to phosphate links, but may use other convenient chemistries,particularly chemistries that are automated. Thus, instead ofphosphorous acid and protected alcohol, one can use carboxy and alcoholor amino, activated olefin and thiol, amino and oxo-carbonyl,particularly with reductive amination, an hydroxy with an active halideor another hydroxy to form an ether, and the like. One may employcompounds that are di-functional, with the same or differentfunctionalities, where one could have a diacid and a diol or a hydroxyacid or cyclic ester for producing the e-tag probe. Numerous examples ofthese types of compounds have already been described and are well knownin the literature. By appropriate selection of the monomers andconditions, one can select a particular order of reaction, namely thenumber of monomers that react or one may separate the mixture by thedifferent mobilities.

[0293] The kits will include at least two detectable regions andsufficient reagents to have at least 10, usually at least 20 andfrequently at least 50 or more different e-tag reporters that can beseparated by their mobility.

[0294] The kits will usually have at least about 5 different e-tags forconjugation, more usually at least about 10, frequently at least about25 and may have 50 or more, usually not more than about 1,000. Thee-tags will differ as to mobility, including mass/charge ratio andnature of charge, e.g. overall positive or negative, detectable moiety,e.g. fluorophor, electrochemical, etc, or functionality for linking adetectable moiety, e.g. maleimide, mercaptan, aldehyde, ketone, etc.

EXAMPLES

[0295] The invention is demonstrated further by the followingillustrative examples. Parts and percentages are by weight unlessotherwise indicated. Temperatures are in degrees Centigrade (° C.)unless otherwise specified. The following preparations and examplesillustrate the invention but are not intended to limit its scope. Unlessotherwise indicated, oligonucleotides and peptides used in the followingexamples were prepared by synthesis using an automated synthesizer andwere purified by gel electrophoresis or HPLC.

[0296] The following abbreviations have the meanings set forth below:

[0297] Tris HCl—Tris(hydroxymethyl)aminomethane-HCl (a 10× solution)from BioWhittaker, Walkersville, Md.

[0298] HPLC—high performance liquid chromatography

[0299] BSA—bovine serum albumin from Sigma Chemical Company, St. LouisMo.

[0300] EDTA—ethylene diamine tetra-acetate from Sigma Chemical Company

[0301] bp—base pairs

[0302] g—grams

[0303] mM—millimolar

[0304] TET—tetrachlorofluorescein

[0305] FAM—fluorescein

[0306] TAMRA—tetramethyl rhodamine

[0307] EOF—electroosmotic flow

[0308] Reagents

[0309] TET and TAMRA were purchased from Perkin Elmer (Foster City,Calif.) as were conjugates of TET, FAM and TAMRA with oligonucleotides.

[0310] Master Mix (2×): 20 mM Tris-HCl, 2.0 mM EDTA, pH 8.0 (8%Glycerol),

[0311] 10 mM MgCl₂, DATP 400 μM, dCTP 400 μM, dGTP 400 μM,

[0312] dUTP 400 μM, AmpliTaq Gold® 0.1 U/μL (from Perkin Elmer),Amperase

[0313] UNG® 0.02 U/μL (from Perkin Elmer)

[0314] Probes and Primers: (10×)

[0315] Forward Primer: 3.5 μM 5′-TCA CCA CAT CCC AGT G-3′ (SEQ ID NO:1)

[0316] Reverse Primer: 2.0 μM 5′-GAG GGA GGTTTG GCTG-3′ (SEQ ID NO:2)

[0317] Plasmid Allele 1 Probe: 2.0 μM (200 nM per reaction)

[0318] 5′ TET-CCA GCA ACC AAT GAT GCC CGT T-TAMRA-3′ (SEQ ID NO:3)

[0319] Plasmid Allele 2 Probe: 2.0 μM (200 nM per reaction)

[0320] 5′ FAM-CCA GCA AGC ACT GAT GCC TGT T-TAMRA-3′ (SEQ ID NO:4)

[0321] Target DNA:

[0322] Plasmid Allele-1:10 fg/μL=approximately 1000 copies/μL

[0323] Plasmid Allele-2: 10 fg/μL=approximately 1000 copies/μL

[0324] Synthesis of Elements of e-tag Probes

[0325] A. Synthesis of 6-Carboxyfluorescein Phosphoramidite Derivatives

[0326] To a solution of 6-carboxyfluorescein (0.5 g, 1.32 mmol) in drypyridine (5 mL) was added drop wise, isobutyric anhydride (0.55 mL, 3.3mmol). The reaction was allowed to stir at room temperature under anatmosphere of nitrogen for 3 h. After removal of pyridine in vacuo theresidue was redissolved in ethyl acetate (150 mL) and washed with water(150 mL). The organic layer was separated, dried over Na₂SO₄, filtered,and concentrated in vacuo to yield a brownish residue. This material wasdissolved in CH₂Cl₂ (5 mL) after which N-hydroxy succinimide (0.23 g,2.0 mmol) and dicyclohexylcarbodiimide (0.41 g, 1.32 mmol) were added.The reaction was allowed to stir at room temperature for 3 h and thenfiltered through a fritted funnel to remove the white solid, which hadformed. To the filtrate was added aminoethanol (0.12 mL, 2.0 mmol)dissolved in 1 mL of CH₂Cl₂. After 3 h the reaction was again filteredto remove a solid that had formed, and then diluted with additionalCH₂Cl₂ (50 mL). The solution was washed with water (150 mL) and thenseparated. The organic layer was dried over Na₂SO₄, filtered, andconcentrated in vacuo to yield a white foam (0.7 g, 95%, 3 steps). ¹HNMR: (DMSO), 8.68 (t, 1H), 8.21 (d, 1H), 8.14 (d, 1H), 7.83 (s, 1H),7.31 (s, 2H), 6.95 (s, 4H), 4.69 (t, 1H), 3.45 (q, 2H), 3.25 (q, 2H),2.84 (h, 2H), 1.25 (d, 12 H). Mass (LR FAB⁺) calculated for C₃₁H₂₉NO₉(M+H⁺) 559.2, found: 560.

[0327] B. Synthesis of Modified Fluorescein Phosphoramidites

[0328] Pivaloyl protected carboxyfluorescein: Into a 50 mL round bottomflask was placed 5(6)-carboxyfluorescein (0.94 g, 2.5 mmol), potassiumcarbonate (1.0 g, 7.5 mmol) and 20 mL of dry DMF. The reaction wasstirred under nitrogen for 10 min, after which trimethylacetic anhydride(1.1 mL, 5.5 mmol) was added via syringe. The reaction was stirred atroom temperature overnight, and then filtered to remove excess potassiumcarbonate and finally poured into 50 mL of 10% HCl. A sticky yellowsolid precipitated out of solution. The aqueous solution was decantedoff and the residual solid was dissolved in 10 mL of methanol. Drop wiseaddition of this solution to 10% HCl yielded a fine yellow precipitate,which was filtered and air dried to yield an offwhite solid (0.88 g,62%). TLC (45:45:10 of Hxn:EtOAc:MeOH).

[0329] NHS ester of protected pivaloyl carboxyfluorescein. Into a 200 mLround bottom flask was placed the protected carboxyfluorescein (2.77 g,5.1 mmol) and 50 mL of dichloromethane. N-hydroxysuccinimide (0.88 g,7.6 mmol) and dicyclohexylcarbodiimide (1.57 g, 7.6 mmol) were added andthe reaction was stirred at room temperature for 3 hours. The reactionwas then filtered to remove the precipitated dicyclohexyl urea byproductand reduced to approx. 10 mL of solvent in vacuo. Drop wise addition ofhexanes with cooling produced a yellow-orange colored solid, which wastriturated with hexanes, filtered and air-dried to yield 3.17 g (95%) ofproduct. TLC (45:45:10 of Hxn:EtOAc:MeOH)

[0330] Alcohol. Into a 100 mL round bottom flask was placed the NHSester (0.86 g, 1.34 mmol) and 25 mL of dichloromethane. The solution wasstirred under nitrogen after which aminoethanol (81 mL, 1 eq) was addedvia syringe. The reaction was monitored by TLC (45:45:10 Hxn,EtOAc,MeOH)and was found to be complete after 10 min. The dichloromethane was thenremoved in vacuo and the residue dissolved in EtOAc, filtered andabsorbed onto 1 g of silica gel. This was bedded onto a 50 g silicacolumn and eluted with Hxn:EtOAc:MeOH (9:9:1) to give 125 mg (20%) ofclean product.

[0331] Phosphoramidite. Into a 10 mL round bottom flask containing 125mgof the alcohol was added 5 mL of dichloromethane. Diisopropyl ethylamine(139 μL, 0.8 mmol) was added via syringe. The colorless solution turnedbright yellow. 2-cyanoethyl diisopropylchlorophosphoramidite (81 μL,0.34 mmol) was added via syringe and the solution immediately wentcolorless. After 1 hour TLC (45:45:10 of Hxn:EtOAc:TEA) showed thereaction was complete with the formation of two closely eluting isomers.Material was purified on a silica column (45:45:10 of Hxn:EtOAc:TEA)isolating both isomers together and yielding 130 mg (85%).

[0332] Carboxylic acid. Into a 4 mL vial was placed 12-aminododecanoicacid (0.1 g, 0.5 mmol) and 2 mL of pyridine. To this suspension wasadded chlorotrimethyl silane (69 μL, 1.1 eq) via syringe. After allmaterial dissolved (10 min) NHS ester (210 mg, 0.66 eq) was added.

[0333] The reaction was stirred at room temperature overnight and thenpoured into water to precipitate a yellow solid, which was filtered,washed with water, and air-dried. TLC (45:45:10 of Hxn:EtOAc:MeOH) showsa mixture of two isomers.

[0334] General Procedure for Remaining Syntheses. The carboxylic acidformed as described above is activated by NHS ester formation with 1.5eq each of N-hydroxysuccinimide and dicyclohexylcarbodiimide indichloromethane. After filtration of the resulting dicyclohexylurea,treatment with 1 eq of varying amino alcohols will effect amide bondformation and result in a terminal alcohol. Phosphitylation usingstandard conditions described above will provide the phosphoramidite.

[0335] C. Synthesis of Biotinylated 2′-Deoxycytosine Phosphoramidite(FIG. 33)

[0336] Compound 1. Synthesis of3′,5′-O-di-t-butyldimethylsilyl-2′-Deoxyuridine(1):

[0337] 2′-deoxyuridine (4 gm, 17.5 mmol) and imidazole (3.47 gm, 52.5mmol) were dissolved in 30 ml of dry DMF and t-butyldimethyl-silylchloride (7.87 gm, 52.5 mmol) added to the stirring solution at roomtemperature. After 3 hrs, TLC on silica gel (10% MeOH+90% CH₂Cl₂) showedthat all starting material had been converted to a new compound withhigher R_(f). The solution was concentrated into a small volume; about200 ml of ether was then added and washed three times with saturatedaqueous NaCl solution. The organic layer was dried over anhydrousNa₂SO₄, and the filtrate was evaporated to give a colorless gummymaterial that converted to a white solid product (eight gm, 100%). Thisproduct was identified with HNMR and ES-MS.

[0338] Compound 2. Synthesis of3′,5′-O-di-t-butyldimethylsilyl-N4-(1,2,4-triazolo)-2′-Deoxycytidine:

[0339] 1,2,4-Triazole (19.45 gm, 282 mmol) was suspended in 300 ml ofanhydrous CH₃CN at 0° C., 8 ml of POCl₃, then 50 ml of triethylamine wasadded slowly in 5 min. After an hour,3′,5′-O-di-t-butyldimethylsilyl-2′-deoxyuridine (Compound 1) (9 gm, 19.7mmol) was dissolved in 200 ml of dry CH₃CN and added to the reactionover 20 min. After stirring the reaction for 16 hours at RT, TLC (100%ether) showed that all starting material was converted to a new compoundwith lower R_(f). The reaction mixture was filtered, reduced the volumeof CH₃CN, diluted with ethyl acetate and washed with saturated aqueousNaHCO₃ then twice with saturated aqueous NaCl. The organic layer wasdried over anhydrous Na₂SO₄ and the solvent was evaporated,co-evaporated from toluene to give a yellow solid product (10 gm, 100%).This product was identified with HNMR and ES-MS.

[0340] Compound 3. Synthesis of3′,5′-O-di-t-butyldimethylsilyl-N⁴-(4,7,10-trioxa-1-tridecaneamino)-2′-deoxycytidine

[0341] 4,7,10-Trioxa-1,13-tridecanediamine (10.44 gm, 47.4 mmol) wasdissolved in 100 ml dioxane, then3′,5′-O-di-t-butyldimethylsilyl-4-(1,2,4-triazolo)-2′-deoxycytidine(Compound 2) (8.03 gm, 15.8 mmol) was dissolved in 200 ml of dioxane(heated to about 50 C and cooling it dawn to RT) and added drop wise in10 min, to the solution of 4,7,10-Trioxa-1,13-tridecanediamine withvigorous stirring at RT. After 5 hrs, TLC on silica gel showed that allstarting material was converted to a new product with lower R_(f), theresulting mixture was evaporated to dryness. The residue was dissolvedin dichloromethane and washed twice with 5 % sodium bicarbonate solutionand saturated sodium chloride solution. The organic layer was dried oversodium sulphate, filtered and evaporated to dryness to give a yellowgummy product (7.87 gm). The product was purified on a silica gel columneluted with a gradient of 0 to 10% methanol in dichloromethane with 1%triethylamine. The product was obtained as a yellowish gum (5.66 gm,54%). This product was identified with HNMR and ES-MS.

[0342] Compound 4. Synthesis of3′,5′-O-di-t-butyldimethylsilyl-4-N-(4,7,10-trioxa-1-tridecaneaminobiotin)-2′-deoxycytidine3′,5′-O-di-t-butyldimethylsilyl-4-N-(4,7,10-trioxa-1-tridecaneamino)-2′-deoxycytidine(Compound 3) (2.657 gm, 4.43 mmol) and Biotin-NHS ester (1.814 gm, 5.316mmol) were dissolved in 20 mL of dry DMF and about 1 mL of triethylaminewas added. After stirring the reaction mixture for 4 hrs at RT, thereaction was stopped by evaporating all DMF to give a yellow gummaterial (4.36 gm). This material was dissolved in dichloromethane andwashed three times with saturated solution of NaCl, dried over sodiumsulphate and evaporated to dryness. TLC on silica gel (5% MeOH+1%TEA+94% CH₂Cl₂) indicated the formation of a new product that was higherR_(f). This product was purified with column chromatography on silicagel using (99% CH₂Cl₂₊₁% TEA) to (1% MeOH+1% TEA+98% CH₂Cl₂) to yield ayellow foamy product (2.13 gm, 60%). This product was identified withHNMR and ES-MS.

[0343] Compound 5. Synthesis of4-N-(4,7,10-trioxa-1-tridecaneaminobiotin)-2′-deoxycytidine

[0344]3′,5′-O-di-t-butyldimethylsilyl-4-N-(4,7,10-trioxa-1-tridecaneaminobiotin)-2′-deoxycytidine(Compound 4) (1.6 gm, 1.8 mmol) was dissolved in 50 mL of dry THF, thenabout 5.5 mL of tetrabutylammonium fluoride in THF was added in 2 min.while stirring at RT. After 3hrs, TLC on silica gel (10% MeOH+1% TEA+89%CH₂Cl₂) showed that a new product with lower R_(f) formed. The solventwas evaporated to give a yellow oily product. Column chromatography onsilica gel eluted with (99% CH₂Cl₂₊₁% TEA) to (7% MeOH+1% TEA+92%CH₂Cl₂) permitted the purification of the product as a gummy colorlessproduct (1.14 gm, 97%). This product was identified with HNMR and ES-MS.

[0345] Compound 6. t-butylbenzoylation of the biotin of4-N-(4,7,10-trioxa-1-tridecaneaminobiotin)-2′-deoxycytidine

[0346] 4-N-(4,7,10-trioxa-1-tridecaneaminobiotin)-2′-deoxycytidine(Compound 5) (14.14 gm, 21.5 mmol ) was dissolved in 100 mL of drypyridine. Chlorotrimethyl silane (11.62 gm, 107.6 mmol) was added andthe mixture was stirred for 2 hrs at RT. 4-t-butylbenzoyl chloride (5.07gm, 25.8 mmol) was added and the mixture was stirred for another 2 hrsat RT. The reaction mixture was cooled with ice-bath and the reactionstopped by adding 50 ml of water and 50 ml of 28% aqueous ammoniasolution. The solution kept stirring at RT for 20 min, then evaporatedto dryness in high vacuum and finally co-evaporated twice from toluene.The material was dissolved in dichloromethane and extracted twice with5% aqueous sodium bicarbonate solution. The organic layer was dried oversodium sulphate, evaporated to dryness, re-dissolved in dichloromethaneand applied to a silica gel column. The column was eluted with gradientfrom 0 to 10% of methanol in dichloromethane and obtained a product as awhite foam (9.4 gm, 53.5%). This product was identified with HNMR andES-MS.

[0347] Compound 7. Synthesis of5′-O-(4,4′-dimethoxytriphenylmethyl)-4-N-(4,7,10-trioxa-1-tridecaneaminobiotin)-2′-deoxycytidine

[0348] Compound 6 (10.82 gm, 13.3 mmol) was co-evaporated twice from drypyridine, then dissolved in pyridine (100 ml) and4,4′-dimethoxytritylchloride(DMT-Cl) (6.76 gm, 19.95 mmol) was added andthe resulting mixture stirred for 3 hrs. TLC (10% MeOH+1% TEA+89%CH₂Cl₂) showed the formation of new product with higher R_(f), and somestarting material remained unreacted, then another amount of DMTCl (2gm) was added and kept stirring for 2 hrs. The reaction was stopped byadding ethanol, and the mixture was stirred for 15 min. Afterevaporation to dryness and co-evaporation from toluene, the material wasdissolved in dichloromethane. The organic layer was washed twice with 5%aqueous sodium bicarbonate solution, dried over sodium sulphate andevaporated to dryness. The product was purified on a silica column usinga gradient of methanol from 0 to 5% in dichloromethane/ 1% TEA. Theproduct was obtained as a white foam (4.55 gm, 31%). This product wasidentified with HNMR and ES-MS.

[0349] Compound 8. Synthesis of 3′-O-[(diisopropylamine)(2-cyanoethoxy)phosphino)]-5′-O-(4,4′-dimethoxytriphenylmethyl)-4-N-(4,7,10-trioxa-1-tridecaneaminobiotin)-2′-deoxycytidine

[0350] The 5′-DMT-Biotin-dC (Compound 7) (507 mg, 0.453 mmol) wasdissolved in dry acetonitrile (30 ml) and dichloromethane (5 ml), thendiisopropylamine (73 mg, 0.56 mmol), tetrazole (1.15 ml, 0.52 mmol) and2-cyanoethyl N,N,N′N′-tetraisopropylphosphane 214 mg, 234 μL, 0.7 mmol)were added and the mixture stirred under nitrogen at RT. After 2 hrs,TLC on silica gel (45%:45%:5%:5%: of ethylacetate:dichloromethane:triethylamine:methanol) showed that only about30% of product was formed and about 70% of starting material wasunreacted. More reagents were added until most of starting material wasconverted, with only about 5% left unreacted. The solvent was evaporatedto dryness, dissolved in dry dichloromethane, washed with sodiumbicarbonate solution (5%), saturated brine solution, then the organiclayer was dried over sodium sulphate, evaporated to dryness. Columnchromatography was carried out on silica gel using (48%:48%:4% of ethylacetate:dichloromethane:triethylamine) to (47%:47%:5%: 1% of ethylacetate:dichloromethane:triethylamine:methanol). The desired product wasobtained as a colorless gummy product (406 mg, 70%). This material wasco-evaporated three times from a mixture of dry benzene anddichloromethane, then was kept in desiccated containing P₂O₅ and NaOHpellets under vacuum for 26 hrs before used in DNA synthesis.

[0351] D. Synthesis of Biotinylated 2′-Deoxyadenosine Phosphoramidite(FIG. 34)

[0352] Compound 1. Synthesis of 8-bromo-2′-deoxyadenosine:

[0353] 2′-deoxyadenosine (7gm, 25.9 mmol) was dissolved in sodiumacetate buffer (150 mL, 1 M, pH 5.0) by worming it to about 50° C., thenwas cooled dawn to 30° C., then 3 mL of bromine in 100 mL of the samebuffer was added drop wise at RT for 15 min, to the reaction. After 6hrs the TLC on silica gel (20% MeOH in CH₂Cl₂) showed that all startingmaterial was converted to a new product. The reaction was discolored byadding some sodium metabisulfite (Na₂S₂O₅) while stirring. The colorchanged to a white solution, and the pH of the reaction was neutralizedby adding IM NaOH. The reaction mixture was kept at 4° C. (refrigerator)for 16 hrs. The solid material was then filtered, washed with coldwater, then acetone to give a solid yellow powder product (5.75 gm,64%). The structure of this product was confirmed by H-NMR and ES-MS.

[0354] Compound 2. Synthesis ofN⁶-benzoyl-8-bromo-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine

[0355] 8-bromo-2′-deoxyadenosine (Compound 1) (7.7 gm. 22.17 mmol) wasdried by co-evaporation with dry pyridine and the solid was suspended in200 ml of dry pyridine followed by the addition of4,4′-dimethoxytriphenylmethyl chloride (DMT-Cl, 9 gm, 26.6 mmol). Afterstirring for 4 hrs at RT, TLC on a silica gel showed that a new productwas formed and some starting material was unreacted. Another amount ofDMT-Cl (3 gm) was added and stirred at RT for 2 hrs. When TLC showedthat all starting material was converted to new product with a higherR_(f), the reaction mixture was cooled to 0° C. andtrimethylchlorosilane (12.042 gm., 14 mL, 110.85 mmol) was added dropwise while cooling and after 40 min while stirring benzoyl chloride(15.58 gm, 12.88 mL, 110.85 mmol) was similarly added. The reaction wasallowed to react at RT over 2hrs. The reaction was quenched by slowaddition of cold water (50 ml), followed by addition of concentratedammonia (30%, 50 ml). After 30 min, the reaction mixture was evaporatedto dryness. The residue was dissolved in water, and the solution wasextracted with ethyl acetate three times, the organic layer washed withsaturated sodium bicarbonate solution, and then brine. The organic phasewas dried over sodium sulphate, then evaporated to dryness. The productwas purified by silica column chromatography, to give a yellowish solidproduct (6.79 gm, 41.6%). The structure of this product was confirmed byH NMR and ES-MS.

[0356] Compound 3. Synthesis ofN⁶-benzoyl-8-bromo-3′-O-t-butyldimethylsilyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine

[0357] 6N-benzoyl-8-bromo-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine(Compound 2) (14 gm, 19 mmol) and imidazole (1.94 gm, 28.5 mmol) weredissolved in 100 mL of dry DMF and t-butyldimethyl-silyl chloride (4.3gm, 28.5 mmol) added to the stirring solution at room temperature. After4 hrs, TLC on silica gel (2.5% MeOH in CH₂Cl₂) showed that all startingmaterial had been converted to a new product with higher R_(f). Thesolution was concentrated into a small volume, then about 400 mL ofether was added and washed three times with saturated aqueous NaClsolution. The organic layer was dried over anhydrous Na₂SO₄, and thefiltrate was evaporated to give an off-white foamy product (16.18 gm,100%). H NMR and ES-MS confirmed the structure.

[0358] Compound 4. Synthesis ofN⁶-benzoyl-8-(4,7,10-trioxa-1-tridecaneamino)-3′-O-t-butyldimethylsilyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine

[0359]N⁶-bBenzoyl-8-bromo-3′-O-t-butyldimethylsilyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine(Compound 3) (8.31 gm, 9.7 mmol) was dissolved in 200 ml of ethanol then4,7,10-trioxa-1,13-tridecanediamine (6.75gm, 6.7 ml, 30 mmol) was addedat once and kept stirring at 50° C. After 16 hrs TLC showed that allstarting material was converted to one major product with lower R_(f)and other minor products. The solvent was evaporated to dryness,dissolved in dichloromethane, washed three times with a solution ofbrine, dried over anhydrous Na₂SO₄, then evaporated to give a yellowgummy material. Column chromatography (1% TEA+CH₂Cl₂) to (1% TEA+5%MeOH+CH₂Cl₂) permitted the purification of the major product as anoff-white gummy material (4.53gm, 47%). This product was identified withHNMR and ES-MS.

[0360] Compound 5. Synthesis ofN⁶-benzoyl-8-(4,7,10-trioxa-1-tridecaneaminobiotin)-3′-O-t-butyldimethylsilyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine

[0361]N⁶-benzoyl-8-(4,7,10-trioxa-1-tridecaneamino)-3′-O-t-butyldimethylsilyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine(Compound 4) (4.53 gm. 4.57 mmol) and biotin-NHS ester (3.12 gm, 9.13mmol) were dissolved in 75 mL of DMF and few drops of TEA were added andthe reaction was stirred at RT. After 2 hrs TLC on silica gel (5%MeOH+1% TEA+94% CH₂Cl₂) showed the formation of one major product lesspolar than starting material and another minor spot has lower R_(f). Thesolvent was evaporated to dryness, then dissolved in CH₂Cl₂ and washedthree times with a saturated solution of NaCl, dried the organic layer,evaporated to dryness to leave a yellow gummy material. This materialwas purified with column chromatography on silica gel by using (1%TEA+CH₂Cl₂) to (1% TEA+2.5% MeOH+CH₂Cl₂) as eluant. After evaporatingthe fractions containing the product, gave a yellowish solid material(3.16g, 78%). HNMR and ES-MS confirmed the structure.

[0362] Compound 6. Synthesis ofN⁶-benzoyl-8-(4,7,10-trioxa-1-tridecaneaminobiotin)-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosineN⁶-benzoyl-8-(4,7,10-trioxa-1-tridecaneaminobiotin)-3′-O-t-butyldimethylsilyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine(Compound 5) (3.16 gm, 2.6 mmol) was dissolved in 100 mL of dry THF, andthen about (3.25 ml, 3.25 mmol) of tetrabutylammonium fluoride in THFwas added in 5 min while stirring at RT. After 8 hrs, TLC on silica gel(10% MeOH+1 % TEA+89% CH₂Cl₂) showed that a new product with lower R_(f)formed. The solvent was evaporated to give a yellow oily material.Column chromatography on silica gel eluted with (99% CH₂Cl₂₊₁% TEA) to(5% MeOH+1% TEA+94% CH₂Cl₂) permitted the purification of the product asa white foamy product (2.86 gm, 100%). HNMR and ES-MS confirmed thestructure.

[0363] Compound 7. Synthesis ofN⁶-benzoyl-8-(4,7,10-trioxa-1-tridecaneaminobiotin)-3′-O-[(diisopropylamine)(2-cyanoethoxy)phosphino)]-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine

[0364]N⁶-benzoyl-8-(4,7,10-trioxa-1-tridecaneaminobiotin)-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine(Compound 6) (0.959 gm, 0.86 mmol) was dissolved in a mixture of dryacetonitrile (200 mL) and dichloromethane (50 mL), and diisopropylamine(224 μL, 1.29 mmol) followed by the addition of 2-cyanoethyl N,N, N′,N′-tetraisopropylphosphane (404 μL, 1.29 mmol) and tetrazole (2.6 ml,1.2 mmol, 0.45 M solution in dry acetonitrile). Theaddition andsubsequent reaction are performed under argon while stirring at RT.After 1.5 h, TLC on silica gel (5% MeOH+5% TEA+45% EA+45% CH₂Cl₂) showedthat only about 50% of starting material (SM) was converted to a newproduct. The same above amount of reagents were added to the reactionand kept stirring for another 2 hrs at RT. TLC showed that about 95% ofSM was converted to a new product with higher R_(f). The solvent wasevaporated to dryness then was dissolved in dichloromethane, extractedonce with 5% solution of bicarbonate, followed by saturated brinesolution and then dried over anhydrous sodium sulfate and evaporated todryness. Column chromatography on silica gel (10% TEA+45% EA+45% CH₂Cl₂)first, then (5% TEA+5% MeOH+45% EA+45% CH₂Cl₂). After evaporating thefractions containing the product, gave a yellow gummy material (774 mg).This material was co-evaporated three times from a mixture of drybenzene and dichloromethane, then was kept in desiccant containing P₂O₅and NaOH pellets under vacuum for 24 hrs before used in DNA synthesis.

[0365] E. Synthesis of Oligonucleotides Containing Biotin-dC andBiotin-dA

[0366] The syntheses of oligonucleotides containing biotin-dC andBiotin-dA, site-specifically located, were performed on a CPG supportusing a fully automated DNA synthesizer and the commercially availablefully protected deoxynucleosides phosphoramidites. Syntheses of allthese oligonucleotides were carried out at 1.0 and 0.4 μmol scale. Thecoupling time for the biotin-dC and dA were extended to 900 seconds. Thecoupling efficiency of the biotin-dC and dA phosphoramidites was foundgreater than 96%. After coupling of the biotinylated phosphoramidites,the remaining residues comprising the e-tag reporter of interest wereadded. Upon completion of the synthesis of the oligonucleotides, theywere deprotected with concentrated ammonia at 65° C. for 1 hour. Theseoligonucleotides were purified by reverse-phase HPLC and desalted by OPCcolumn, then used as such.

[0367] F. Synthesis of ACLA001 (FIG. 17) on an ABI 394 DNA Synthesizer

[0368] 6-Carboxyfluorescein (6-FAM) phosphoramidite is prepared by theaddition of 2.96 ml of anhydrous acetonitrile to a 0.25 gram bottle ofthe fluorescein phosphoramidite, to give a 0.1 M solution. The bottle isthen loaded onto the ABI 394 DNA synthesizer at position 8 using thestandard bottle change protocol. The other natural [dA^(bz) (0.1 M: 0.25g/2.91 mL anhydrous acetonitrile), dC^(AC) (0.1 M: 0.25g/3.24 mLanhydrous acetonitrile), dT(0.1 M: 0.25 g/3.36 mL anhydrousacetonitrile), dG^(dmf) (0.1 M: 0.25 g/2.81 mL anhydrous acetonitrile)]phosphoramidite monomers are loaded in a similar fashion to ports 1-4.Acetonitrile is loaded onto side port 18, standard tetrazole activatoris loaded onto port 9, CAP A is loaded onto port 11, CAP B is loadedonto port 12, oxidant is loaded onto port 15, and deblock solution isloaded onto port 14 all using standard bottle change protocols.

[0369] Standard Reagents Employed for DNA Synthesis:

[0370] Oxidizer: 0.02 M Iodine (0.015 M for MGB Probes)

[0371] DeBlock: 3% trichloracetic acid in dichloromethane

[0372] Activator: 1H-Tetrazole in anhydrous acetonitrile

[0373] HPLC Grade Acetonitrile (0.002% water)

[0374] Cap A: acetic anhydride

[0375] Cap B: N-methyl imidazole

[0376] The target sequence of interest is then input with a terminalcoupling from port 8 to attach ACLA001 to the 5′-end of the sequence. Amodified cycle is then chosen such that the desired scale (0.2 μmol, 1.0μmol, etc.) of DNA is synthesized. The modified cycle contains anadditional wait step of 800 seconds after any addition of 6-FAM. Astandard DNA synthesis column containing the support upon which the DNAwill be assembled is then loaded onto one of four positions of the DNAsynthesizer. DNA containing e-tag reporters have been synthesized onvarious standard 500 A CPG supports (Pac-dA-CPG, dmf-dG-CPG, Ac-dC-CPG,dT-CPG ) as well as specialty supports containing 3′-biotin, 3′-aminolinker, and minor grove binding species.

[0377] Upon completion of the synthesis, the column is removed from thesynthesizer and either dried under vacuum or by blowing air or nitrogenthrough the column to remove residual acetonitrile. The column is thenopened and the CPG is removed and placed in a 1-dram vial. Concentratedammonia is added (2.0 mL) and the vial is sealed and placed into a heatblock set at 65° C. for a minimum of two hours. After two hours the vialis allowed to cool to room temperature after which the ammonia solutionis removed using a Pasteur pipette and placed into a 1.5 mL Eppendorftube. The solution is concentrated in vacuo and submitted for HPLCpurification.

[0378] G. Synthesis of ACLA002 (FIG. 17) on an ABI 394 DNA Synthesizer

[0379] 6-Carboxyfluorescein (6-FAM) phosphoramidite is prepared by theaddition of 2.96 mL of anhydrous acetonitrile to a 0.25 gram bottle ofthe fluorescein phosphoramidite, to give a 0.1 M solution. The bottle isthen loaded onto the ABI 394 DNA synthesizer at position 8 using thestandard bottle change protocol. The other natural [dA^(bz) (0.1 M: 0.25g/2.91 mL anhydrous acetonitrile), dC^(AC) (0.1 M: 0.25 g/3.24 mLanhydrous acetonitrile), dT (0.1 M: 0.25 g/3.36 mL anhydrousacetonitrile), dG^(dmf) (0.1 M: 0.25 g/2.81 mL anhydrous acetonitrile)]phosphoramidite monomers are loaded in a similar fashion to ports 1-4.Acetonitrile is loaded onto side port 18, standard tetrazole activatoris loaded onto port 9, CAP A is loaded onto port 11, CAP B is loadedonto port 12, oxidant is loaded onto port 15, and deblock solution isloaded onto port 14 all using standard bottle change protocols. Thetarget sequence of interest is then input with a terminal coupling fromport 8 and a penultimate coupling of thymidine to the 5′-end of thesequence to assemble ACLA002. A modified cycle is then chosen such thatthe desired scale (0.2 μmol, 1.0 μmol, etc.) of DNA is synthesized. Themodified cycle contains an additional wait step of 800 seconds after anyaddition of 6-FAM. A standard DNA synthesis column containing thesupport upon which the DNA will be assembled is then loaded onto one offour positions of the DNA synthesizer. DNA containing e-tag reportershave been synthesized on various standard 500 A CPG supports(Pac-dA-CPG, dmf-dG-CPG, Ac-dC-CPG, dT-CPG) as well as specialtysupports containing 3′-biotin, 3′-amino linker, and minor grove bindingspecies.

[0380] Upon completion of the synthesis the column is removed from thesynthesizer and either dried under vacuum or by blowing air or nitrogenthrough the column to remove residual acetonitrile. The column is thenopened and the CPG is removed and placed in a 1-dram vial. Concentratedammonia is added (2.0 mL) and the vial is sealed and placed into a heatblock set at 65° C. for a minimum of two hours. After two hours the vialis allowed to cool to room temperature after which the ammonia solutionis removed using a Pasteur pipette and placed into a 1.5 mL Eppendorftube. The solution is concentrated in vacuo and submitted for HPLCpurification.

[0381] H. Synthesis of ACLA003 (FIG. 17) on an ABI 394 DNA Synthesizer

[0382] 6-Carboxyfluorescein (6-FAM) phosphoramidite is prepared by theaddition of 2.96 mL of anhydrous acetonitrile to a 0.25 gram bottle ofthe fluorescein phosphoramidite, to give a 0.1 M solution. The bottle isthen loaded onto the ABI 394 DNA synthesizer at position 8 using thestandard bottle change protocol. The other natural [dA^(bz) (0.1 M: 0.25g/2.91 mL anhydrous acetonitrile), dC^(AC)(0.1 M: 0.25 g/3.24 mLanhydrous acetonitrile), dT (0.1 M: 0.25 g/3.36 mL anhydrousacetonitrile), dG^(dmf) (0.1 M: 0.25 g/2.81 mL anhydrous acetonitrile)]phosphoramidite monomers are loaded in a similar fashion to ports 1-4.Acetonitrile is loaded onto side port 18, standard tetrazole activatoris loaded onto port 9, CAP A is loaded onto port 11, CAP B is loadedonto port 12, oxidant is loaded onto port 15, and deblock solution isloaded onto port 14 all using standard bottle change protocols. Thetarget sequence of interest is then input with a terminal coupling fromport 8 and two penultimate couplings of thymidine to the 5′-end of thesequence to assemble ACLA003. A modified cycle is then chosen such thatthe desired scale (0.2 μmol, 1.0 μmol, etc.) of DNA is synthesized. Themodified cycle contains an additional wait step of 800 seconds after anyaddition of 6-FAM. A standard DNA synthesis column containing thesupport upon which the DNA will be assembled is then loaded onto one offour positions of the DNA synthesizer. DNA containing e-tags have beensynthesized on various standard 500 A CPG supports (Pac-dA-CPG,dmf-dG-CPG, Ac-dC-CPG, dT-CPG ) as well as specialty supports containing3′-biotin, 3′-amino linker, and minor grove binding species.

[0383] Upon completion of the synthesis, the column is removed from thesynthesizer and either dried under vacuum or by blowing air or nitrogenthrough the column to remove residual acetonitrile. The column is thenopened and the CPG is removed and placed in a 1-dram vial. Concentratedammonia is added (2.0 mL) and the vial is sealed and placed into a heatblock set at 65° C. for a minimum of two hours. After two hours the vialis allowed to cool to room temperature after which the ammonia solutionis removed using a Pasteur pipette and placed into a 1.5 mL Eppendorftube. The solution is concentrated in vacuo and submitted for HPLCpurification.

[0384] I. Synthesis of ACLA016 (FIG. 17) on an ABI 394 DNA Synthesizer

[0385] 6-Carboxyfluorescein (6-FAM) phosphoramidite is prepared by theaddition of 2.96 mL of anhydrous acetonitrile to a 0.25 gram bottle ofthe fluorescein phosphoramidite, to give a 0.1 M solution. The bottle isthen loaded onto the ABI 394 DNA synthesizer at position 8 using thestandard bottle change protocol. Spacer phosphoramidite C3 (0.25 g) isdissolved in 5.0 mL of anhydrous acetonitrile and loaded onto position 5of the synthesizer. The other natural [dA^(bz) (0.1 M: 0.25 g/2.91 mLanhydrous acetonitrile), dC^(AC) (0.1 M: 0.25 g/3.24 mL anhydrousacetonitrile), dT (0.1 M: 0.25 g/3.36 mL anhydrous acetonitrile),dG^(dmf) (0.1 M: 0.25 g/2.81 mL anhydrous acetonitrile)] phosphoramiditemonomers are loaded in a similar fashion to ports 1-4. Acetonitrile isloaded onto side port 18, standard tetrazole activator is loaded ontoport 9, CAP A is loaded onto port 11, CAP B is loaded onto port 12,oxidant is loaded onto port 15, and deblock solution is loaded onto port14 all using standard bottle change protocols. The target sequence ofinterest is then input with a terminal coupling from port 8 and apenultimate coupling of the C3 spacer from port 5 to assemble ACLA016. Amodified cycle is then chosen such that the desired scale (0.2 μmol, 1.0μmol, etc.) of DNA is synthesized. The modified cycle contains anadditional wait step of 800 seconds after any addition of 6-FAM. Astandard DNA synthesis column containing the support upon which the DNAwill be assembled is then loaded onto one of four positions of the DNAsynthesizer. DNA containing e-tag reporters have been synthesized onvarious standard 500 A CPG supports (Pac-dA-CPG, dmf-dG-CPG, Ac-dC-CPG,dT-CPG ) as well as specialty supports containing 3′-biotin, 3′-aminolinker, and minor grove binding species.

[0386] Upon completion of the synthesis the column is removed from thesynthesizer and either dried under vacuum or by blowing air or nitrogenthrough the column to remove residual acetonitrile. The column is thenopened and the CPG is removed and placed in a 1-dram vial. Concentratedammonia is added (2.0 mL) and the vial is sealed and placed into a heatblock set at 65° C. for a minimum of two hours. After two hours the vialis allowed to cool to room temperature after which the ammonia solutionis removed using a Pasteur pipette and placed into a 1.5 mL Eppendorftube. The solution is concentrated in vacuo and submitted for HPLCpurification.

[0387] All other e-tag s are synthesized in a similar manner to thatdescribed above. FIG. 17 provides a list of different e-tags with theirstructures. FIG. 6 provides a list of elution times of some of thesee-tags on an ABI 3100 using POP4 as the separation matrix. C₃, C₆, C₉and C₁₈ are commercially available phosphoramidite spacers from GlenResearch, Sterling, Va. The units are derivatives of N,N-diisopropyl,O--cyanoethyl phosphoramidite, which is indicated by Q. The subscriptsindicate the number of atoms in the chain, which comprises units ofethyleneoxy terminating in Q with the other terminus protected with DMT.The letters without subscripts A, T, C and G indicate the conventionalnucleotides, while T^(NH) ^(₂) intends amino thymidine and C^(Br)intends bromocytidine. In FIG. 8, the numbers indicate the e-tagreporter as indicated in FIG. 17.

Example 1

[0388] Singleplex Amplifications of Allele 1 and Allele 2

[0389] The experiment was set up to run in the following fashion (6samples, a triplicate for Allele 1 and another triplicate for Allele-2):

[0390] 22 μL of Mastermix

[0391] 13 μL of probes and primers (both the probes are present)

[0392] 4.0 μL of Allele-1 or Allele-2

[0393] 11 μL of buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)

[0394] Allele 1 was labeled with tetrachloro fluorescein (TET), andAllele 2 was labeled with fluorescein (FAM), each having characteristicsas set forth in FIG. 1B.

[0395] The above volumes were added to a PCR tubes and the reactionmixtures were cycled on a Gene Amp® system 9600 thermal cycler (PerkinElmer) as follows:

[0396] 50° C.; 2 MIN (for optimal AmpErase UNG activity)

[0397] 96° C.; 10 MIN (required to activate AmpliTaq Gold DNAPolymerase)

[0398] 40 cycles of:

[0399] 95° C.; 15 SEC

[0400] 60° C.; 60 SEC

[0401] 70° C.; 10 MIN

[0402] 4° C.; storage

[0403] Results from experiments with Allele-1 are shown in FIGS. 18A andB: CE separation of the reaction products of Allele 1 after 0 and 40cycles. CE instrument was Beckman P/ACE 5000 with LIF detection. BGE:2.5% LDD30, 7 M urea, 1×TBE. Capillary: 100 μm i.d., 375 μm o.d., Lc=27cm, Ld=6.9 cm. Detection: λ_(ex)=488 nm, λ_(em)=520 nm. Injection: 5 sat 2.0 kV. Field strength: 100 V/cm at room temperature. Peaks:P=unreacted primer, P′=primer product.

[0404] Results from experiments with Allele-2 are shown in FIGS. 19A andB: CE separation of the reaction products of Allele 2 after 0 and 40cycles. Experimental conditions were as given above for the FIG. 18experiment except for the BGE composition: 2.0% LDD30, 1×TBE.

Example 2

[0405] A Multiplexed Reaction With Both Allele 1 and Allele 2 Present inEqual Ratio

[0406] The experiment was set up in the following fashion (3 reactiontubes, a triplicate):

[0407] 22 μL of Mastermix

[0408] 13 μL of probes and primers (both of the probes were present)

[0409] 4.0 μL of Allele-l

[0410] 4.0 μL of Allele-2

[0411] 7 μL of buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)

[0412] The above volumes were added to a PCR tubes and the reactionmixtures were cycled on a Gene Amp® system 9600 thermal cycler (PerkinElmer) as follows:

[0413] 50° C.; 2 MIN (for optimal AmpErase UNG activity)

[0414] 96° C.; 10 MIN (required to activate AmpliTaq Gold DNAPolymerase)

[0415] 40 cycles of:

[0416] 95° C.; 15 SEC

[0417] 60° C.; 60 SEC

[0418] 70° C.; 10 MIN

[0419] 4° C.; storage

[0420] The results are shown in FIG. 20: CE separation of a 1: 1 mixtureof the 40 cycles products of Alleles 1 and 2. Experimental conditionswere as given above for the experiments of FIG. 18.

Example 3

[0421] A Multiplexed Reaction With Both Allele 1 and Allele 2, WhereAllele 1 is 10 Times More Concentrated Than Allele 2

[0422] The experiment was set up in the following fashion (3 reactiontubes, a triplicate):

[0423] 22 μL of Mastermix

[0424] 13 μL of probes and primers (both the probes were present)

[0425] 5.0 μL of Allele 1

[0426] 0.5 μL of Allele 2

[0427] 9.5 μL of buffer (10 mM Tris-HCl, 11 mM EDTA, pH 8.0)

[0428] The above volumes were added to a PCR tubes and the reactionmixtures were cycled on a Gene Amp® system 9600 thermal cycler (PerkinElmer) as follows:

[0429] 50° C.; 2 MIN (for optimal AmpErase UNG activity)

[0430] 96 C; 10 MIN (required to activate AmpliTaq Gold DNA Polymerase)

[0431] 40 cycles of:

[0432] 95° C.; 15 SEC

[0433] 60° C.; 60 SEC

[0434] 70C; 10MIN

[0435] 4 C; storage

[0436] The results are shown in FIG. 21: CE separation of a 1:10 mixtureof the 40 cycles products of Alleles 1 and 2. Experimental conditionswere as given for the experiments of FIG. 18.

Example 4

[0437] Electroseparation of Label Conjugates on Microfluidic Chip

[0438] 1. Label conjugates comprising fluorescein linked to threedifferent peptides, namely, KKAA (SEQ ID NO:5), KKKA (SEQ ID NO:6) andKKKK (SEQ ID NO:7) were prepared as follows: The protected tetrapeptidewas prepared on resin using Merrifield reagents. The N-terminus of thelast amino acid was reacted with fluorescein N-hydroxysuccinimide(Molecular Probes). The peptides were cleaved from the resin andpurified by high performance liquid chromatography (HPLC).

[0439] The label conjugates, prepared as described above, andfluorescein were combined in an aqueous buffered solution and wereseparated and detected in an electrophoresis chip. Detection was 0.5 cmfor the injection point on the anodal side of an electrophoresischannel. FITC-KKKK exhibited a negative charge and FITC-KKKA andFITC-KKKK exhibited a positive charge as determined by the migrationtime relative to EOF. The net charge of FITC-KKKK was greater than +1and FITC-KKKA and FITC-KKKK migrated electrophoretically against theEOF. The results are shown in FIG. 22.

Example 5

[0440] Multiplexed Analysis of CFTR snp Loci with e-tag Probes

[0441] A. Capillary Electrophoresis of CFTR PCR Products with e-tagProbes on ABI 310

[0442] The following example demonstrates separation in a gel basedcapillary electrophoresis of cleavage of a probe. The conditionsemployed were: Gel: 2.5% LDD30 in lx TBE with 7 M urea; CE: PE ABI 310;Capillary: 47 cm long; 36 cm to window; 75 μm ID; Running Buffer: 1×TBE.(LDD30 is a linear copolymer of N,N-diethyl acrylamide andN,N-dimethylacrylamide, 70:30).

[0443] The ABI310 was set up in accordance with the directions of themanufacturer. The parameters used were: injection: 5 sec, 2.0 kV; run:9.4 kV, 45° C., 10 min. To determine the relative mobilities of thedigested probes, a spike-in system was used. First one digested probewas separated and its peak site determined, then a second probe wasspiked into the first probe and the two separated. Then, a third probewas spiked in and separated, and so on until the sites of all six probeswas determined. The singleplex PCR runs were first separated followed byseparation of the multiplex PCR, which was compared to the S1 digestedseparation.

[0444] B. Multiplexed Amplification of CFTR Fragments with e-tag Probes

[0445] In this study, reactions involved a plurality of probes in thesame PCR reaction mixture for different SNPs in the gene for the CysticFibrosis transmembrane conductance regulator (CFTR). Taq DNA Polymeraseexhibits 5′ to 3′ exonuclease activity, causing degradation of an e-tagprobe hybridized to template DNA at the 3′ end of a PCR primer. In thesubject example, sequence-specific e-tag probes with a fluorescent dyeattached to the 5′ terminus of the probe were employed. PCR wasperformed with these probes, followed by separation by gel-basedcapillary electrophoresis to determine cleavage of the e-tag probe.Table 5 indicates the mutation name, exon location, and the nucleotidechange and position of the snp in the CFTR sequence. The name of theoligonucleotide reagents, including e-tag probes and PCR primers, areindicated for each snp locus. Two PCR primers were generated to amplifyeach snp locus, where F indicates the primer in the forward direction,and R indicates the primer in the reverse direction. Two e-tag probeswere generated for each snp locus—one hybridizing in the sense directionand one in the antisense direction, indicated as “s” or “as,”respectively. The sequence ID numbers of each of these primers andprobes are given in Table 6. TABLE 5 CFTR snps, e-tag Probes, and PCRPrimers Predicted Mutation Exon Nucleotide PCR e-tag PCR Name LocationChange Primers Probe Product Size R560T Exon 11 G1811C CF10P (F/R) CF10s108 R560T Exon 11 G1811C CF10P (F/R) CF10as 108 D1152H Exon 18 G3586CCF11P (F/R) CF11s 188 D1152H Exon 18 G3586C CF11P (F/R) CF11as 188G1349D Exon 22 G4178A CF13P (F/R) CF13as 138

[0446] TABLE 6 Sequence ID Numbers Oligonucleotide SEQ ID NO. CF10P FSEQ ID NO: 8  CF11P F SEQ ID NO: 9  CF13P F SEQ ID NO: 10 CF10P R SEQ IDNO: 11 CF11P R SEQ ID NO: 12 CF13P R SEQ ID NO: 13 CF10s SEQ ID NO: 14CF10as SEQ ID NO: 15 CF11s SEQ ID NO: 16 CF11as SEQ ID NO: 17 CF13as SEQID NO: 18

[0447] The procedure employed in carrying out the singleplex PCRreaction was as follows:

[0448] 1. Make up Master Mix 1x Component 8 μL 25 mM MgCl₂ 2.5 μL 10xPCR Buffer 8 μL 10 ng/μL DNA template 0.2 μL 25 mM dNTPs 1 μL 5 U/μL TaqGold (added just prior to start of reaction)

[0449] Combine 0.8 μL of 5 μM probe and 1 μL of 10 μM primers to PCRtubes, as indicated below.

[0450] 2. 2. Primers Probe CF10P CF10s CF10P CF10as CF11P CF11s CF11PCF11as CF13P CF13as

[0451] 2. Aliquot 20.2 μL of the Master Mix to each tube.

[0452] 3. In a PE2400 thermalcycler:

[0453] 96° C.; 10 MIN

[0454] 40 cycles of:

[0455] 95° C.; 10 SEC

[0456] 55° C.; 30 SEC

[0457] 65° C.; 1 MIN

[0458] 70° C.; 10 MIN

[0459] 4° C.; storage

[0460] The results are shown in FIG. 23. Results clearly demonstrateformation of a unique electrophoretic tag with a distinct mobility foreach amplified sequence. Even in the multiplexed amplification eachdetection probe gave rise to a unique e-tag with a distinct mobility.

Example 6

[0461] Electroseparation of Nine e-tags on Microfluidic Chip

[0462] Label conjugates comprising 9 different fluorescein derivativeslinked to thymine (FIG. 24, e-tag numbers 1-9): poly deoxythymidine(20-mer; with a 5′ thiol group) is reacted with differentmaleimide-functionalized fluoresceins after which the product is ethanolprecipitated. In a reaction of 12 μL in volume, 10 μL of 25 μM oligo, 1μL 10×S1 nuclease reaction buffer, 1 μL of S1 nuclease incubated at 37°C. for 30 min followed by 96° C. for 25 min. The digested fragments arepurified by HPLC.

[0463] The nine different e-tags prepared as described above andfluorescein were combined in an aqueous buffered and were separated anddetected in an electrophoresis chip. Detection was 0.5 cm for theinjection point on the anodal side of an electrophoresis channel. Theresults are shown in FIG. 24.

Example 7

[0464] Effect of Thiophosphate on 5′-3′Cleavage RT-PCR Conditions:

[0465] 10 μL from a total volume of 25 μL of each mRNA was analyzed in atotal volume of 50 μL containing 0.5 μM of each of the oligonucleotideprimers, 0.2 mM of each dNTP, 100 nM of each e-tag labeledoligonucleotide probe, 1×RT PCR buffer, 2.5 mM MgCl₂, 0.1 U/μL Tfl DNApolymerase and 0.1 U/μL AMV Reverse Transcriptase (Promega Access,RT-PCR system).

[0466] Reverse Transcription was performed for 45 minutes at 48° C.followed by PCR. (40 thermal cycles of 30 s at 94° C., 1 min at 60° C.and 2 min at 69° C.). mRNA was obtained from M. Williams, Genentech,Inc. Probe and primer design was performed as described in AnalyticalBiochemistry, 270, 41-49 (1999). Phosphorothioates were attached to the2, 3, 4 and phosphate moieties from the 5′ end. Separation was performedas described in the previous section.

[0467]FIG. 25A demonstrates the formation of 5 different cleavageproducts in the PCR amplification of ANF (anti-nuclear factor) with ane-tag labeled at the 5′ end of the sequence detection probe. In thesecond experiment, phosphate groups at the 2, 3, 4 and 5 positions areconverted into thiophosphate groups. PCR amplification of ANF using athiophosphate-modified sequence detection probe yielded only onecleavage product (FIG. 25B). 1s FIG. 25C demonstrates the formation of 3different cleavage products in the PCR amplification of GAPDH with ane-tag attached to the 5′ end of the sequence detection probe. In asecond experiment, phosphate groups at positions 2 and 3 are convertedinto thiophosphate groups. PCR amplification of GAPDH using thethiophosphate-modified sequence detection probe yielded one predominantcleavage product (FIG. 25D).

[0468] The results clearly demonstrate for two different genes thatthiophosphate linkages prevent cleavage at multiple sites of a detectionprobe. A single detectable entity (a single e-tag reporter, FIGS. 25Band D) is generated as a consequence of the amplification reaction.

Example 8

[0469] S1 Nuclease Digestion of e-tag Reporter Probes

[0470] In a 1.5 ml tube, 10 μL of e-tag reporter probe was added at aconcentration of 10 μM, followed by addition of 1.5 μL of 10×S1 nucleasereaction buffer, 0.5 μL of S1 nuclease (Promega, Cat. # M5761, 20-100unit/μL), and 3 μL of Tris-EDTA buffer to bring the final volume to 15μL. The reaction was incubated at 37° C. for 20 min followed by 25 minat 96° C. to inactivate the nuclease.

Example 9

[0471] 5′ Nuclease Assays for Monitoring Specific mRNA Expression inCell Lysates

[0472] THP-1 cells (American Type Culture Collection, Manassas, Va.)were cultured in the presence or absence of 10 nM phorbol 12-myristate13-acetate (Sigma-Aldrich, St. Louis, Mo.) in RPMI 1640 medium with 10%fetal bovine serum (v/v), 2 mM L-glutamine, 10 mM HEPES, 0.05 mM2-mercaptoethanol. Twenty-four hours after the induction, cells wereharvested and washed twice with PBS before lysed with lysis buffer (20mM Tris pH 7.5, 0.5% Nonidet P-40, 5 mM MgCl₂, 20 ng/pL tRNA) at 25° C.,for 5 min. The lysate was heated at 75 40° C. for 15 min before testingin a 5′ nuclease assay.

[0473] Ten microliters of a cell lysate was combined with a singlestranded upstream invader DNA oligo, (5′CTC-TCA-GTT-CT), a singlestranded downstream biotinylated signal DNA oligo (e-tag-labeled), and 2ng/μL 5′ nuclease (Cleavase IX) in 20 μL of buffer (10 mM MOPS pH 7.5,0.05% Tween-20 and 0.05% Nonidet P-40, 12.5 mM MgCl₂, 100 μM ATP, 2 U/μLRNase inhibitor). The reactions were carried out at 60° C. for 4 hoursbefore analysis by capillary electrophoresis. To eliminate backgroundsignal, due to the non-specific activity of the enzyme, 1 μL of 1 mg/mLavidin was added to the reactions to remove all the e-tag-labeleduncleaved oligo, or e-tag-labeled non-specifically cleavedoligonucleotides. FIGS. 26 and 27, respectively, show separations thatwere conducted both with and without the addition of avidin.

Example 10

[0474] PCR Amplification with 5′ Nuclease Activity Using e-tag Reporters

[0475] Exemplary e-tag reporters are shown in FIG. 17. Elution times forsome of these reporters on an ABI 3100 using POP4 as the separationmatrix are provided in FIG. 6. The e-tag reporters that were preparedwere screened to provide 20 candidates that provided sharp separations.31 e-tag reporters were generated with synthetic targets using theTaqMan (reagents under conditions as shown in the following tabularformat. There were 62 reactions with the synthetic targets (one reactionand one negative control for e-tag reporter). Each 25 μL reactioncontained 200 nM probe, 500 nM primer, and 5 fM template in 0.5×TaqManmaster mix.

[0476] All the individual reactions were then run on an ABI 3100 usingPOP4 as the separation matrix. The samples were diluted 1:20 in0.5×TaqMan buffer and 1 μL of avidin (10 mg/mL) was added to bind to anyintact probe. The sample was further diluted 1:2 with formamide beforeinjecting the sample into the ABI 3100 capillaries. The following arethe conditions used with the ABI 3100 for the separation:

[0477] Temperature 60° C.

[0478] Pre-run voltage 15 kV

[0479] Pre-run time 180 sec

[0480] Matrix POP4

[0481] Injection voltage 3 kV

[0482] Injection time 10 sec

[0483] Run voltage 15 kV

[0484] Run time 900 sec

[0485] Run module e-tag reporter POP4

[0486] Dye set D

[0487] Subsequent separation of multiple e-tag reporters in a single runwas accomplished as shown in FIG. 8, the structures of which areidentified in FIG. 17.

Example 11

[0488] e-tag Reporter Assay for Protein Analysis

[0489] A. Labeling of Aminodextran (MW˜500,000) with e-tag Reporter andBiotin

[0490] Aminodextran was used as a model for demonstrating e-tag reporterrelease in relation to a high molecular weight molecule, which alsoserves as a model for proteins. The number of amino groups for 10 mgaminodextran was calculated as 2×10⁻⁸ moles. For a ratio of 1:4 biotinto e-tag reporter, the number of moles of biotin NHS ester employed was1.85×10⁻⁶, and the number of moles of maleimide NHS ester was 7.4×10⁻⁶.10.9 mg of aminodextran was dissolved in 6 mL of 0.1% PBS buffer. 10 mgof Biotin-x-x NHS ester and 23.7 mg of EMCS were dissolved together in 1mL of DMF, and added in 50 μL portions at 30 min intervals to theaminodextran solution while it was stirring and keeping away from thelight. After the final addition of the DMF solution, the mixture waskept overnight (while stirring and away from the light). Then, themixture was dialyzed using a membrane with a molecular weight cut-off of10,000 Daltons. The membrane was immersed in a beaker containing 2 L ofwater while stirring. The water was changed four times in a 2 hinterval. The membrane was kept in the water overnight (while stirringand keeping away from the light). Then the solution was lyophilized andthe lyophilized powder was used for e-tag reporter labeling.

[0491] B. Reaction of Biotin and Maleimide Labeled Aminodextran with thee-tag Reporter, SAMSA.

[0492] SAMSA[5-(((2-(and-3)-S-acetylmercapto)succinoyl)amino)fluorescein]wasemployed as an e-tag reporter to react with maleimide in theaminodextran molecule. For this purpose 0.3 mg (˜5.3×10⁻⁹ moles) ofbiotin and EMCS labeled with aminodextran were dissolved in 10 μl ofwater and then reacted with 10 times the mol ratio of SAMSA, for thecomplete conversion of the maleimide to the e-tag reporter. Therefore,1.1 mg of SAMSA (˜1.2×10⁻⁶ moles) is dissolved in 120 μL of 0.1 M NaOHand incubated at room temperature for 15 min (for the activation of thethiol group). Then the excess of NaOH was neutralized by the addition of2 μL of 6M HCl, and the pH of the solution was adjusted to 7.0 by theaddition of 30 μL of phosphate buffer (200 mM, pH 7.0). The activatedSAMSA solution was added to the 10 μL solution of the labeledaminodextran and incubated for 1 h. The e-tag reporter labeledaminodextran was purified with gel filtration using Sephadex G-25(Amersham), and purified samples were collected.

[0493] C. The Release of e-tag from Labeled Aminodextran

[0494] 2 μL of streptavidin coated sensitizer beads (100 μg/mL) wereadded carefully in the dark to the 5 μL of purified labeled aminodextranand incubated in the dark for 15 min. Then the solution was irradiatedfor 1 min at 680 nm. The release of the e-tag reporter was examined beCE using CE² LabCard™ device. As shown in FIG. 28A, the CE² LabCard 1consists of two parts; evaporation control and injection/separation. Theevaporation control incorporates an evaporation control channel 2 (450μm wide and 50 μm deep) with two replenishment buffer reservoirs 3 (2 mmin diameter) and the evaporation-controlled sample well 4 (1 mmdiameter) in the middle of the evaporation control channel. The volumeof the replenishment buffer reservoirs are 4.7 μL while the volume ofthe sample well is only 1.2 μL, and the volume of the channel 2 beneaththe middle sample well is about 40 nL. The second part of the CE²device, which is used for injection and separation, consists of aninjection microchannel 5 and a separation microchannel 6, intersectingat a junction 7, and having dimensions of 120 μm wide and 50 μm deep.Both ends of the separation channel and one end or the injection channelconnect with buffer reservoirs 8, while the second end of the injectionchannel connects directly to the evaporation-controlled sample well 4.The channels are enclosed by laminating a film (MT40) to the LabCard™. Adetector 9 is positioned 10 mm from the junction. After filling the CE²LabCard device with separation buffer (20 mM HEPES, pH 7.4 and 0.5%PEO), 300 nL of the assay mixture is added to the sample well 4. Thesample was injected into the microchannel junction 7 by applyingvoltages to the buffer reservoirs as indicated in FIG. 28B. The samplewas then separated as is shown in FIG. 28C.

[0495]FIG. 29 shows the electropherograms of purified labeledaminodextran with and without sensitizer beads. As shown, the additionof the sensitizer beads leads to the release of the e-tag reporter fromthe aminodextran using singlet oxygen produced by the sensitizer uponirradiation at 680 nm. In order to optimize the irradiation time,different tubes containing the same mixture of beads and sensitizer wereirradiated for different lengths of time ranging from 1 to 10 min. Thereis no significant increase in the e-tag reporter release for irradiationtimes longer than 1 min. FIG. 30 shows the effect of sensitizer beadconcentration on e-tag reporter release. As depicted in FIG. 30, ahigher concentration of sensitizer beads leads to greater release ofe-tag reporters from the labeled aminodextran. FIG. 31 depicts a linearcalibration curve for the release of e-tag reporters as a function ofsensitizer bead concentration. In addition, the effect of theconcentration of labeled aminodextran on e-tag reporter release was alsoexamined, with the results shown in FIG. 32. As can be seen, a lowerconcentration of labeled aminodextran for a given concentration ofsensitizer beads leads to more efficient e-tag reporter release (orhigher ratio of e-tag reporter released to the amount of labeledaminodextran).

[0496] It is evident from the above results that the subject inventionsprovide powerful ways of preparing compositions for use in multiplexeddeterminations and methods for performing multiplexed determinationsusing such compositions. The methods provide for homogeneous andheterogeneous protocols, both with nucleic acids and proteins, asexemplary of other classes of compounds. In the nucleic aciddeterminations, SNP determinations are greatly simplified where theprotocol can be performed in only one to four vessels and a large numberof SNPs readily determined within a short period of time with greatefficiency and accuracy. For other sequences, genomes can beinvestigated from both prokaryotes and eukaryotes, including for theprokaryotes, drug resistance, species, strain, etc., and for theeukaryotes, species, cell type, response to external stimuli, e.g.drugs, physical changes in environment, etc., mutations, chiasmas, etc.With proteins, one can determine the response of the host cell,organelles or the like to changes in the chemical and physicalenvironments in relation to a plurality of pathways, changes in thesurface protein population, changes due to aging, neoplasia, activation,or other naturally occurring phenomenon, where the amount of protein canbe quantitated.

[0497] Particularly as to nucleic acid determinations, the subject e-tagreporters can be synthesized conveniently along with the synthesis ofthe oligonucleotides used as probes, primers, etc., where the e-tagreporter is released in the presence of the homologous target sequence.Kits of building blocks or e-tag reporters are provided for use in thedifferent determinations.

[0498] It is further evident from the above results that the subjectinvention provides an accurate, efficient and sensitive process, as wellas compositions for use in the process, to perform multiplexedreactions. The protocols provide for great flexibility in the manner inwhich determinations are carried out and maybe applied to a wide varietyof situations involving haptens, antigens, nucleic acids, cells, etc.,where one may simultaneously perform a number of determinations on asingle or plurality of samples and interrogate the samples for aplurality of events. The events may vary from differences in nucleicacid sequence to proteomics to enzyme activities. The results of thedetermination are readily read in a simple manner using electrophoresisor mass spectrometry. Systems are provided where the entire process,after addition of the sample and reagents, may be performed under thecontrol of a data processor with the results automatically recorded.

[0499] All publications and patent applications cited in thisspecification are herein incorporated by reference as if each individualpublication or patent application were specifically and individuallyindicated to be incorporated by reference. Although the foregoinginvention has been described in some detail by way of illustration andexample for purposes of clarity of understanding, it will be readilyapparent to those of ordinary skill in the art in light of the teachingsof this invention that certain changes and modifications may be madethereto without departing from the spirit or scope of the appendedclaims.

1 18 1 16 DNA Artificial Sequence oligonucleotide 1 tcaccacatc ccagtg 162 16 DNA Artificial Sequence oligonucleotide 2 gagggaggtt tggctg 16 3 22DNA Artificial Sequence oligonucleotide 3 ccagcaacca atgatgcccg tt 22 422 DNA Artificial Sequence oligonucleotide 4 ccagcaagca ctgatgcctg tt 225 4 PRT Artificial Sequence peptide linker 5 Lys Lys Ala Ala 1 6 4 PRTArtificial Sequence peptide linker 6 Lys Lys Lys Ala 1 7 4 PRTArtificial Sequence peptide linker 7 Lys Lys Lys Lys 1 8 25 DNAArtificial Sequence oligonucleotide 8 gaccaggaaa tagagaggaa atgta 25 927 DNA Artificial Sequence oligonucleotide 9 gaaggagaag gaagagttggtattatc 27 10 21 DNA Artificial Sequence oligonucleotide 10 ttgggctcagatctgtgata g 21 11 27 DNA Artificial Sequence oligonucleotide 11catctaggta tccaaaagga gagtcta 27 12 27 DNA Artificial Sequenceoligonucleotide 12 cggtatatag ttcttcctca tgctatt 27 13 20 DNA ArtificialSequence oligonucleotide 13 gcaagatctt cgccttactg 20 14 32 DNAArtificial Sequence probe 14 ttccattttc tttttagagc agtatacaaa ga 32 1532 DNA Artificial Sequence probe 15 tctttgtata ctgctctaaa aagaaaatgg aa32 16 28 DNA Artificial Sequence probe 16 aaactccagc atagatgtgg atagcttg28 17 28 DNA Artificial Sequence probe 17 caagctatcc acatctatgc tggagttt28 18 23 DNA Artificial Sequence probe 18 aactgcttgt ggccatggct tag 23

It is claimed:
 1. A composition for detecting each or any of a pluralityof known, selected nucleotide target sequences, said compositioncomprising: (a) one or more uncleaved or partially cleavedelectrophoretic tag (e-tag) probes from a set of e-tag probes, the setcomprising j members, and each of said e-tag probes having the form: (D,M_(j))-N-T_(j), where (i) D is a detection group comprising a detectablelabel; (ii) T_(j) is an oligonucleotide target-binding moiety having asequence of nucleotides U_(i) connected by intersubunit linkagesB_(i, j+1), where i includes all integers from 1 to n, and n issufficient to allow the moiety to hybridize specifically with a targetnucleotide sequence; (iii) N is a nucleotide joined to U₁ in T_(j)through a nuclease-cleavable bond; (iv) M_(j) is a mobility modifierhaving a charge/mass ratio that imparts a unique and knownelectrophoretic mobility to the corresponding e-tag reporter of the form(D, M_(j))-N, within a selected range of electrophoretic mobilities withrespect to other e-tag reporters of the same form in the probe set,where the e-tag reporter (D, M_(j))-N does not itself containnuclease-cleavable bonds; (v) (D, M_(j))- includes both D-M_(j)- andM_(j)-D-; and (b) at least one e-tag reporter out of a possible set ofe-tag reporters, each e-tag reporter having the form: (D, M_(j))-N,where D, N, and M_(j) are as in (a), and (c) a capture agent bound tosaid uncleaved or partially cleaved e-tag probes, where binding of saidcapture agent is effective to (i) impart a mobility to the probes boundto capture agent that prevents the probes from electrophoreticallymigrating within said range of electrophoretic mobilities or (ii)immobilize the probes on a solid support.
 2. The composition of claim 1,wherein each e-tag reporter has the form D-M_(j)-N.
 3. The compositionof claim 1, wherein each e-tag reporter has the form M_(j)-D-N.
 4. Thecomposition of claim 1, wherein at least one nucleotide U_(i), i≧1 insaid oligonucleotide contains a capture ligand capable of bindingspecifically to said capture agent.
 5. The composition of claim 4,wherein the capture ligand is biotin, and the capture agent is avidin orstreptavidin.
 6. The composition of claim 4, wherein the capture ligandis an antigen and the capture agent is an antibody or antibody fragmentthat binds specifically to the antigen.
 7. The composition of claim 1,wherein the capture agent is a polycation and the oligonucleotide has anegatively charged backbone.
 8. The composition of claim 1, wherein theN-U₁ linkage is a phosphodiester bond, and the nuclease-resistantbond(s) in the target-binding moiety is one or more linkages selectedfrom the group consisting of thiophosphate, phosphinate,phosphoramidate, amide, and boronate linkages.
 9. The composition ofclaim 8, wherein at least one nucleotide U₁, i≧1 in said oligonucleotidecontains a capture ligand capable of binding specifically to saidcapture agent.
 10. The composition of claim 1, wherein each M_(j) has aunique charge/mass ratio by virtue of variations in mass, but notcharge.
 11. The composition of claim 1, wherein each M_(j) has a uniquecharge/mass ratio, by virtue of changes in both mass and charge.
 12. Thecomposition of claim 11, containing at least 5 probes whosecorresponding e-tag reporters have unique charge/mass ratios of between-0.001 and 0.5.
 13. The composition of claim 11, containing at least 9probes whose corresponding e-tag reporters have unique charge/massratios of between -0.001 and 0.5.
 14. The composition of claim 11,wherein each M_(j) is formed of a selected number of negatively chargedand/or positively charged amino acids.
 15. The composition of claim 11,wherein each M_(j) includes an alkyl chain, and differs from other M_(j)in the set by 1-3 methylene groups in the chain.
 16. The composition ofclaim 1, wherein the detectable label is selected from the groupconsisting of a fluorophore, a chromophore, and an electrochemicalcompound capable of a detectable reaction in the presence of a redoxagent.
 17. The composition of claim 16, wherein the detectable label hasa selected mass and charge.
 18. The composition of claim 16, containingsubsets of probes, each subset having a label with a unique mass/chargeratio.
 19. The composition of claims 17 and 18, wherein the detectablelabel is a fluorophore.